EX-10.32



 Exhibit 10.32 
  

			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT 

BY AND AMONG 
 CELL
THERAPEUTICS, INC., 
 BAXTER INTERNATIONAL INC., 

BAXTER HEALTHCARE CORPORATION 

AND 
 BAXTER HEALTHCARE
SA 
 DATED: NOVEMBER 14, 2013 







 TABLE OF CONTENTS 

			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

  

									
	 	 	 	  	 	  	Page	 
			
	ARTICLE I.	  	DEFINITIONS	  	 	1	  
				
		 	1.1.	  	Definitions	  	 	1	  
			
	ARTICLE II.	  	GRANT OF LICENSES	  	 	17	  
				
		 	2.1.	  	License to Baxter	  	 	17	  
				
		 	2.2.	  	License to CTI	  	 	18	  
				
		 	2.3.	  	CTI Reservation of Rights	  	 	18	  
				
		 	2.4.	  	Sublicenses	  	 	18	  
				
		 	2.5.	  	No Other Licenses	  	 	19	  
				
		 	2.6.	  	Controlled IP	  	 	19	  
				
		 	2.7.	  	Co-Promotion	  	 	19	  
				
		 	2.8.	  	Subcontracting	  	 	20	  
			
	ARTICLE III.	  	GOVERNANCE	  	 	20	  
				
		 	3.1.	  	General Committee Procedures	  	 	20	  
				
		 	3.2.	  	Joint Steering Committee	  	 	22	  
				
		 	3.3.	  	Joint Development Committee	  	 	22	  
				
		 	3.4.	  	Joint Manufacturing Committee	  	 	23	  
				
		 	3.5.	  	Joint Commercialization Committee	  	 	24	  
				
		 	3.6.	  	Alliance Managers	  	 	25	  
			
	ARTICLE IV.	  	DEVELOPMENT RESPONSIBILITIES	  	 	25	  
				
		 	4.1.	  	Development Obligations	  	 	25	  
			
	ARTICLE V.	  	DEVELOPMENT COOPERATION	  	 	25	  
				
		 	5.1.	  	Sharing of Development Updates and Related Information	  	 	25	  
				
		 	5.2.	  	Information Sharing Coordination	  	 	26	  
			
	ARTICLE VI.	  	REGULATORY MATTERS	  	 	26	  
				
		 	6.1.	  	Regulatory Roles	  	 	26	  
				
		 	6.2.	  	Cooperation	  	 	27	  


  
 -i- 









 TABLE OF CONTENTS 

(continued) 

			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

  


									
	 	 	 	  	 	  	Page	 
			
	ARTICLE VII.	  	LAUNCH AND COMMERCIALIZATION OF LICENSED PRODUCTS	  	 	28	  
				
		 	7.1.	  	Launch and Commercialization	  	 	28	  
				
		 	7.2.	  	Co-Promotion	  	 	29	  
				
		 	7.3.	  	Coordination of Marketing Efforts	  	 	31	  
				
		 	7.4.	  	Recalls	  	 	32	  
				
		 	7.5.	  	Safety Information; Adverse Events; Pharmacovigilance	  	 	33	  
				
		 	7.6.	  	Medical and Scientific Affairs	  	 	34	  
				
		 	7.7.	  	Springback Option	  	 	35	  
			
	ARTICLE VIII.	  	MANUFACTURING AND SUPPLY	  	 	36	  
				
		 	8.1.	  	General Supply Terms	  	 	36	  
				
		 	8.2.	  	Supply Agreement	  	 	36	  
				
		 	8.3.	  	Fill/Finish Option	  	 	37	  
				
		 	8.4.	  	Quality Agreement	  	 	37	  
				
		 	8.5.	  	Manufacturing Licenses	  	 	37	  
			
	ARTICLE IX.	  	PAYMENTS	  	 	38	  
				
		 	9.1.	  	Upfront Fee	  	 	38	  
				
		 	9.2.	  	Milestones	  	 	39	  
				
		 	9.3.	  	Royalty Payment; Audits	  	 	40	  
				
		 	9.4.	  	Development Costs and Expenses	  	 	42	  
				
		 	9.5.	  	Profit & Loss Share for Co-Promotion	  	 	46	  
				
		 	9.6.	  	Upstream Agreements	  	 	46	  
				
		 	9.7.	  	Exchange Rate; Manner and Place of Payment	  	 	46	  
				
		 	9.8.	  	Taxes	  	 	46	  
				
		 	9.9.	  	Late Payments	  	 	47	  
				
		 	9.10.	  	Reporting	  	 	47	  
			
	ARTICLE X.	  	INVENTIONS; ACCESS TO IMPROVEMENTS; PATENTS	  	 	47	  
				
		 	10.1.	  	Improvements and Inventions	  	 	47	  
				
		 	10.2.	  	Ownership of Inventions	  	 	48	  


  
 -ii- 









 TABLE OF CONTENTS 

(continued) 

			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

  


									
	 	 	 	  	 	  	Page	 
				
		 	10.3.	  	Disclosure of Inventions	  	 	48	  
				
		 	10.4.	  	Prosecution of Patents	  	 	48	  
				
		 	10.5.	  	Infringement of Patents by Third Parties	  	 	50	  
				
		 	10.6.	  	Infringement of Third Party Rights in the Licensed Territory	  	 	52	  
				
		 	10.7.	  	Patent Oppositions and Other Proceedings	  	 	52	  
				
		 	10.8.	  	Patent Term Extensions in the Licensed Territory	  	 	53	  
				
		 	10.9.	  	Registration of License	  	 	54	  
				
		 	10.10.	  	Patent Marking	  	 	54	  
			
	ARTICLE XI.	  	TRADEMARKS	  	 	54	  
				
		 	11.1.	  	Baxter Trademarks	  	 	54	  
				
		 	11.2.	  	Use of CTI Trademarks	  	 	54	  
				
		 	11.3.	  	Infringement of Baxter Trademarks by Third Parties	  	 	56	  
			
	ARTICLE XII.	  	REPRESENTATIONS AND WARRANTIES	  	 	56	  
				
		 	12.1.	  	The Parties’ Representations and Warranties	  	 	56	  
				
		 	12.2.	  	CTI’s Representations and Warranties	  	 	57	  
				
		 	12.3.	  	Baxter’s Representation and Warranties	  	 	61	  
				
		 	12.4.	  	The Parties’ Covenants	  	 	62	  
				
		 	12.5.	  	CTI’s Covenants	  	 	62	  
			
	ARTICLE XIII.	  	CONFIDENTIALITY	  	 	63	  
				
		 	13.1.	  	Confidentiality Obligations of Baxter	  	 	63	  
				
		 	13.2.	  	Confidentiality Obligations of CTI	  	 	65	  
				
		 	13.3.	  	Press Releases; Publicity	  	 	66	  
			
	ARTICLE XIV.	  	INDEMNIFICATION	  	 	67	  
				
		 	14.1.	  	CTI Indemnity	  	 	67	  
				
		 	14.2.	  	Baxter Indemnity	  	 	68	  
				
		 	14.3.	  	Indemnification Procedure	  	 	68	  
				
		 	14.4.	  	Limitation of Liability; Exclusion of Damages; Disclaimer	  	 	70	  


  
 -iii- 









 TABLE OF CONTENTS 

(continued) 

			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

  


									
	 	 	 	  	 	  	Page	 
			
	ARTICLE XV.	  	TERM; TERMINATION	  	 	70	  
				
		 	15.1.	  	Term	  	 	70	  
				
		 	15.2.	  	Early Termination	  	 	71	  
				
		 	15.3.	  	Obligations upon Early Termination	  	 	72	  
				
		 	15.4.	  	Force Majeure	  	 	73	  
				
		 	15.5.	  	Survival	  	 	74	  
				
		 	15.6.	  	Other Remedies	  	 	74	  
			
	ARTICLE XVI.	  	GENERAL PROVISIONS	  	 	74	  
				
		 	16.1.	  	Assignment	  	 	74	  
				
		 	16.2.	  	Headings	  	 	74	  
				
		 	16.3.	  	Waiver	  	 	75	  
				
		 	16.4.	  	Notices	  	 	75	  
				
		 	16.5.	  	Severability	  	 	76	  
				
		 	16.6.	  	Entire Agreement	  	 	76	  
				
		 	16.7.	  	Amendment; No Waiver	  	 	76	  
				
		 	16.8.	  	Counterparts	  	 	76	  
				
		 	16.9.	  	Agency	  	 	76	  
				
		 	16.10.	  	Further Actions	  	 	76	  
				
		 	16.11.	  	Compliance with Laws	  	 	76	  
				
		 	16.12.	  	Governing Law	  	 	76	  
				
		 	16.13.	  	Dispute Resolution; Jurisdiction	  	 	77	  
				
		 	16.14.	  	Bankruptcy Code	  	 	77	  
				
		 	16.15.	  	Joint and Several Obligations	  	 	77	  


  
 -iv- 









			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

  

			
	 Exhibits
	  	 
		
	Exhibit 1.26	  	Chemical Structure of Pacritinib Citrate
		
	Exhibit 1.34	  	Co-Promotion Terms
		
	Exhibit 1.46	  	CTI Patents
		
	Exhibit 1.47	  	CTI Trademarks
		
	Exhibit 1.54	  	Development Plan
		
	Exhibit 1.132	  	Form of Registration Rights Agreement
		
	Exhibit 1.160	  	Upstream Agreement
		
	Exhibit 8.2	  	Manufacturing and Supply Agreement Terms
		
	Exhibit 9.1.2	  	Preferred Stock Terms
		
	Exhibit 13.3.1	  	Form of Press Release
		
	Exhibit 16.13	  	Alternative Dispute Resolution


  
 -v- 









			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

 DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT 

This DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 14th day of November, 2013 (the “Effective Date”), by and among CELL THERAPEUTICS, INC., a company organized under the laws of the State of Washington with its principal place of
business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXTER INTERNATIONAL INC., a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015
(“BII”), BAXTER HEALTHCARE CORPORATION, a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), and BAXTER HEALTHCARE SA, a company
organized under the laws of Switzerland with its principal place of business at Postfach 8010, Zurich, Switzerland (“BHSA” and together with BII and BHC, “Baxter”). CTI and Baxter may each be referred to herein
individually as a “Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, CTI is developing pacritinib for use in oncology and potentially additional therapeutic areas, and owns or controls certain
patents, and proprietary technology, know-how and information relating to such compound; 
 WHEREAS, Baxter is engaged in the
research, development and commercialization of pharmaceutical products, and desires to acquire a license in the Licensed Territory (as defined below) under CTI’s patents, technology, know-how and other information relating to such compound, and
CTI desires to grant such license, on the terms and conditions of this Agreement; and 
 WHEREAS, the Parties wish to co-promote such
product in the Co-Promotion Territory (as defined below), on the terms and conditions of this Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 ARTICLE I. 

The following terms as used in this Agreement shall have the meanings set forth in this Article I (which meanings shall be applicable both to the
singular and the plural forms of such terms): 
 1.1. “Additional Indication” means any indication other than the Initial
Indication. 









			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.2. “Affiliate” means with respect to each Party, any Person that directly
or indirectly is controlled by, controls or is under common control with a Party. For the purposes of this definition only, the term “control” (including, with correlative meanings, the terms “controlled by” and “under
common control with”) as used with respect to a Person means (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of
directors, (b) in the case of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests or (c) with respect to any Person, the power to direct the management and policies of such
entity. 
 1.3. “Alliance Manager” has the meaning set forth in Section 3.6. 

1.4. “Bankruptcy Laws” has the meaning set forth in Section 16.14. 

1.5. “Baxter Approved Supplier” has the meaning set forth in Section 12.5.2. 

1.6. “Baxter Confidential Information” has the meaning set forth in Section 13.2.1(a). 

1.7. “Baxter Exclusive Territory” means all of the Licensed Territory except for the
Co-Promotion Territory, subject to the provisions of Section 7.1.4. 
 1.8.
“Baxter Indemnitees” has the meaning set forth in Section 14.1. 
 1.9. “Baxter Know-How”
means Information Controlled by Baxter or its Affiliates that is necessary for the Development, manufacture, use, Commercialization, sale, offer for sale and/or importation of the Licensed Products in the Licensed Field. Notwithstanding anything
herein to the contrary, Baxter Know-How shall exclude Baxter Patents. 
 1.10. “Baxter Patents” means Patents Controlled by
Baxter or its Affiliates that claim inventions necessary for the Development, manufacture, use, Commercialization, sale, offer for sale and/or importation of Licensed Products within the Licensed Field, including without limitation Baxter’s
interest in any Joint Patents. 
 1.11. “Baxter Trademarks” has the meaning set forth in Section 11.1. 

1.12. “Business Day” means a day other than Saturday, Sunday or other day on which commercial banks in New York, New York are
authorized or required by Law to close. 
 1.13. “Calendar Quarter” means the successive periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.14. “Calendar Year” means any calendar year. 

  
 2 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.15. “Clinical Trial” means a clinical study conducted on certain numbers
of human subjects (depending on the phase of the trial) that is designed to (a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its
intended use, and to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product in the dosage range to be prescribed, and/or (c) support Marketing Approval or Reimbursement Approval of such
pharmaceutical product or label expansion of such pharmaceutical product. 
 1.16. “CMO” means contract manufacturing
organization. 
 1.17. “Combination Product” has the meaning set forth in the definition of Net Sales. 

1.18. “Commercial Failure” means: **. 

1.19. “Commercialization” means all activities related to the commercial exploitation of the Compound, the Drug Product
and/or the Licensed Products, including, without limitation, importation, exportation, marketing, Promotion, distribution, pre-launch, launch, sale or offering for sale of the Licensed Products. When used as a verb, “Commercialize” or
“Commercializing” means to engage in Commercialization. 
 1.20. “Commercialization Obligations” has the meaning
set forth in Section 7.1.3. 
 1.21. “Commercialization Plan” has the meaning set forth in
Section 7.1.5. 
 1.22. “Commercially Reasonable Efforts” means with respect to either Party, a level of
efforts consistent with the efforts ** typically devotes to a product of similar market potential, ** at a similar stage in its development or product life, taking into account conditions then prevailing, including its safety and efficacy, product
profile, cost to develop, cost and availability of supply, the time required to complete development, the competitiveness of the marketplace, the patent position with respect to such product (including the ability to obtain or enforce, or have
obtained or enforced, such patent rights), the third-party patent landscape relevant to the product, the regulatory structure involved, the likelihood of regulatory approval, the anticipated or actual profitability of the applicable product and
other technical, legal, scientific, regulatory and medical considerations. 
 1.23. “Committee” means the JSC, JDC, JCC
and/or JMC as the context requires. 
 1.24. “Common Stock” has the meaning set forth in Section 9.1.2. 

1.25. “Company SEC Documents” has the meaning set forth in Section 12.2.12. 

1.26. “Compound” means 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]
heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (including any of its salt forms), the chemical structure of its citrate salt form of which is shown in Exhibit 1.26 attached hereto **. 

  
 3 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.27. “Confidential Information” means Baxter Confidential Information
and/or CTI Confidential Information. 
 1.28. “Confidentiality Agreement” means that certain Mutual Confidential Disclosure
Agreement between Baxter and CTI dated February 8, 2013. 
 1.29. “CONSOB” has the meaning set forth in
Section 12.3.3. 
 1.30. “Control” means, with respect to Patents, know-how, trademarks, copyrights, trade
secrets and Confidential Information, the possession of the ability to grant a license, sublicense or access as provided for under this Agreement without (a) violating the terms of any agreement or other arrangement with any Third Party or
(b) increasing at any time the amount of any payments required under any such agreement or arrangement; provided that this clause (b) shall not apply to Upstream Agreements. 

1.31. “Co-Promotion Agreement” has the meaning set forth in Section 2.7. 

1.32. “Co-Promotion” means the activities conducted pursuant to Section 7.3, the Co-Promotion Terms and the
Commercialization Plans. 
 1.33. “Co-Promotion Rights” means those rights retained by CTI pursuant to
Section 2.7. 
 1.34. “Co-Promotion Terms” means the terms attached hereto as Exhibit 1.34. 

1.35. “Co-Promotion Territory” means the U.S. 

1.36. “Cost of Goods Sold” or “COGS” shall mean the cost of manufacturing of bulk drug substance,
encapsulation, and packaging. The manufacturing costs shall include (a) the cost of material, labor, and appropriate administrative overhead of the contract manufacturer, (b) costs associated with logistics and shipping/transport and
(c) costs for production line validation, quality assurance and quality control. 
 1.37. “CPR” has the meaning set
forth in Section 16.13. 
 1.38. “CTI Assigned Joint Patents” has the meaning set forth in
Section 10.2. 
 1.39. “CTI Assigned Patents” has the meaning set forth in Section 10.2. 

1.40. “CTI Confidential Information” has the meaning set forth in Section 13.1.1(a). 

1.41. “CTI Development Cost Budget” means the budget for CTI Development Costs included in an approved Development Plan. 

1.42. “CTI Development Cost Threshold” has the meaning set forth in Section 9.4.2.1. 

  
 4 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.43. “CTI Development Costs” means expenses incurred by CTI in conducting
Development activities in accordance with an approved Development Plan and the CTI Development Cost Budget approved by the JSC (with such JSC approval subject to the JDC governance provisions included in Section 3.1.6) or agreed by the
Parties in writing, consisting of (a) the cost of actual direct FTEs, as recorded in CTI’s time reporting system, with costs calculated at the FTE Rate and (b) direct
out-of-pocket expenses incurred in the performance of Development activities assigned to CTI under such Development Plan. 

1.44. “CTI Indemnitees” has the meaning set forth in Section 14.2. 

1.45. “CTI Know-How” means Information Controlled by CTI or its Affiliates that is necessary for the Development,
manufacture, use, Commercialization, sale, offer for sale and/or importation of Licensed Products in the Licensed Field in the Licensed Territory. Notwithstanding anything herein to the contrary, CTI Know-How
shall exclude CTI Patents. 
 1.46. “CTI Patents” means all Patents Controlled by CTI or its Affiliates that claim
inventions necessary for the Development, manufacture, use, Commercialization, sale, offer for sale and/or importation of Licensed Products within the Licensed Field in the Licensed Territory, including CTI’s interest in any Joint Patents. CTI
Patents include the Patents listed on Exhibit 1.46. 
 1.47. “CTI Trademarks” means the trademarks set forth on
Exhibit 1.47 and such trademarks as CTI Controls during the Term and elects in its sole discretion to add to such Exhibit 1.47. 

1.48. “Damages” has the meaning set forth in Section 14.1. 

1.49. “Detail” means a face-to-face interaction with a targeted healthcare stakeholder where Licensed Product knowledge
and/or information is exchanged. 
 1.50. “Development” means all activities related to the development of drug products
and obtaining Regulatory Approval for drug products, including without limitation all activities related to research, development, preclinical testing, preclinical toxicology, preclinical pharmacokinetics, preclinical pharmacodynamics, stability
testing, toxicology, formulation, Clinical Trials, regulatory affairs, statistical analysis, report writing, manufacturing process scale up (including without limitation, registration batches/process validation, engineering studies qualification and
validation, process validation, characterization and stability, scale and technology transfer to CMOs), qualification and validation activities, quality assurance/quality control development and Regulatory Filing creation and submission related to
obtaining Regulatory Approval for a Licensed Product. When used as a verb, “Develop” means to engage in Development. 
 1.51.
“Development Account” has the meaning set forth in Section 9.4.4. 
 1.52. “Development Cost
Summary” has the meaning set forth in Section 9.4.4. 

  
 5 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.53. “Development Milestone” has the meaning set forth in Section
9.2.1 
 1.54. “Development Plan” means the Development Plan attached hereto as Exhibit 1.54 setting forth
the specific activities to be undertaken in connection with the Development of the Licensed Product including, but not limited to: **. 

1.55. “Drug Approval Application” means an application for Marketing Approval required before commercial sale or use of a
pharmaceutical product as a drug in a regulatory jurisdiction or country. 
 1.56. “Drug Product” means bulk drug product
containing the Compound that is encapsulated, but excluding any final packaging, finishing and labeling. Once so packed, finished and labeled, a Drug Product is a Licensed Product. 

1.57. “Election Time Period” has the meaning set forth in Section 14.3.1. 

1.58. “EMA” means the European Medicines Agency or any successor agency or agencies thereto. 

1.59. “Enforcing Party” has the meaning set forth in Section 10.5.3. 

1.60. “Equity Consideration” has the meaning set forth in Section 9.1.2. 

1.61. “European Union” or “EU” means all countries of the European Union, as may be included from time to
time. 
 1.62. “Exchange Act” has the meaning set forth in Section 12.2.17. 

1.63. “Executive Officers” has the meaning set forth in Section 3.1.6.2. 

1.64. “FCPA” means the Foreign Corrupt Practices Act, as amended (15 U.S.C.
§§ 78dd-1, et. seq.). 
 1.65. “FDA” means the U.S. Food and Drug
Administration or any successor agency or agencies thereto. 
 1.66. “FDCA” means the United States Food, Drug and Cosmetic
Act, as amended (21 U.S.C. §§ 301, et seq.). 
 1.67. “Field Correction” means any action taken or changes
performed affecting a distributed product to mitigate a risk to health or correct issues with misbranded or non-conforming product. 

1.68. “Field Representative” means a Sales Representative or a Medical Science Liaison, or both, as applicable. 

  
 6 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.69. “Fill/Finish Option” has the meaning set forth in
Section 8.3. 
 1.70. “First Commercial Sale” means, with respect to a Licensed Product in any country in the
Licensed Territory, the first sale of such Licensed Product under this Agreement for use in the Licensed Field to a Third Party in such country, after such Licensed Product has been granted Marketing Approval. ** be deemed to have occurred on such
six (6) month anniversary. 
 1.71. “Force Majeure” has the meaning set forth in Section 15.4.1. 

1.72. “FTE” means the full time equivalent effort of one CTI or Baxter (as applicable) employee who participates directly in
the activities under an approved Development Plan or Commercialization Plan. For purposes of this definition, “full time equivalent effort” shall mean ** hours of work per year with reimbursement based on actual hours worked. 

1.73. “FTE Rate” means the hourly rate of ** per hour for Development work pursuant to the Development Plan during Calendar
Year 2013, increasing at the beginning of each subsequent Calendar Year over the prior year amount by the increase of the Consumer Price Index-All Urban Consumers during the prior year. 

1.74. “Global Dossier” has the meaning set forth in Section 6.1.1. 

1.75. “Governmental Authority” means any nation or government, any state, local or other political subdivision thereof, and
any entity, department, commission, bureau, agency, authority, board, court, official or officer, domestic or foreign, exercising executive, judicial, regulatory or administrative governmental functions. 

1.76. “Improvement” means any improvement or modification of a Licensed Product, Drug Product and/or the Compound that is
developed by (a) CTI, (b) Baxter or, if rights thereto are obtained by Baxter pursuant to Section 10.1.3., its Sublicensees or (c) jointly by CTI and Baxter, for use in the Licensed Field. 

1.77. “Indemnification Claim Notice” has the meaning set forth in Section 14.3.1. 

1.78. “Indemnified Party” has the meaning set forth in Section 14.3.1. 

1.79. “Indemnifying Party” has the meaning set forth in Section 14.3.1. 

1.80. “Independently Active Pharmaceutical Ingredient” means an active pharmaceutical ingredient having a different target or
mode of action, or is otherwise treated or designated by the applicable Regulatory Authority as a separate active ingredient, than the Compound. 

1.81. “Information” means techniques, data, inventions, practices, methods, knowledge, know-how, skill, experience, test data
including pharmacological, toxicological, 

  
 7 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
preclinical and clinical test data and analytical and quality control data or descriptions, including all proprietary information submitted to relevant Regulatory Authorities to support a Drug
Approval Application. 
 1.82. “Initial Indication” means Myelofibrosis. 

1.83. “Invention” means any and all discoveries, Developments, Improvements, modifications, formulations, compositions of
matter, Processes and other inventions (whether patentable or not patentable) specifically related to the Compound, Drug Product and/or a Licensed Product or otherwise necessary or useful for the Development, manufacturing and/or Commercialization
of the Compound, Drug Product and/or a Licensed Product made in the course of activities performed under this Agreement by or on behalf of either Party or both Parties. 

1.84. “Investigator-Sponsored Trial” means any Clinical Trial of the Compound, Drug Product and/or Licensed Product for which
either or both of the Parties provide Compound, Drug Product and/or Licensed Product and/or financial support, but do not sponsor the trial, it being understood and agreed that all such trials must be conducted in compliance with applicable Law and
consistent with Baxter-specific requirements and policies for an investigator-sponsored trial, provided that in the case of conduct by CTI, such Baxter-specific requirements shall have been communicated to CTI in a timely manner. 
 1.85.
“Joint Commercialization Committee” or “JCC” means the joint commercialization committee established pursuant to Section 3.5. 

1.86. “Joint Development Committee” or “JDC” means the joint development committee established pursuant to
Section 3.3. 
 1.87. “Joint Inventions” has the meaning set forth in Section 10.2. 

1.88. “Joint Manufacturing Committee” or “JMC” means the joint manufacturing committee established pursuant
to Section 3.4. 
 1.89. “Joint Patent” has the meaning set forth in Section 10.2. 

1.90. “Joint Steering Committee” or “JSC” means the joint steering committee established pursuant to
Section 3.2. 
 1.91. “Last Patient First Dose” means the administration of the first dose of Licensed Product
or comparator to the last patient randomized in the PERSIST-1 or PERSIST-2 Clinical Trial (as applicable) as specified in the
then-current protocol for such Clinical Trial. 
 1.92. “Law” means all applicable
laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign, including


  
 8 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
without limitation all laws pertaining to the pharmaceutical industry or the healthcare industry and all anti-bribery or
anti-corruption laws, including without limitation the FDCA and the FCPA and their implementing regulations and all foreign equivalents thereof. 

1.93. “Licensed Field” means all human therapeutic indications. 

1.94. “Licensed Product” means a pharmaceutical product in finished form that contains the Compound and all present and
future formulations, dosages and dosage forms thereof. 
 1.95. “Licensed Rights” has the meaning set forth in
Section 2.1. 
 1.96. “Licensed Territory” means worldwide, subject to the
Co-Promotion Rights in the U.S. 
 1.97. “Litigation Conditions” has the meaning
set forth in Section 14.3.1. 
 1.98. “Major Market Countries” means Australia, Canada, China, France, Germany,
Italy, Japan, Spain, the United Kingdom and the U.S. 
 1.99. “Manufacturing Plan” has the meaning set forth in
Section 3.4.1. 
 1.100. “Marketing Approval” means, with respect to a particular country or regulatory
jurisdiction, the registrations, authorizations and approvals of the applicable Regulatory Authority or Governmental Authority in such country or regulatory jurisdiction (including, but not limited to, the EMA) that are necessary to market and sell
a Licensed Product in such country or regulatory jurisdiction (e.g., a Marketing Authorization in the EMA) with respect to such Licensed Product in such country or region. 

1.101. “Medical Affairs Representative” means a non-field-based medical science representative responsible for responding to
unsolicited requests for medical information and otherwise engaging in the exchange of scientific information with healthcare stakeholders regarding Licensed Products. 

1.102. “Medical Science Liaison” means a field-based medical science representative responsible for responding to unsolicited
requests for medical information and otherwise engaging in the exchange of scientific information with healthcare stakeholders regarding Licensed Products. 

1.103. “Myelofibrosis” means the disease or condition referred to and recognized by the FDA as myelofibrosis as of the date
of this Agreement (whether or not such disease or condition continues to be known by such name in the U.S. after the date of this Agreement, and whether or not any Regulatory Authority outside of the U.S. refers to such disease or condition by that
name or another name as of or after the date of this Agreement). 

  
 9 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.104. “Net Sales” means the gross amount invoiced for sales of Licensed
Product by Baxter and/or its Affiliates or Sublicensees to Third Parties, less the following deductions from such gross amounts to the extent attributable to such Licensed Product and to the extent actually incurred, allowed, accrued or specifically
allocated: 
 (a) trade, cash and quantity discounts actually given, credits, price adjustments or allowances actually granted customers for
damaged Licensed Products, returns or rejections of Licensed Products; 
 (b) chargeback payments and rebates (or the equivalent thereof)
for the Licensed Products granted to group purchasing organizations, Third Party payors (including managed health care organizations) or federal, state/provincial, local and other governments, including their agencies, or to trade customers; 

(c) reasonable and customary freight, shipping, insurance and other transportation charges directly related to the sale of the Licensed
Products separately stated on the invoice to the Third Party; and 
 (d) sales, value added, excise taxes, tariffs and duties, and other
taxes and government charges directly related to the sale, to the extent that such items are included in the gross invoice price of the Licensed Products and actually borne by Baxter or its Affiliates, Sublicensees or distributors without
reimbursement from any Third Party (but not including taxes assessed against the income derived from such sale); 
 all as determined in
accordance with U.S. GAAP on a basis consistent with Baxter’s annual audited financial statements. 
 The Parties agree that none of:
(w) the transfer of Licensed Product between or among Baxter and its Affiliates and Sublicensees for resale (which resale will give rise to Net Sales), (x) use of Licensed Product in a preclinical or Clinical Trial, (y) use of
Licensed Product as free marketing samples or (z) the transfer of Licensed Product by Baxter and/or its Affiliates to a Third Party in connection with the sale or donations for charitable, compassionate use or expanded access program purposes
will be considered a sale for purposes of calculating any amounts due to CTI hereunder. 
 Upon the sale or other transfer of a Licensed
Product, such sale or transfer will be deemed to constitute a sale with the consideration for the sale being the consideration for the relevant transaction and constituting Net Sales hereunder, or if the consideration is not a monetary amount, a
sale will be deemed to have occurred for a price assessed on the value of whatever consideration has been provided in exchange for the sale. Disposal of a Licensed Product for or use of a Licensed Product in Clinical Trials or as free samples will
not give rise to any deemed sale under this definition. For clarity, there will be no limit on the quantity of Licensed Products which may be used in Clinical Trials but the quantity of Licensed Products to be given away as free samples will be such
quantities customary in the industry for this sort of Licensed Product. Such amounts will be determined from the books and records of Baxter, its Affiliates and Sublicensees maintained in accordance with U.S. GAAP, consistently applied throughout
the organization. 

  
 10 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 In the event a Licensed Product is sold in a finished dosage form containing the Compound in
combination with one or more other Independently Active Pharmaceutical Ingredients (a “Combination Product”), Net Sales, for purposes of determining royalty payments under Section 9.3 on such Licensed Product, will be
calculated by multiplying the Net Sales of the end user product by the fraction A over A+B, in which A is the net selling price of the Licensed Product portion of the Combination Product when such Licensed Products is sold separately during the
applicable accounting period in which the sales of the Combination Product were made, and B is the net selling price of the other Independently Active Pharmaceutical Ingredients of the Combination Product sold separately during the accounting period
in question. All net selling prices of the Licensed Product portion of the Combination Product and of the other Independently Active Pharmaceutical Ingredients of such Combination Product will be calculated as the average net selling price of the
said ingredients during the applicable accounting period for which the Net Sales are being calculated in the particular country where the Combination Product is sold. In the event that, in any country or countries, no separate sale of either such
above designated Licensed Product or such above designated other Independently Active Pharmaceutical Ingredients of the Combination Product are made during the accounting period in which the sale was made or if the net retail selling price for an
Independently Active Pharmaceutical Ingredient cannot be determined for an accounting period, Net Sales allocable to the Licensed Product in each such country will be determined by mutual agreement reached in good faith by Baxter and CTI prior to
the end of the accounting period in question based on an equitable method of determining same that takes into account, on a country by country basis, variations in potency, the relative contribution of the Compound and each other Independently
Active Pharmaceutical Ingredient in the combination, and relative value to the end user of the Compound and each such other Independently Active Pharmaceutical Ingredient. Baxter and CTI agree that, for purposes of this paragraph, drug delivery
vehicles, devices, adjuvants, half-life extenders, solubilizers and excipients will not be deemed to be Independently Active Pharmaceutical Ingredients. 

1.105. “Operating Profit or Loss” has the meaning set forth in Exhibit 1.34. 

1.106. “Other Joint Invention” has the meaning set forth in Section 10.4.2. 

1.107. “Other Joint Patents” has the meaning set forth in Section 10.4.2. 

1.108. “Outside Contractor” means any Person, other than a Sublicensee, contracted by a Party to provide products or services
relating to the performance of such Party’s obligations under this Agreement, including without limitation CMOs and clinical research service providers. 

  
 11 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.109. “Pacritinib Citrate” means the citrate salt of
11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene, the chemical structure of which is shown in Exhibit 1.26 attached hereto. 

1.110. “Patent” means (a) unexpired and currently in-force letters patent (or
other equivalent legal instrument), including without limitation utility and design patents, and including without limitation any extension, substitution, registration, confirmation, reissue, re-examination or
renewal thereof, (b) applications for letters patent, a reissue application, a continuation application, a continuation-in-part application, a divisional
application or any equivalent of the foregoing applications, that are pending at any time during the term of this Agreement before a government patent authority and (c) all foreign or international equivalents of any of the foregoing in any
country. 
 1.111. “Patent Term Extensions” has the meaning set forth in Section 10.8. 

1.112. “Paying Party” has the meaning set forth in Section 9.8. 

1.113. “PERSIST-1” means the Clinical Trial entitled “A Randomized Controlled Phase 3 Study of Oral Pacritinib versus
Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis,” CTI Protocol
# PAC325, registered under EUDRA CT 2012-004239-21 and IND 78,406. 

1.114. “PERSIST-2” means the Clinical Trial entitled “A Randomized Controlled Phase 3 Study of Oral Pacritinib versus
Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia
Myelofibrosis,” CTI Protocol # PAC326, registered under EUDRA CT 2013-004000-19 and IND 78,406. 

1.115. “Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint
venture, Governmental Authority, association or other entity. 
 1.116. “Pharmacovigilance Agreement” has the meaning set
forth in Section 7.5.2. 
 1.117. “Phase 3 Clinical Trial” means a Clinical Trial as defined in 21 C.F.R.
312.21(c), as may be amended from time to time, or the equivalent thereto in any jurisdiction other than the U.S. in the Licensed Territory. 

1.118. “Post-Marketing Approval Study” means any Clinical Trial conducted following receipt of Marketing Approval of a
Licensed Product in the applicable country or region, carried out for purposes of conducting safety surveillance, ongoing technical support of the Licensed Product, market access, or line extensions of existing approved indications but expressly
excluding: (a) any safety registries mandated as a condition to the granting of any Marketing Approval and (b) any Investigator-Sponsored Trials. 

  
 12 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.119. “Preferred Stock” has the meaning set forth in
Section 9.1.2. 
 1.120. “Principal Market” has the meaning set forth in Section 12.2.17. 

1.121. “Product Infringement” has the meaning set forth in Section 10.5.2(a). 

1.122. “Profit & Loss Share” has the meaning set forth in Section 9.4.10. 

1.123. “Promote” means those activities, including without limitation Detailing and distributing samples of a product,
normally undertaken by a pharmaceutical company’s sales force in accordance with applicable Laws to implement marketing plans and strategies aimed at encouraging the appropriate use of a particular prescription pharmaceutical product. When used
as a verb, “Promote” shall mean to engage in such activities. “Promotion” and “Promotional” have correlative meanings. 

1.124. “Prosecuting Party” has the meaning set forth in Section 10.4.2. 

1.125. “Publications” has the meaning set forth in Section 13.1.3. 

1.126. “Quality” has the meaning set forth in Section 8.4. 

1.127. “Quality Agreement” has the meaning set forth in Section 8.4. 

1.128. “Recall” means the removal or correction of a marketed product that the FDA or other Regulatory Authority considers to
be in violation of the laws it administers and against which the agency would initiate legal action (e.g., seizure). A Recall may be conducted on a firm’s own initiative, by FDA or other Regulatory Authority request, or by FDA or other
Regulatory Authority order under statutory authority. The words ‘Recalled,’ ‘Recalling,’ etc., shall have correlative meanings. 

1.129. “Recall Costs” means all out-of-pocket
expenses directly relating to or arising out of compliance with any order of a Regulatory Authority for a Recall, Withdrawal or Field Correction and out-of-pocket
expenses incurred by either Party relative to notification, shipping, disposal and return of the Recalled or Withdrawn product and the notification and correction of any product subject to a Field Correction. 

1.130. “Recipient Party” has the meaning set forth in Section 9.8. 

1.131. “Registration Directed” means, with respect to a Clinical Trial, a Clinical Trial that is intended to serve as the
basis for an application for Marketing Approval in the U.S. or the EU and would be successful if such Clinical Trial meets its primary endpoint or co-primary endpoints, as applicable. 

  
 13 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.132. “Registration Rights Agreement” means the agreement attached hereto
substantially in the form of Exhibit 1.132. 
 1.133. “Regulatory Approval” has the meaning set forth in the
definition of Regulatory Filings. 
 1.134. “Regulatory Authority” means any national,
supra-national, regional, state or local regulatory authority, department, bureau, commission, council or other Governmental Authority in such country (including, but not limited to, the FDA and EMA) that is
responsible for overseeing the development (including the conduct of Clinical Trials), manufacture, distribution, importation, exportation, transport, storage, marketing, Promotion, offer for sale, use or sale of the Compound, Drug Product and/or
Licensed Product. 
 1.135. “Regulatory Exclusivity” means any rights or protections which are recognized, afforded or
granted by any Regulatory Authority in any country or region of the Licensed Territory in association with the Marketing Approval of the Licensed Product, providing such Licensed Product: (a) a period of marketing exclusivity during which the
applicable Regulatory Authority shall refrain from either reviewing or approving a Marketing Approval application or similar regulatory submission submitted by a Third Party seeking to market a competing product, or (b) a period of data
exclusivity during which a Third Party seeking to market a competing product is precluded from either referencing or relying upon, without an express right of reference from the dossier holder, such Licensed Product’s clinical dossier or
relying on previous Regulatory Authority findings of safety or effectiveness with respect to such Licensed Product to support the submission, review or approval of a Marketing Approval application or similar regulatory submission before the
applicable Regulatory Authority. Regulatory Exclusivity shall include rights conferred in the European Union pursuant to Section 10.1(a)(iii) of Directive 2001/EC/83. 

1.136. “Regulatory Filings” means any Drug Approval Application and any application for Reimbursement Approval, notification
or other submission made to or with a Regulatory Authority that is necessary or reasonably desirable to Develop, manufacture or Commercialize the Licensed Product in the Licensed Field in a particular country or regulatory jurisdiction, whether made
before or after receipt of Marketing Approval in the country or regulatory jurisdiction, and any approval resulting from any such application is a “Regulatory Approval”. The term ‘Regulatory Filings’ shall include all
amendments and supplements to any of the foregoing and all proposed labels, labeling, package inserts, monographs and packaging for a Licensed Product in a particular country. 

1.137. “Regulatory Role” has the meaning set forth in Section 6.1. 

1.138. “Reimbursement Approval” means with respect to a particular country or regulatory jurisdiction, any pricing and
reimbursement approvals of the applicable Regulatory Authority or Governmental Authority in such country or regulatory jurisdiction that are necessary or of material use in order to Commercialize a Licensed Product in such country or region at the
relevant time. 

  
 14 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.139. “Rest of World” or “ROW” means the Baxter Exclusive
Territory, excluding the EU, Canada and Switzerland. 
 1.140. “Royalty Term” has the meaning set forth in
Section 9.3.3. 
 1.141. “Sales Milestone” has the meaning set forth in Section 9.2.2. 

1.142. “Sales Report” means with respect to each Calendar Quarter a report detailing 

(a) the relevant gross amounts invoiced or billed in each local currency by Baxter or its Affiliates or Sublicensees to Third Parties,
including wholesalers, hospitals or other intermediate Third Parties, indicating the breakdown of sales by each type of the Licensed Product; 

(b) the deductions from gross amounts invoiced or billed used to calculate Net Sales; 

(c) the Net Sales in each local currency; 

(d) the Bloomberg exchange rates and dates used; and 

(e) the sum of royalties due pursuant to Section 9.3. 

1.143. “Sales Representative” means a field-based sales representative charged with Detailing targeted healthcare stakeholder
regarding Licensed Products. 
 1.144. “S*BIO Agreement” means the Asset Purchase Agreement dated May 31, 2012,
between S*BIO Pte Ltd. (“S*BIO”) and CTI, as amended from time to time. 
 1.145. “SEC” has the meaning
set forth in Section 12.2.12. 
 1.146. “Securities” has the meaning set forth in Section 9.1.2. 

1.147. “Securities Act” has the meaning set forth in Section 9.1.2. 

1.148. “Sole Inventions” has the meaning set forth in Section 10.2. 

1.149. “Subject Country” has the meaning set forth in Section 7.1.4. 

1.150. “Subject Patents” has the meaning set forth in Section 10.4.1. 

1.151. “Sublicensee” means, with respect to Baxter, any Affiliate or Third Party to which Baxter sublicenses the Licensed
Rights and, with respect to CTI, any Affiliate or Third Party to which CTI sublicenses the rights granted under Section 2.2. 

  
 15 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.152. “Supply Agreement” means a Manufacturing and Supply Agreement between
CTI and Baxter pursuant to which CTI will, by itself or through one or more Third Party CMOs selected by CTI and reasonably acceptable to Baxter, supply to Baxter its requirements of Licensed Product (or, if Baxter exercises its Fill/Finish Option,
Drug Product) for sale and distribution in the Licensed Territory. 
 1.153. “Supply Cap” means, for Calendar Year 2014 the
following price per capsule of Pacritinib Citrate in Drug Product form, which price shall be increased at the beginning of each subsequent Calendar Year over the prior year amount by the percentage increase of the Consumer Price Index-All Urban Consumers during the prior year or, for applicable European countries, by the percentage increase in the Harmonized Indices of Consumer Prices: 

 

					
	 Volume (number of capsules)
	  	Price Per Capsule	 
	 **
	  	 	*	* 
	 **
	  	 	*	* 
	 **
	  	 	*	* 
	 **
	  	 	*	* 

 For the avoidance of doubt, the prices are not incremental. That is, if Baxter purchases ** capsules in a calendar year, the
maximum supply price (excluding packaging) is ** (subject to the annual adjustment noted above). Should any backup supplier (as agreed by the JMC and/or the JSC) materially increase the expected cost per capsule, then the Parties shall negotiate in
good faith to modify the Supply Cap to reflect the additional costs of such backup supplier. 
 1.154. “Supply Failure”
shall have the meaning set forth in the Supply Agreement. 
 1.155. “Target Product Profile” or “TPP”
means the written document with respect to a Licensed Product that: (a) specifies the labeling concepts that are the ‘base case’ goals of the Development program, (b) documents the specific studies intended to support the
labeling concepts for such Licensed Product, and (c) forms the basis for a constructive dialogue with the FDA or EMA. The Target Product Profile sets forth the preferred version of what is requested to be claimed in labeling for such Licensed
Product which then guide the design, conduct, and analysis of Clinical Trials to maximize the efficiency of the Development of such Licensed Product. The TPP shall be determined on an Indication-by-Indication basis by the JDC. It is expected but not
certain that the final version of the TPP would be similar in content to the annotated draft labeling submitted with a new drug application or biologics license application; provided, however, that there shall be no consequences
hereunder if the labeling meets at least the foregoing minimum acceptable labeling. The Parties acknowledge that the TPP attached hereto as part of the Exhibit 1.54 does not contain the ‘minimum acceptable labeling’ for the Licensed
Product. The Parties shall, no later than March 31, 2015, agree on and document the minimum acceptable labeling which shall then become a part of the TPP and shall be incorporated therein; provided, however, that in developing
such ‘minimum acceptable labeling’, Section 3.1.6.3(a) shall not apply. 

  
 16 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 1.156. “Term” has the meaning set forth in Section 15.1. 

1.157. “Third Party” means any Person other than CTI and Baxter and their respective Affiliates. 

1.158. “Trademark Infringement” has the meaning set forth in Section 11.2.5. 

1.159. “Upfront Fee” has the meaning set forth in Section 9.1.1. 

1.160. “Upstream Agreement” means each agreement existing as of the Effective Date under which CTI obtains or has obtained a
license or other right from a Third Party to Develop, make, use, sell, offer for sale or import the Compound, Drug Product and/or Licensed Product in the Licensed Territory, but excluding Clinical Trial agreements, material transfer agreements, or
other agreements which do not grant material rights with respect to the Licensed Rights. Exhibit 1.160 sets forth a true and complete list of all Upstream Agreements. 

1.161. “U.S.” means the United States of America, its territories and possessions. 

1.162. “U.S. GAAP” means U.S. Generally Accepted Accounting Principles. 

1.163. “USD” means U.S. Dollar. 

1.164. “Valid Claim” means any claim within a pending, allowed or issued U.S. Patent application or Patent or pending,
accepted or issued Patent application or Patent in a jurisdiction outside the U.S. that has not expired, lapsed, been cancelled or abandoned, or been held unenforceable, invalid, or cancelled by a court of competent jurisdiction in an order or
decision from which no appeal has been or can be taken. For purposes of this definition, a “pending” Patent application will include any such Patent application that has been pending for seven (7) or fewer years in the case of U.S.
Patent applications or eight (8) or fewer years in the case of all other Patent applications. 
 1.165. “Withdrawal”
means a removal or correction of a distributed product which involves a minor violation that would not be subject to legal action by the FDA or other Regulatory Authority, or which involves no violation of a Law. The words ‘withdrawn’
‘withdrawing’, etc. shall have correlative meanings. 
 1.166. “Withholding Taxes” has the meaning set forth in
Section 9.8. 
 ARTICLE II. 

GRANT OF LICENSES 
 2.1.
License to Baxter. Subject to the terms and conditions of this Agreement, CTI hereby grants to Baxter, and Baxter accepts, an exclusive (even as to CTI, except as provided in Section 2.3 and Section 2.7), royalty-bearing, non-transferable (except pursuant to Section 16.1) right and license under CTI Know-How and CTI Patents,
with the right, subject to Section 2.4, to 

  
 17 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
grant sublicenses through multiple tiers of Sublicensees, to research, Develop, make, have made, import, export, use, sell, offer for sale, have sold and otherwise Commercialize Licensed Products
in the Licensed Field in the Licensed Territory (the “Licensed Rights”). Notwithstanding the foregoing, Baxter shall not have the right to exercise its right to “make or have made” with respect to the Licensed Product (or,
if Baxter exercises its Fill/Finish Option, Drug Product) unless there has been a Supply Failure. 
 2.2. License to CTI. Subject to
the terms and conditions of this Agreement, Baxter hereby grants to CTI, and CTI accepts, a non-exclusive, royalty-free,
non-transferable (except pursuant to Section 16.1 and for sublicenses to Affiliates ), non-sublicensable right and license under Baxter Know-How and Baxter Patents to: (a) research, Develop, import, export and use, in the Licensed Field in the Licensed Territory as contemplated under the Development Plan, as amended in accordance herewith, and
as contemplated under Section 4.1, (b) manufacture and have manufactured the Licensed Product in the Licensed Territory to fulfill its obligations under the Supply Agreement and (c) import, sell, offer for sale, have sold and
otherwise directly Commercialize Licensed Products in the Co-Promotion Territory. 
 2.3. CTI
Reservation of Rights. CTI hereby retains the right under the CTI Patents and CTI Know-How to (a) conduct research and Development activities with respect to the Licensed Products in the Licensed
Territory as contemplated under the Development Plan and as contemplated under Section 4.1, (b) subject to: (i) the rights granted to Baxter to manufacture or have manufactured Licensed Products and/or Drug Product in the event
of a Supply Failure and (ii) Baxter’s exercise of its option to perform the final packaging pursuant to Section 8.3, manufacture and have manufactured Licensed Product and/or Drug Product (as applicable) in the Licensed
Territory to fulfill its obligations under the Supply Agreement and (c) exercise the Co-Promotion Rights set forth in Section 2.7. 

2.4. Sublicenses. Baxter shall have the right to sublicense its rights under Section 2.1 to its Affiliates and, excluding
the Co-Promotion Territory, to Third Parties; provided that if Baxter proposes to grant a sublicense to a Third Party granting the Third Party the right to Commercialize the Licensed Product in a Major Market Country in the Baxter Exclusive
Territory, Baxter shall provide CTI with written notice of such sublicense at least thirty (30) days in advance of executing such sublicense, which notice shall include a reasonable level of detail regarding the terms of the proposed
sublicense, and CTI shall have the right to approve or reject such sublicense (such approval not to be unreasonably withheld). Each agreement between Baxter and a Sublicensee (a) shall be in writing and subject and subordinate to, and
consistent with, the terms and conditions of this Agreement; (b) shall not diminish, reduce or eliminate any of Baxter’s obligations under this Agreement; (c) shall require the Sublicensee(s) to comply with all applicable terms of
this Agreement (except for payment obligations, for which Baxter shall remain financially responsible); and (d) shall prohibit further sublicensing except on terms consistent with this Section 2.4. Baxter shall provide written
notice to CTI of any agreement entered into with a Sublicensee, and shall provide a complete copy of such agreement to CTI within thirty (30) days of its execution, which copy may be redacted by Baxter to the extent that such redactions do not
reasonably impair CTI’s ability to ensure compliance with this 

  
 18 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Agreement. Baxter shall be responsible for the performance of each Sublicensee and shall ensure that each Sublicensee complies with all relevant provisions of this Agreement. In the case of any
such Sublicense **, Baxter shall pay to CTI ** an amount equal to ** of any Sublicensee fee, upfront license fee or milestone (whether regulatory, based on sales or otherwise) or other payment related to such Sublicense not based on a royalty on net
sales paid to Baxter by or on behalf of such Sublicensee, it being understood that if such payment is made in a form other than in cash, the Parties shall use good faith reasonable efforts to agree on the fair market value thereof and the cash
equivalent shall be paid to CTI. 
 2.5. No Other Licenses. Neither Party grants to the other Party any rights, licenses or covenants
in or to any intellectual property, whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement or the Supply Agreement. Notwithstanding anything to the contrary herein, neither Party
grants to the other Party any license or other right to manufacture, Develop or Commercialize any active ingredients other than the Compound, including without limitation any method of making any active ingredients other than the Compound, any
composition or formulations of any active ingredients other than the Compound, or any method of using or administering any active ingredients other than the Compound. 

2.6. Controlled IP. Subject to Section 9.3.2, if, after the Effective Date, either Party enters into an agreement or other
arrangement to obtain a license or other rights to or under Information or Patents that are owned or controlled by a Third Party and that would, solely but for the operation of subsection (b) of the definition of Control, in the case of CTI be
included in the CTI Information or CTI Patents or, in the case of Baxter, be included in the Baxter Information or Baxter Patents, then the Party obtaining such license or rights shall promptly notify the other Party and shall specify in such notice
the type and amount of payments that would be due to such Third Party by reason of the practice or use of, or access to, such Information or Patents by the other Party pursuant to the license set forth in Section 2.1 or
Section 2.2, as applicable (but not by reason of the practice or use of, or access to, such Information or Patents outside the scope of such license). The Party receiving such notice may elect in writing to bear the responsibility for
such additional payments, and upon such receiving Party’s written election to bear such responsibility, the Information or Patents as applicable, shall thereafter be deemed “Controlled” by the Party originally obtaining such license
or rights (notwithstanding subsection (b) of the definition of Control), and shall be subject to the license under Section 2.1 or 2.2, as applicable. 

2.7. Co-Promotion. CTI hereby retains the co-exclusive
right (with Baxter) under the CTI Know-How and CTI Patents, and Baxter hereby grants to CTI, the co-exclusive right (with Baxter) under the Baxter Know-How and Baxter Patents, to Promote the Licensed Products in the Co-Promotion Territory, in accordance with the terms and conditions of the
Co-Promotion Terms attached hereto as Exhibit 1.34, the Commercialization Plan and Section 7.2. It is anticipated that at an appropriate time following the Effective Date, the Parties will
enter into a separate agreement (a “Co-Promotion Agreement”) that more precisely details the Co-Promotion activities of the Parties in the Co-Promotion Territory and this Agreement shall be appropriately


  
 19 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
amended to defer all Co-Promotion matters to the Co-Promotion Agreement. Unless otherwise mutually agreed by the Parties, the Co-Promotion Agreement shall be consistent with the terms of this
Agreement and the Co-Promotion Terms. 
 2.8. Subcontracting. Baxter acknowledges that in connection with CTI’s obligations to
perform the Development of the Licensed Product and to manufacture and supply Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product) to Baxter pursuant to the Supply Agreement, CTI may need to use certain Outside
Contractors; provided, however, that CTI shall notify Baxter in writing prior to engaging any Outside Contractor for any material activities (excluding activities conducted under Clinical Trial agreements and other less significant agreements) for
which it is obligated under this Agreement and each agreement with an Outside Contractor: (a) shall be in writing and be consistent with the terms and conditions of this Agreement; (b) shall not diminish, reduce or eliminate any of
CTI’s obligations under this Agreement; (c) shall require the Outside Contractor to comply with all applicable terms of this Agreement (except for payment obligations, for which CTI shall remain financially responsible); and (d) shall
prohibit further subcontracting. For the avoidance of doubt, CTI may not subcontract its Co-Promotion Rights in the Co-Promotion Territory. 

ARTICLE III. 
 GOVERNANCE

 3.1. General Committee Procedures. 

3.1.1. Authority. Each Committee shall have the responsibilities and authority allocated to it in this Article III and elsewhere
in this Agreement. The following procedures shall apply to the Committees under this Agreement. 
 3.1.2. Composition. Within **
after the Effective Date, each Party shall appoint ** of its employees to serve on the JSC and ** employees to the JDC. Within ** after the effective date of the Supply Agreement, each Party shall appoint ** of its employees to serve on the JMC, and
at least ** prior to filing any application for Marketing Approval, each Party shall appoint ** of its employees to serve on the JCC. Each Party may replace its representatives to the JSC by written notice to the other Party. Each Party may replace
representatives of Committees at their own discretion. 
 3.1.3. Chairperson; Qualifications. For the JSC initial meeting, the
chairperson shall be appointed by CTI, and thereafter shall alternate between the Parties annually. The chairperson will be responsible for calling meetings and, after seeking input from the other Party, setting the agenda (which shall include a
list of all participants expected at a meeting) and circulating such agenda at least ** prior to each meeting and distributing minutes of the meetings within ** following such meeting, but will not otherwise have any greater power or authority than
any other member of the JSC. The Committee members of the JDC, JMC and JCC shall have such expertise as appropriate to the activities of the Committee from time to time, and the Committee may invite personnel of the Parties having non-clinical safety and animal pharmacology, pharmaceutical development, clinical, biostatistical, regulatory affairs, 

  
 20 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
pharmacovigilance, formulation, manufacturing, commercial, marketing, legal and other expertise to participate in discussions of the Committee from time to time as appropriate to assist in the
activities of the Committee. 
 3.1.4. Meetings. The JSC and each Committee shall, after appointment of its initial members, meet at
least once every ** at times mutually agreed upon by the Parties. At least two (2) meetings each year shall be held in person. The location of the meetings of the Committee to be held in person shall be agreed upon by the Parties (with the
intent that it should alternate between the Parties’ respective headquarters locations and/or be held at the time and sites of major medical conferences attended by both Parties such as ASH annually in December, EHA annually in June and ASCO
annually in June). Each Party shall use reasonable efforts to cause its representatives to attend the meetings of the Committee. If a representative of a Party is unable to attend a meeting, such Party may designate an alternate to attend such
meeting in place of the absent representative. Each Party shall bear all the expenses of its representatives on the Committee. 
 3.1.5.
Minutes. The minutes of each Committee meeting shall be distributed to the members within ** after the completion of the relevant Committee meeting and shall provide a description in reasonable detail of the discussions held at the meeting
and a list of any actions, decisions or determinations approved by the Committee. Minutes of each Committee meeting shall be approved or disapproved, and revised as necessary, within ** after the applicable Committee meeting. 

3.1.6. Matter Resolution; Escalation. 

3.1.6.1 Each Party shall have one (1) vote on all matters that are within the responsibility of a Committee, regardless
of the number of such Party’s representatives on such Committee. The members of each Committee will use best reasonable efforts to reach unanimous consensus on all decisions. 

3.1.6.2 In the event that the members of the JDC, JCC or the JMC are unable to reach consensus on a particular issue within **
after such issue is first presented to the JDC, JCC or the JMC (as applicable), such issue shall be referred to the JSC. If the members of the JSC are unable to reach consensus on a particular issue (including any payments or amounts due from one
Party to the other) within ** after such issue is first presented to the JSC, such issue shall be referred to an executive officer of each Party or their designees selected for such purpose and notified to other Party (the “Executive
Officers”) for resolution. Each Party shall use good faith efforts to resolve issues at the lowest level possible within the governance structure established by this Article III and, notwithstanding the escalation procedures set
forth herein, to limit any such escalations. 
 3.1.6.3 If the Executive Officers are unable to resolve such issue within **
after such issue is referred to them, then the following will control: **. 

  
 21 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 3.1.6.4 In the event an issue arises which is not covered by the foregoing,
including without limitation the fulfilling of the obligation to use Commercially Reasonable Efforts in any respect, either Executive Officer may invoke the dispute resolution provisions of Section 16.13. 

3.1.6.5 For the avoidance of doubt, no Committee shall have the power to amend or waive compliance with this Agreement nor,
without the consent of the affected Party, to materially increase or reduce the obligations of the Parties under this Agreement. 
 3.2.
Joint Steering Committee. The JSC shall have the responsibility for the overall strategic and operational direction of the Parties’ collaboration under this Agreement and shall have the authority (but not the obligation) in connection
therewith, to establish certain sub-Committees or other Committees in addition to the JDC, JCC and/or JMC. The JSC shall have responsibility for overseeing the activities of the JDC, JCC, JMC and any
additional sub-Committees established during the course of this Agreement (with all JSC responsibilities subject to the JDC, JCC and JMC governance provisions included in Section 3.1.6). The
JSC’s responsibilities shall also include: 
 3.2.1. reviewing and evaluating progress under the Development Plan and the Manufacturing
Plan; 
 3.2.2. reviewing and approving each Development Plan, Manufacturing Plan and Commercialization Plan, including amendments thereto,
submitted by the JDC, JMC and JCC (with such approvals subject to the JDC, JCC and JMC governance provisions included in Section 3.1.6); 

3.2.3. identifying, prioritizing and approving Additional Indications for the Licensed Product beyond the Initial Indication; and 

3.2.4. appointing additional Committees and sub-Committees as desired, such Committees and sub-Committees to have equal representation from the Parties and subject to governance by the JSC (such committees would be sub-committees of either the JDC, JCC or JMC and would be subject to the JDC, JCC and JMC
governance provisions included in Section 3.1.6). 
 3.3. Joint Development Committee. The JDC shall oversee and direct
the Development and regulatory strategy of the Licensed Product in the Licensed Field in the Licensed Territory, and shall coordinate communications among the Parties and the exchange of Information regarding the Development and regulatory
activities pursuant to the Agreement. The JDC’s responsibilities shall include: 
 3.3.1. discussing, preparing and approving for
submission to the JSC the Development Plan for each Licensed Product in the Licensed Territory, including any amendments thereto (subject to the JDC governance provisions included in Section 3.1.6); 

  
 22 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 3.3.2. discussing, preparing and approving for submission to the JSC budgets for the
activities contemplated by the Development Plan, as amended, including without limitation the CTI Development Cost Budget (which shall be deemed part of the Development Plan, as amended) (subject to the JDC governance provisions included in
Section 3.1.6); 
 3.3.3. overseeing implementation of each Development Plan, including monitoring progress of preclinical,
pharmaceutical and clinical studies of the Licensed Product, proposing additional studies for the Licensed Product, and reviewing and commenting on regulatory submissions in the Licensed Territory relating to the Licensed Product; 

3.3.4. reviewing and commenting on worldwide publication strategy with respect to the Compound, Drug Product and/or Licensed Product; 

3.3.5. establishing procedures regarding the collection, sharing and reporting of Adverse Event information related to the Licensed Products
consistent with the Pharmacovigilance Agreement to be entered into in accordance with the terms of Section 7.5 and reviewing and assessing compliance therewith; 

3.3.6. evaluating and establishing the patent prosecution and maintenance strategy together with appropriate legal counsel for each Party;

 3.3.7. coordinate and confer concerning Investigator-Sponsored Trials; 

3.3.8. coordinate and confer concerning Regulatory Filings by the Parties as provided in Article VI, including establishing procedures
for preparing, coordinating and approving such Regulatory Filings which shall be based to the extent reasonably possible on Baxter’s templates and processes; 

3.3.9. overseeing and coordinating the Parties’ activities regarding medical and scientific affairs under Section 7.6; and

 3.3.10. performing such other functions as appropriate to further the purposes of this Agreement, as directed by the JSC (for the
avoidance of doubt, all JDC responsibilities included in this Section 3.3 are subject to the governance provisions included in Section 3.1.6). 

3.4. Joint Manufacturing Committee. The JMC shall oversee and direct the manufacturing strategy of the Licensed Products in the
Licensed Field in the Licensed Territory, and shall coordinate communications among the Parties and the exchange of Information regarding the manufacturing activities pursuant to this Agreement as further specified in Article VIII. The
JMC’s responsibilities shall include: 
 3.4.1. discussing, preparing and approving for submission to the JSC a manufacturing plan for
each Licensed Product in the Licensed Territory, including any amendments thereto (each, a “Manufacturing Plan”); 

  
 23 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 3.4.2. overseeing implementation of each Manufacturing Plan; 

3.4.3. meeting, discussing and using good faith efforts to resolve issues which arise with respect to manufacturing due to circumstances out
of the control of the Parties (e.g. implementation of regional or global directives or regulations of Governmental Authorities which require changes to the manufacturing process or specifications for the Licensed Product) or the occurrence of any
Force Majeure event, including without limitation changes to be made to either the supply timelines and/or Supply Cap, as necessary or appropriate; and 

3.4.4. performing such other functions as appropriate to further the purposes of this Agreement, as directed by the JSC (for the avoidance of
doubt, all JMC responsibilities included in this Section 3.4 are subject to the governance provisions included in Section 3.1.6). 

3.5. Joint Commercialization Committee. The JCC shall oversee and direct the Commercialization strategy for the Licensed Products in
the Licensed Field in the Licensed Territory, taking into consideration CTI’s Co-Promotion Rights, and shall coordinate communications among the Parties and the exchange of Information regarding the
Commercialization activities pursuant to this Agreement as further specified in Article VII. The JCC’s responsibilities shall include: 

3.5.1. discussing and reviewing the Commercialization Plans prepared by Baxter and amendments thereto; 

3.5.2. overseeing implementation of each Commercialization Plan (including discussion and implementation of approaches to minimize the risk of
enforcement actions by Regulatory Authorities in connection with the Promotion of the Licensed Product); 
 3.5.3. discussing and preparing
amendments to the Co-Promotion Terms (or, if a separate Co-Promotion Agreement is executed by the Parties, discussing and preparing amendments to the Co-Promotion Agreement); 

3.5.4. assessing performance on each Commercialization Plan, including forecasting relevant matters including without limitation sales and
expenses, and assessing the accuracy of such forecasts; 
 3.5.5. coordinating branding on a global basis for Licensed Products; 

3.5.6. discussing and submitting to the JSC for approval, Third Party vendors to be engaged to perform marketing research and other marketing
services; and 
 3.5.7. performing such other functions as appropriate to further the purposes of this Agreement, as directed by the JSC
(for the avoidance of doubt, all JCC responsibilities included in this Section 3.5 are subject to the governance provisions included in Section 3.1.6). 

  
 24 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 3.6. Alliance Managers. Promptly after the Effective Date, each Party shall appoint an
individual to act as alliance manager for such Party, which may be one of the representatives of such Party on the JSC (each, an “Alliance Manager”). The Alliance Managers shall be the primary point of contact for the Parties
regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder. The Alliance Managers shall attend all meetings of the JSC and shall be responsible for assisting the JSC in performing its oversight
responsibilities. The name and contact information for each Party’s Alliance Manager, as well as any replacement(s) chosen by such Party, in its sole discretion, from time to time, shall be promptly provided to the other Party in accordance
with Section 16.4. 
 ARTICLE IV. 

DEVELOPMENT RESPONSIBILITIES 

4.1. Development Obligations. 

4.1.1. CTI shall, subject to the oversight of the JSC, use its Commercially Reasonable Efforts to direct, coordinate and manage the
Development of Licensed Products for the Initial Indication and Additional Indications in accordance with this Agreement and the Development Plan (as such may be amended from time to time). Through the JDC and/or the JSC, each Party shall have the
right to propose changes and additions to the Development Plan on an ongoing basis as necessary. The JSC shall have the authority to review and approve such changes and additions, provided that the Development Plan shall at all times contain
terms that are consistent with this Article IV. Each Party may suggest to the other changes and additions to the Development Plan and the other Party shall reasonably consider including such changes and additions when developing amendments to
the Development Plan in accordance with this Section 4.1. 
 4.1.2. ** The Parties shall, through the JDC, coordinate efforts to
ensure that for any Development costs and expenses incurred prior to the achievement of the CTI Development Cost Threshold (and in particular for those Development costs and expenses for Additional Indications beyond those set forth in the
Development Plan as of the Effective Date), priority shall be given to spending for the Initial Indication; provided, however, that the Parties may alter the priority if a Commercial Failure has occurred with respect to the Initial
Indication or the Parties have otherwise determined to de-prioritize the Initial Indication. 
 ARTICLE V. 

DEVELOPMENT COOPERATION 

5.1. Sharing of Development Updates and Related Information. 

5.1.1. Whenever any material event occurs in the course of the Development of a Licensed Product by either Party of which such Party becomes
aware, but in no event less than once every Calendar Quarter until such time as Marketing Approval for the Licensed Product has been obtained in each country of the Licensed Territory, such Party shall disclose to the other Party Information
regarding and resulting from all Development and Commercialization 

  
 25 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
activities with respect to the Compound, Drug Product and/or Licensed Product conducted by such Party, which Information is necessary or useful for Development or Commercialization of the
Licensed Product in the Licensed Territory, and a description of the status of such Development efforts. 
 5.1.2. Each Party shall have the
right, at no additional expense, to use all Information disclosed to it pursuant to Section 5.1.1 for the Development and Commercialization of the Licensed Product, and to grant to its Sublicensees the right to use such Information for
the Development and Commercialization of the Licensed Product, without any obligation to the other Party except as otherwise set forth in this Agreement. 

5.2. Information Sharing Coordination. The JSC shall coordinate the Parties’ sharing of Information as required under this
Agreement or under applicable Laws: 
 5.2.1. Each Party shall share with the other Party, free of charge (except for amounts becoming due
and payable to CTI pursuant to Article IX), any and all Information generated or compiled during the term of this Agreement for use in Development and Commercialization of the Licensed Product in the Licensed Territory. 

5.2.2. Baxter agrees that all Information delivered by CTI or any of its Affiliates hereunder shall, as between the Parties, at all times be
and remain sole and exclusive property of CTI or its Affiliates, respectively. 
 5.2.3. CTI agrees that all Information delivered by Baxter
or any of its Affiliates or Sublicensees hereunder shall, as between the Parties, at all times be and remain sole and exclusive property of Baxter or its Affiliates or Sublicensees, respectively. 

ARTICLE VI. 
 REGULATORY
MATTERS 
 6.1. Regulatory Roles. Subject to the obligations set forth in Article XV, the Parties shall have
responsibility for the following activities with respect to Regulatory Filings for the Licensed Product (each Party’s activities, its “Regulatory Role”): 

6.1.1. CTI will be responsible (in collaboration with Baxter through the JDC) for the creation of a global dossier (the “Global
Dossier”) that will be the basis for all Regulatory Filings in the Licensed Territory. 
 6.1.2. CTI shall (in collaboration with
Baxter through the JDC) prepare all Regulatory Filings (which shall be reviewed in a timely manner by Baxter) necessary for obtaining Marketing Approval in the name of CTI with respect to Licensed Products in the
Co-Promotion Territory for the Initial Indication, such Regulatory Filings to be based on the Global Dossier. CTI shall promptly (but in any event within ten (10) Business Days of receipt thereof) assign
such Marketing Approval to Baxter upon receipt of such Marketing Approval. In addition, CTI will transfer all the source documentation, analysis files, source program files (e.g., 

  
 26 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
SAS files, etc.), Clinical Trial master files, case report forms, validation reports, study reports and all documentation supporting the Drug Approval Application to Baxter in a reasonable
time-frame (as determined by the JSC) following receipt of Marketing Approval in the first country or geography, provided that CTI may retain copies of all of the foregoing for use in connection with its activities under this Agreement. Final
approval for all such Regulatory Filings shall be in accord with the governance provisions of Section 3.3. 
 6.1.3. CTI shall
be responsible (in coordination with Baxter through the JDC) for responding to all requests and for managing all inspections/audits from any Regulatory Authority in the Territory related to the PERSIST-1 and/or PERSIST-2 Clinical Trials until
receipt of Marketing Authorization in the applicable country. CTI shall also be responsible for implementing any commitments resulting from such inspections/audits. All costs resulting from any such inspections/audits shall be considered Development
expenses. 
 6.1.4. Baxter shall (in collaboration with CTI through the JDC) prepare all Regulatory Filings necessary for obtaining
Marketing Approvals and Reimbursement Approvals in the name of Baxter with respect to Licensed Products in the Baxter Exclusive Territory for all Additional Indications, such Regulatory Filings to be based on the Global Dossier. Further, Baxter
shall also be responsible for submitting the Regulatory Filings necessary for obtaining Marketing Approvals (as prepared by CTI based upon the Global Dossier) and Reimbursement Approvals in the name of Baxter with respect to Licensed Products in the
Baxter Exclusive Territory for the Initial Indication. Baxter may, as necessary, appoint CTI as its agent for the purposes of the foregoing in this Section 6.1.4. 

6.1.5. If at any time Reimbursement Approval becomes necessary or advisable in the Co-Promotion
Territory, the Parties shall cooperate and work together to obtain such Reimbursement Approval. 
 6.1.6. Baxter shall own and be the
license holder for all Marketing Approvals. Subject to the cost allocation provisions set forth in Section 9.4, Baxter shall be responsible for complying with all requirements of Regulatory Authorities in the Licensed Territory after
receipt of the applicable Marketing Approval(s); provided, however, that with respect to the Co-Promotion Territory, the Parties shall be jointly responsible for such compliance including the
cost thereof. 
 6.1.7. Except as set forth in Section 9.4 with respect to the filing fees for the Regulatory Filings for
Licensed Products, each Party shall bear its own costs and expenses for effecting its respective Regulatory Role. 
 6.2.
Cooperation. 
 6.2.1. The Parties will cooperate in providing technical regulatory expertise for assistance in developing the
submission strategy for Regulatory Filings and defining technical content. Each Party shall designate a global regulatory affairs representative (who shall be a member of the JDC) to represent it in connection with Regulatory Filings. Each such


  
 27 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
representative will be invited to attend critical meetings with Regulatory Authorities associated with the submission of Regulatory Filings for Licensed Products. Each Party shall provide
required support to the other through the JDC to ensure timely regulatory submissions during the review cycle for the Marketing Approval in each of the geographies/countries within the Licensed Territory and for any
Post-Marketing Approval regulatory submission on an as-needed basis. All significant regulatory correspondence will be reviewed in a timely manner by Baxter prior to
submission to the regulatory authorities in each of the geographies/countries within the Licensed Territory. Final approval for all such Regulatory Filings shall be in accord with the governance provisions of Section 3.3. 

6.2.2. Through the JDC, each Party shall have the right to review the content of all Regulatory Filings for the Licensed Product prepared by
such other Party and each Party agrees to consider in good faith the comments of the other Party with respect to each such Regulatory Filing. 

6.2.3. Each Party shall, within their respective Regulatory Roles, use Commercially Reasonable Efforts to obtain Marketing Approvals and,
where applicable, Reimbursement Approvals for the Licensed Products in the Licensed Territory. 
 6.2.4. Without limiting the foregoing,
each Party shall endeavor to keep the other Party well informed with respect to the contents of any Regulatory Filings related to the Licensed Products in the Licensed Territory and all discussions with the applicable Regulatory Authorities. 

6.2.5. CTI shall inform Baxter of all changes (including both changes in process as well as new contracts with CMOs to be entered into after
December 1, 2013) that are being considered with respect to the manufacturing process for the Licensed Product that may reasonably be expected to impact the manufacture of the Licensed Product or the Commercialization thereof, and shall obtain
Baxter’s consent (which consent shall not be unreasonably withheld, conditioned or delayed) prior to the implementation of any such manufacturing changes. 

ARTICLE VII. 
 LAUNCH AND
COMMERCIALIZATION 
 OF LICENSED PRODUCTS 

7.1. Launch and Commercialization. 

7.1.1. Baxter shall have full responsibility for and control of all Commercialization activities for the Licensed Products in the Baxter
Exclusive Territory, at Baxter’s sole cost and expense, and shall use Commercially Reasonable Efforts to market, Promote, sell and otherwise Commercialize Licensed Products in the Baxter Exclusive Territory in accordance with the terms of this
Agreement and in compliance with all applicable Laws. Notwithstanding anything to the contrary, the provisions of this Article VII are all subject to CTI’s Co-Promotion Rights pursuant to
Sections 2.7 and 7.2. 

  
 28 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 7.1.2. After receiving Marketing Approval and Reimbursement Approval of a Licensed Product
for a country in the Baxter Exclusive Territory, Baxter shall use Commercially Reasonable Efforts to market, Promote and sell the Licensed Product in such country. ** Baxter shall notify CTI promptly of the date of First Commercial Sale of a
Licensed Product in each country of the Baxter Exclusive Territory. 
 7.1.3. Baxter shall use Commercially Reasonable Efforts to
(a) launch commercially a Licensed Product in a given country as set forth in Section 7.1.2 above and (b) not withdraw a Licensed Product from sale or abandon the sale of a Licensed Product after First Commercial Sale; **. 

7.1.4. **. 
 7.1.5. In
connection with Baxter’s Commercialization Obligations, Baxter shall undertake appropriate activities related to pre-launch, launch and Commercialization of a Licensed Product, which activities may
include the development of: (a) a market access strategy including Licensed Product pricing and Reimbursement Approval, (b) a pre-launch and post-launch publication strategy and the scheduling of
targeted meetings for presentations of clinical data, (c) a product supply chain distribution strategy, (d) a patient education plan for the Licensed Products, (e) an overall sales and marketing strategy for the Licensed Product,
(f) patient support programs, (g) a physician and hospital targeting plan, and (h) a sales execution plan. At least one (1) year prior to the first anticipated approval of an application for Marketing Approval in any Major Market
Country in the Baxter Exclusive Territory, Baxter shall have prepared and delivered to the JCC a preliminary, non-binding commercialization plan documenting the activities, plans and strategies that will be
implemented to market and commercialize such Licensed Product, which shall be reviewed by the JCC. Baxter shall provide to the JCC a final, binding version of such commercialization plan (the “Commercialization Plan”) ** in the
applicable country within the Licensed Territory. The Parties shall review and discuss each version of the Commercialization Plan through the JCC, and Baxter will, in good faith, consider any changes proposed by CTI to each version of the
Commercialization Plan. Baxter shall use Commercially Reasonable Efforts to implement and execute the Commercialization Plan. The Commercialization Plan shall also cover Co-Promotion activities consistent with
the Co-Promotion Terms in order to reflect developments subsequent to the initial preparation thereof; provided, however, that no amendment to the
Co-Promotion Terms may be made without the unanimous approval of the Parties. 
 7.2.
Co-Promotion. Pursuant to the rights granted under Section 2.7, the following provisions, in addition to the Co-Promotion Terms, shall govern the Parties’ activities regarding
Commercialization of Licensed Products in the Co-Promotion Territory: 
 7.2.1. The obligations of
Baxter in Section 7.1 for the Baxter Exclusive Territory shall apply to each Party in the Co-Promotion Territory. 

  
 29 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 7.2.2. Baxter and CTI will jointly direct the training of both Parties’ Sales
Representatives for the Co-Promotion Territory (together with the first line managers who oversee such Sales Representatives) and will prepare and implement a training program and training materials for such
Sales Representatives. Both Parties will cause its Sales Representatives assigned to Promote Licensed Products to attend and complete a training program developed by Baxter and CTI for the Licensed Product in the
Co-Promotion Territory to assure a consistent, focused on-label Promotional strategy and message as and to the extent consistent with applicable Law. 

7.2.3. Each Party will be solely responsible for recruiting, hiring and maintaining its sales force of Sales Representatives for Promotion of
Licensed Products in the Co-Promotion Territory in accordance with its standard procedures and the requirements of this Agreement. Each Party will be responsible for the activities of its Sales
Representatives, including compliance by its Sales Representatives with training and Detailing requirements. In particular, each Party will provide its Sales Representatives assigned to Promote Licensed Products in the
Co-Promotion Territory with the level of oversight, management, direction and sales support with respect to the Promotion of the Licensed Product necessary to effectively and efficiently Promote Licensed
Product in accordance with the terms of this Agreement and applicable Law. If either Party or a knowledgeable Third Party, such as a health care professional or representative of a competitor, raises any concern with the other Party regarding the
performance or fitness of such other Party’s Sales Representative, such other Party will appropriately address such concerns in a manner consistent with the provisions of this Agreement, the Commercialization Plan, such Party’s policies
and procedures and applicable Law, including removal of such Field Representative from the Promotion of Licensed Products and shall inform the notifying Party of the resolution of the concern. 

7.2.4. Each Party’s Sales Representatives assigned to Promote the Licensed Product in the
Co-Promotion Territory will utilize only Promotional materials that have been approved by the JCC and Baxter’s and CTI’s promotional review committees. Neither Party, including without limitation,
their Sales Representatives, is permitted to create “home-made” promotional pieces, and each Party shall maintain policies that prohibit such activity. All Detailing activities conducted by each Party’s Sales Representatives will be
consistent in all material respects with the Promotional materials so approved. Each Party will train and instruct their respective Sales Representatives to make only those statements and claims regarding the Licensed Product, including as to
efficacy and safety, that are consistent with the Licensed Product labeling and accompanying inserts and the approved Promotional materials, as well as applicable Laws and regulations. 

7.2.5. For the purposes of cost allocation, and to the extent a Sales Representative is Detailing additional products beyond the Licensed
Product, such FTE cost will reflect the time actually spent on the Licensed Product, and not any other additional products. 
 7.2.6. If
either Party is not at any particular time able to provide, for any reason, the number of Sales Representatives specified in the Commercialization Plan, Co-Promotion Terms 

  
 30 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
or Co-Promotion Agreement (as applicable), then the other Party will have the right to make up such shortfall using its Sales Representatives until such time as such Party is able to provide its
agreed upon number of Sales Representatives, and, for clarity, appropriate costs related to such shortfall incurred by the other Party shall be included in the calculation of Operating Profit or Loss. CTI and Baxter will engage Sales Representatives
having the minimum qualifications set forth in the Co-Promotion Terms. Each Party agrees that any of its Sales Representatives conducting activities with respect to the Licensed Product will not have any legal
or regulatory disqualifications, bars or sanctions, and if a Party learns that a Sales Representative is subject to such disqualifications, bars or sanctions, such Sales Representative shall be terminated immediately (subject to applicable Law).

 7.2.7. Each Party will maintain records and otherwise establish procedures designed to ensure compliance with all applicable Laws and
professional requirements that apply to the Promotion and marketing of Licensed Product in the Co-Promotion Territory, including compliance with the PhRMA Code on Interactions with Healthcare Professionals.

 7.2.8. Each Commercialization Plan shall include a section planning and updating the Co-Promotion
activities of the Parties. 
 7.3. Coordination of Marketing Efforts. Sales and Marketing efforts within the Co-Promotion Territory will be under the direction of the JCC and subject to the principles described below: 

7.3.1. The JCC shall establish policies and procedures to ensure coordinated branding on a global basis for the Licensed Products. Each Party
shall share with the other Party free of charge any and all of marketing information in the control of the Party with respect to the Licensed Products, including without limitation, complete Promotion plans and strategies, as well as all Promotional
and sales activities and materials used for the launch and marketing of the Licensed Product in the Licensed Territory. 
 7.3.2. If
practicable, the Parties shall conduct joint, and not separate, sales training and education events such as Plan of Action meetings, annual sales meetings, and other such usual and customary commercial activities that are limited to and specific to
the Licensed Products. This section does not prohibit either Party from having independent training and education events that are not limited to and specific to the Licensed Product. For example, Baxter may continue to hold compliance training or
its annual sales meetings for its businesses and CTI personnel shall only be able to attend at the sole discretion of Baxter. Such activities shall be coordinated by the JCC. 

7.3.3. Baxter shall share with CTI free of charge any and all of marketing information in the control of Baxter with respect to the Licensed
Products, including without limitation copies of complete Promotion plans and strategies, as well as all Promotional and sales activities and materials used for the launch and marketing of the Licensed Product in the Licensed Territory, whether
generated by Baxter or its Sublicensees. All such information (other than materials used or to be used for such launch and marketing) shall be treated as Baxter Confidential Information. 

  
 31 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 7.4. Recalls. 

7.4.1. Generally. In the event that either Party: 

7.4.1.1 determines that an event, incident, or circumstance has occurred which may result in the need for a Recall,
Withdrawal, Field Correction or other removal of any Licensed Product or any lot or lots thereof from the market in the Licensed Territory; 

7.4.1.2 determines that an event, incident, or circumstance that could reasonably adversely affect the Licensed Product in the
Licensed Territory has occurred which is reasonably likely to result in the need for a Recall, Withdrawal, Field Correction or other removal of any Licensed Product, or any lot or lots thereof from the market; 

7.4.1.3 becomes aware that a Regulatory Authority is threatening or has initiated an action to remove the Licensed Product
from the market in the Licensed Territory or, if such event could reasonably adversely affect the Licensed Product in the Licensed Territory, any Regulatory Authority is threatening or has initiated an action to remove the Licensed Product from the
market; or 
 7.4.1.4 is required by any Regulatory Authority to distribute a “Dear Doctor” letter or its
equivalent regarding use of the Licensed Product in the Licensed Territory, 
 it shall promptly advise the other Party in writing with respect thereto, and
shall provide to the other Party copies of all relevant correspondence, notices, and the like in the possession or control of such Party. In such event, Baxter shall have the sole authority to determine if a Recall or other removal of the Licensed
Product is required in the Licensed Territory, and shall be responsible for conducting any such Recall, Withdrawal, Field Correction or other removal of any Licensed Product from the Licensed Territory, whether voluntary or involuntary, or taking
such other remedial action required by applicable Laws in the Licensed Territory. 
 7.4.2. CTI Assistance. At Baxter’s
reasonable request, CTI shall assist Baxter with respect to any such Recall, Withdrawal or Field Correction, and shall provide Baxter with all information that Baxter may reasonably request in connection with its dealings with a Regulatory Authority
in connection with such Recall, Withdrawal or Field Correction. 

  
 32 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 7.4.3. Recall Costs. Notwithstanding anything else contained in this Agreement to the
contrary, if a Recall, Withdrawal, Field Correction or other removal of any Licensed Product or any lot or lots thereof from the market in the Licensed Territory: 

7.4.3.1 results solely from a breach by CTI or its Affiliates or agents of the terms of this Agreement or the Supply
Agreement, then CTI shall bear all Recall Costs and shall bear all costs for any assistance provided by CTI to Baxter or its Affiliates or agents in connection with such Recall, Withdrawal, Field Correction or other removal; 

7.4.3.2 results solely from a breach by Baxter or its Affiliates or agents of the terms of this Agreement or the Supply
Agreement, then Baxter shall bear all Recall Costs and shall bear all costs for any assistance provided by CTI to Baxter or its Affiliates or agents in connection with such Recall, Withdrawal, Field Correction or other removal; 

7.4.3.3 results both from a breach by Baxter or its Affiliates or agents of the terms of this Agreement or the Supply
Agreement and a breach by CTI or its Affiliates or agents of the terms of this Agreement or the Supply Agreement, then all Recall Costs and all costs for any assistance provided by CTI to Baxter or its Affiliates or agents in connection with such
Recall, Withdrawal, Field Correction or other removal shall be allocated to each of Baxter and CTI in an amount proportional to the contribution of each Party’s breach to the necessity of the Recall, Withdrawal, Field Correction or other
removal; and 
 7.4.3.4 does not result from a breach by either Party or its Affiliates or agents of the terms of this
Agreement or Supply Agreement, then ** of all ** in connection with such Recall, Withdrawal, Field Correction or other removal. 
 7.5.
Safety Information; Adverse Events; Pharmacovigilance. 
 7.5.1. During the Term, each Party shall provide to the other Party, all
information of which it becomes aware relating to the occurrence of any serious adverse event or any adverse event related to the Licensed Product in accordance with the Pharmacovigilance Agreement contemplated in Section 7.5.2. In
addition, all information learned in connection with the Development of the Licensed Product shall be exchanged by the Parties per procedures developed by the Joint Development Committee in accordance with Section 3.3.5. The Parties will
mutually agree upon, and the JSC (or a sub Committee thereof) will coordinate the preparation and maintenance of, safety databases, periodic safety update reports, global safety reports, etc. 

7.5.2. Ninety (90) days prior to the submission of a Regulatory Filing for Marketing Approval in any country in the Licensed Territory,
but in no event later than twelve (12) months after the Effective Date, the Parties shall enter into a Pharmacovigilance Agreement substantially in the form of the Baxter Pharmacovigilance Agreement template previously made available to CTI
(the “Pharmacovigilance Agreement”) concerning all matters relating to pharmacovigilance and the exchange of safety information for the Licensed Product, including, but not limited to: (a) the maintenance by the Parties of an
adverse event database for the Licensed Product 

  
 33 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
following FDA Marketing Approval, (b) AE or ADR reporting (as such acronyms are commonly understood in the industry) including literature review and associated reporting, (c) AE or ADR follow-up reporting, (d) preparation and submission of all safety reports to the Regulatory Authorities as required by local laws and/or regulations in the Licensed Territory, (e) global safety database
maintenance, (f) management of all interactions with health authorities relating to the safety of the Licensed Product, including establishment and maintenance of a formal process to adequately communicate urgent issues regarding safety and
labeling, (g) periodic submissions, (h) labeling modifications, (i) safety monitoring and detection, and (j) safety measures (e.g., “Dear Doctor” letter, restriction on distribution). 

7.5.3. All costs and expenses related to the establishment and maintenance of any safety registry mandated as part of Marketing Approvals
shall be shared as follows: (a) if the safety registry is applicable solely to the Co-Promotion Territory, **, (b) if the safety registry is applicable to the Co-Promotion Territory and one or more countries outside the Co-Promotion
Territory, Baxter shall be responsible for ** of the costs and expenses and CTI shall be responsible for ** of the costs and expenses and (c) in all other cases, **. 

7.6. Medical and Scientific Affairs. 

7.6.1. Subject to Section 3.1.6 and Section 3.5, Baxter and CTI shall discuss and approve a medical affairs plan
within three (3) months of the Effective Date and Baxter and CTI shall jointly develop and execute medical and scientific affairs and programs (including supporting professional symposia and other educational activities, and medical affairs
studies based upon approved protocols) within the Co-Promotion Territory. All materials must be reviewed and approved by the Parties’ respective Medical Affairs and Legal departments (as applicable).
Baxter will have the exclusive authority to execute medical and scientific affairs and programs (including professional symposia and other educational activities, and medical affairs studies based upon approved protocols) for all other geographies
within the Licensed Territory. 
 7.6.2. Subject to Section 3.1.6 and Section 3.5, Baxter and CTI shall jointly
develop guidelines for market access approach within three (3) months of the Effective Date and thereafter shall jointly develop and execute market access activities (including wholesaler and distributor management, local contracting and
pricing, payor relations and patient support programs and the designation of any personnel for any of the foregoing) in the Co-Promotion Territory. Baxter will have exclusive authority to develop and execute
market access activities (including wholesaler and distributor management, local contracting and pricing, payor relations and patient support programs and the designation of any personnel for any of the foregoing) for all other geographies within
the Licensed Territory. 
 7.6.3. All questions and requests for information about Licensed Products received by CTI or Baxter with respect
to the Co-Promotion Territory that: (a) warrant a clinical response beyond the competence of a Sales Representative, or (b) are beyond the scope of labels and package inserts for the Licensed Product
(whether within or outside of the Co-Promotion Territory) shall be referred to Baxter’s or CTI’s Medical Affairs Representatives or to the 

  
 34 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
relevant Third Party vendor, it being understood that the Parties’ goal and intent is a coordinated response. Should such request require more interaction than simply providing reprints of
published research (in which case Baxter’s medical information department or Third Party vendor may so provide such reprint), such referral will result in either a CTI or a Baxter Medical Affairs Representative having the exclusive right to
respond to such questions and requests for information about Licensed Products, depending on which Party is responsible for servicing the account asking such question or making such request for information and other relevant considerations. 

7.6.4. Both Parties for the Co-Promotion Territory and Baxter for the Baxter Exclusive Territory shall
be solely responsible for recruiting, hiring and maintaining its own staff of Medical Affairs Representatives and Medical Science Liaisons for responding to questions and requests for information about Licensed Products, in accordance with its
standard procedures and the requirements of this Agreement. Each Party shall be responsible for the activities of its Medical Affairs Representatives and Medical Science Liaisons, including compliance by its Medical Affairs Representatives and
Medical Science Liaisons with training requirements. In particular, each Party shall provide its Medical Affairs Representatives and Medical Science Liaisons assigned to respond to questions and requests for information about Licensed Products with
the level of oversight, management, direction and support with respect to activities related to the Licensed Product in accordance with the terms of this Agreement and applicable Law. 

7.6.5. Each Party’s Medical Affairs Representatives and Medical Science Liaisons for the
Co-Promotion Territory and Baxter’s Medical Affairs Representatives and Medical Science Liaisons for the Baxter Exclusive Territory assigned to respond to questions and requests for information about
Licensed Products may use available clinical information that has been approved by the JCC. All activities conducted by each Party’s Medical Affairs Representatives will be consistent in all material respects with the materials so approved.
Each Party shall train and instruct its respective Medical Affairs Representatives and Medical Science Liaisons to make only those statements and claims regarding the Licensed Product, including as to efficacy and safety, that are consistent with
the Licensed Product labeling and accompanying inserts, applicable Laws and regulations and the materials approved by the JCC unless responding to an unsolicited request for off-label information. 

7.7. Springback Option. 

7.7.1. Upon the one (1) year anniversary of receipt of the first Regulatory Approval of a Licensed Product in a Major Market Country, and
on each yearly anniversary thereafter, Baxter shall provide to CTI a report setting forth, for each Major Market Country (other than those which are members of the EU) and each country within the Baxter Exclusive Territory with a population greater
than ** people (as identified by the CIA World Fact Book) ** (collectively, the “Springback Countries”), whether or not Regulatory Approval has been received for a Licensed Product. If Regulatory Approval has been received for a
given Springback Country, the report shall specify whether Baxter is actively Commercializing the Licensed Product in such country. If Regulatory Approval has not been received for any such country, the report shall specify whether Baxter, in its
own good-faith determination, is actively pursuing Regulatory Approval of the Licensed Product in such country. 

  
 35 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 7.7.2. Following the one (1) year anniversary of receipt of the first Regulatory
Approval in a Major Market Country, if CTI receives a bona fide offer from any Third Party with respect to the potential Commercialization of the Licensed Product in a Springback Country in which Baxter is not actively pursuing Regulatory Approval
or Commercialization (as applicable), CTI shall refer such inquiry to Baxter in writing. If, within a period of ** following such referral, Baxter has not: (a) entered into a sublicense with such Third Party with respect to such Springback
Country or (b) undertaken reasonable efforts directed toward obtaining Regulatory Approval for or, if Regulatory Approval has been received, Commercialization of, the Licensed Product in such Springback Country, CTI may, upon written notice to
Baxter, terminate the Agreement with respect to such Springback Country. Upon termination of the Agreement with respect to such country, CTI shall have the right, at its sole cost and expense, either on its own or through a Third Party, to Develop
and Commercialize the Licensed Product in such Springback Country. ** 
 ARTICLE VIII. 

MANUFACTURING AND SUPPLY 

8.1. General Supply Terms. As between the Parties, and subject to the provisions of the Supply Agreement: CTI will be solely
responsible, by itself or through one or more CMOs, for the manufacture and supply of Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product). CTI shall be responsible for all capital expenditures associated with the
engagement of any CMOs by CTI for the manufacture and supply of Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product) to Baxter. Unless otherwise agreed to by the Parties, CTI shall not be responsible for capital
expenditures associated with the engagement of any CMOs by Baxter or otherwise incurred by Baxter for the manufacture and supply of Licensed Product to Baxter and/or CTI hereunder. If Baxter exercises its Fill/Finish Option (as defined below),
Baxter will be solely responsible, by itself or through one or more CMOs, for the manufacture and supply of the fill and finish (such as blistering and package inserts), freight, insurance and other subsequent supply chain expenses to produce
Licensed Product from Drug Product. The Parties will use Commercially Reasonable Efforts to perform their respective obligations under this Article VIII. 

8.2. Supply Agreement. On or before a date to be established by the JSC but in no event later than one hundred eighty (180) days
after the Effective Date, the Parties shall enter into the Supply Agreement. The terms of such Supply Agreement shall be negotiated in good faith by the Parties and will contain customary terms and conditions that are consistent with this Agreement
and the terms attached hereto as Exhibit 8.2. The purchase price for the Drug Product under the Supply Agreement will be CTI’s actual Cost of Goods Sold through manufacture of the Drug Product in capsule form, subject to the Supply Cap.
Fill and finish (such as blistering and package inserts), freight, insurance and other subsequent supply chain expenses are not subject to the Supply Cap. The Supply Agreement will provide appropriate


  
 36 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
technology transfer provisions (including provision of drug master files and other customary terms in the industry) sufficient to enable Baxter or CTI, as appropriate, to manufacture the Licensed
Product in the event that there is a Supply Failure. 
 8.3. Fill/Finish Option. During the Term of this Agreement, Baxter shall have
the option, exercisable by providing written notice to CTI to perform, by itself or through one or more CMOs, the packaging, finishing and labeling activities (such as blistering and package inserts), to produce Licensed Product from Drug Product
(the “Fill/Finish Option”). Upon exercise of the Fill/Finish Option the Parties (a) shall cooperate to execute any technology transfer that is necessary to allow Baxter or its CMO(s) to perform such activities and
(b) enter into a second supply agreement pursuant to which Baxter will agree to convert the Drug Product supplied by CTI pursuant to the Supply Agreement into Licensed Product and will thereafter supply such Licensed Product to CTI for sale by
CTI in the Co-Promotion Territory. The terms of such second supply agreement will be negotiated by the Parties in good faith. 
 8.4.
Quality Agreement. In connection with the negotiation and execution of the Supply Agreement, the Parties shall also, within one hundred eighty (180) days of the effective date of the Supply Agreement, enter into a separate agreement
governing the quality control, quality assurance and validation (the “Quality”) of any Drug Product and/or Licensed Product (as applicable) delivered to Baxter under the Supply Agreement (the “Quality Agreement”).
The Quality Agreement shall be negotiated in good faith by the Parties, will contain customary terms and conditions that are consistent with this Agreement, and shall set forth the respective requirements, roles and responsibilities of the Parties
which shall be consistent with the following: 
 8.4.1. Prior to receipt of Marketing Approval in the United States: (a) CTI shall
have final functional Quality decision-making authority with respect to the Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product) and the manufacture thereof and (b) CTI shall have responsibility for Quality oversight
of all Third Party manufacturers for the Licensed Product that are engaged by CTI for the manufacture and supply of Licensed Product and/or Drug Product (as applicable) to Baxter (including, as applicable, any Third Party vendors). 

8.4.2. Following receipt of Marketing Approval in the United States: (a) Baxter shall have final functional Quality decision-making
authority with respect to the Licensed Product and the manufacture thereof and (b) Baxter shall have responsibility for Quality oversight of the Third Party manufacturers for Licensed Product (including, as applicable, any Third Party vendors).

 8.5. Manufacturing Licenses. Notwithstanding anything contained in this Agreement to the contrary, but subject to Baxter’s
right to manufacture or have manufactured the Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product) in the event of a CTI Supply Failure as provided in the Supply Agreement, the Parties acknowledge and agree that CTI or its
CMO shall hold all manufacturing licenses for the Licensed Product and/or Drug Product (as applicable). 

  
 37 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 ARTICLE IX. 

PAYMENTS 
 9.1. Upfront
Fee. 
 9.1.1. License Fee. In consideration of the licenses and other rights granted to Baxter under this Agreement, in addition
to the payments specified in Section 9.2 and Section 9.3, Baxter shall pay to CTI or an Affiliate designated by CTI, upon the Effective Date or the next Business Day, a one-time, non-refundable, non-creditable license fee equal to sixty million U.S. dollars (USD 60,000,000) (the “Upfront Fee”), provided that, in the
event that Baxter purchases any Preferred Stock (defined below) pursuant to Section 9.1.2, said Upfront Fee shall be reduced by the aggregate stated value of the dollar amount of Equity Consideration paid by Baxter for such
Preferred Stock. 
 9.1.2. Equity Investment. At Baxter’s option, Baxter shall purchase from CTI, and CTI shall issue and sell
to Baxter on the Effective Date, up to 30,000 shares of convertible preferred stock of CTI (any such shares actually purchased by Baxter, the “Preferred Stock”) for up to thirty million U.S. dollars (USD 30,000,000) at a
purchase price of $1,000 per share of Preferred Stock (the aggregate purchase price of such Preferred Stock, the “Equity Consideration”), such Preferred Stock to have terms substantially as set forth as Exhibit 9.1.2, in
accordance with the following provisions of this Section 9.1.2; provided, however, that at CTI’s option, CTI may, in lieu of issuing shares of Preferred Stock, issue a number of shares of CTI common stock equal to the
quotient obtained by dividing the Equity Consideration by an amount equal to one hundred ten percent (110%) of the last consolidated closing bid price per share of CTI common stock on NASDAQ immediately prior to the effectiveness of this
Agreement, rounded to the nearest whole share. The purchase and sale of the applicable Securities (defined below) for the Equity Consideration shall occur as soon as practicable following the Effective Date (and in no event later than three
(3) Business Days following the Effective Date). The Preferred Stock shall be convertible into CTI common stock (such common stock into which the Preferred Stock is convertible, together with any CTI common stock issued in lieu of the Preferred
Stock, the “Common Stock,” and together with the Preferred Stock, the “Securities”) and have a stated value per share of $1,000, and the conversion price for the purpose of determining the number of shares of Common
Stock to be issued upon conversion of the shares of Preferred Stock shall be equal to one hundred ten percent (110%) of the last consolidated closing bid price per share of CTI common stock on NASDAQ immediately prior to the effectiveness of
this Agreement. The Securities will not initially be registered under the Securities Act of 1933, as amended (“Securities Act”) and will accordingly bear applicable restricted securities legends, but CTI has agreed to register
the Common Stock pursuant to the terms of the Registration Rights Agreement, to be executed and delivered on the Effective Date. Notwithstanding any other provision of this Agreement to the contrary, CTI shall in no event be required to issue any
Securities to Baxter pursuant to this Section 9.1.2 to the extent that such issuance (a) in the aggregate constitutes, or is convertible into, CTI common stock that constitutes, greater than 13.9% of CTI common stock outstanding
after giving effect to any Preferred Stock issuance hereunder, (b) in the aggregate constitutes, or is convertible into 

  
 38 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Common Stock that constitutes, greater than 19.9% of the common stock or voting power of CTI outstanding as of the date of this Agreement prior to the issuance of the Securities, (c) would
constitute a change of control under NASDAQ rules, (d) would otherwise trigger a shareholder approval requirement under NASDAQ rules or (e) would cause Baxter, together with its Affiliates, to become a Beneficial Owner (as defined in the
Shareholder Rights Agreement between CTI and Computershare Trust Company, N.A. as rights agent dated December 28, 2009, as amended or as may be amended from time to time) of 20% or more of CTI’s outstanding common stock, except in the case
of the foregoing clauses (b), (c) and (d), with the prior approval of CTI’s stockholders. In the event that Baxter purchases any Securities under this Section 9.1.2, CTI shall deliver to Baxter, on the Effective Date, copies of
the certificate(s) representing such Securities, and shall, promptly thereafter, deliver to Baxter the original certificate(s). 
 9.2.
Milestones. In addition to the payments specified in Section 9.1 and Section 9.3, Baxter shall make the following payments to CTI in consideration of the licenses and other rights granted to Baxter under this
Agreement: 
 9.2.1. Development Milestones. Baxter shall pay to CTI or an Affiliate designated by CTI the following non-creditable, non-refundable amounts ** (each, a “Development Milestone”): 
  

					
	Events with respect to the Initial Indication	  	 Milestone

Payment
	 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 

  

					
	Event with respect to an Additional Indication	  	 Milestone

Payment
	 
		
	 ** Registration Directed ** Clinical Trial **
	  	$	15,000,000	  


  
 39 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 9.2.2. Sales Milestones. Baxter shall pay to CTI or an Affiliate designated by CTI the
following non-creditable, non-refundable amounts ** (each, a “Sales Milestone”): 

 

					
	First time Calendar Year Net Sales exceed the following amounts:	  	 Milestone

Payment
	 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 
		
	 **
	  	$	*	* 

 For purposes of clarity, Baxter shall be obligated to make a Sales Milestone payment corresponding to each of
the foregoing events only once, regardless of whether such Sales Milestone event occurs during more than one Calendar Year. If more than one Sales Milestone event is first achieved in the same Calendar Year, Baxter shall be obligated to pay the
corresponding milestone payment for all such events. 
 9.2.3. No Set-Off. Subject to Section 9.6, all payments under
this Section 9.2 shall be made without setoff or deduction of any kind. 
 9.3. Royalty Payment; Audits. 

9.3.1. Royalty Payments. In addition to the payments specified in Section 9.1 and Section 9.2, in consideration
of the rights granted to Baxter under this Agreement, Baxter shall pay to CTI or an Affiliate designated by CTI (a) a royalty of ** of Net Sales of the Licensed Product in the Baxter Exclusive Territory for Licensed Products for all Additional
Indications, and (b) the following royalties on annual Net Sales of the Licensed Product in the Baxter Exclusive Territory for the Initial Indication: 
  

					
	Calendar Year Net Sales	  	 Royalty

Rate
	 
		
	 **
	  	 	*	* 
		
	 **
	  	 	*	* 

 9.3.2. Royalty Stacking. If Baxter, in the opinion of reputable patent counsel, is required to obtain a
license under any Patent from any Third Party in order to fulfill its obligations under this Agreement, and if Baxter is required to pay a royalty under such license, and in such opinion the infringement of such Patent cannot be avoided by Baxter
absent such license, then Baxter’s obligation to pay royalties to CTI with respect to such Licensed Product shall be reduced by fifty percent (50%) of the amount of the royalty paid to such Third Party with respect to such Licensed
Product, provided the following conditions are met: (a) the 

  
 40 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
royalties payable to CTI shall not be reduced to less than fifty (50%) of the royalty payment that would otherwise be due to CTI in the absence of the reduction hereunder and (b) Baxter
shall provide CTI with written documentation regarding the payments to Third Parties for such Patent rights. 
 9.3.3. Royalty Term.
Baxter’s obligation to pay royalties pursuant to Section 9.3.1 shall expire, on a country-by-country and Licensed Product-by-Licensed Product basis, upon the last to expire of (a) the last to expire Valid Claim of a CTI Patent, Subject Patent or Joint Patent in such country that covers the manufacture, use, sale,
offer for sale or importing of such Licensed Product in the Licensed Field in such country, taking into consideration all applicable patent extensions, (b) all applicable Regulatory Exclusivity for such Licensed Product in the Licensed Field in
such country, and (c) ** from the First Commercial Sale of such Licensed Product in such country (the “Royalty Term”); provided, however, that on a country-by-country basis, if no Valid Claim or Regulatory
Exclusivity remains during any portion of the Royalty Term in a particular country, the royalties due during such portion of the Royalty Term for such country shall be reduced to fifty percent (50%) of the amounts specified in
Section 9.3.1 (subject to any other deductions provided for herein including, without limitation, those set forth in Section 9.3.2). 

9.3.4. Royalty Payment Timing; Royalty Reports. ** following the end of each Calendar Quarter during the period in which royalties
accrue, Baxter shall provide CTI with a Sales Report and any other information reasonably required by CTI for the purpose of calculating royalties and Sales Milestone payments due under this Agreement. Any royalty payments due to CTI will be paid on
the date of delivery of such report. In the event that either Party determines that the calculation of Net Sales for a Calendar Quarter deviates from the amounts previously reported to CTI for any reason (such as, on account of additional amounts
collected or Licensed Product returns), Baxter and CTI shall reasonably cooperate to reconcile any such deviations to the extent necessary under applicable legal or financial reporting requirements. 

9.3.5. Audit. Until the expiration of all royalty payment obligations hereunder and for a period of three (3) years thereafter,
Baxter shall keep complete and accurate records pertaining to the sale or other disposition of Licensed Products by Baxter, its Affiliates and Sublicensees in sufficient detail to permit CTI to confirm the accuracy of the royalties and Sales
Milestone payments due hereunder. CTI shall have the right to cause an independent, certified public accountant reasonably acceptable to Baxter to audit such records to confirm Net Sales and royalties for a period covering not more than the
preceding three (3) fiscal years. Baxter may require such accountant to execute a reasonable confidentiality agreement with Baxter prior to commencing the audit. Such audits may be conducted during normal business hours upon reasonable prior
written notice to Baxter, but no more than frequently than once per year. No accounting period of Baxter shall be subject to audit more than one time by CTI, unless after an accounting period has been audited by CTI, Baxter restates its financial
results for such accounting period, in which event CTI may conduct a second audit of such accounting period in accordance with this Section 9.3.5. Prompt adjustments (including remittances of


  
 41 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
underpayments or overpayments disclosed by such audit) shall be made by the Parties to reflect the results of such audit. CTI shall bear the full cost of such audit unless such audit discloses an
underpayment by Baxter of five percent (5%) or more of the amount of royalties due under this Agreement, in which case Baxter shall bear the full cost of such audit. 

9.4. Development Costs and Expenses. 

9.4.1. CTI Development Costs Generally. CTI shall be responsible for and shall pay all CTI Development Costs incurred prior to
January 1, 2014. CTI shall pay for all CTI Development Costs incurred by it as part of the Development under the Development Plan, subject to reimbursement for costs incurred on or after January 1, 2014 by Baxter in accordance with the
remainder of this Section 9.4. 
 9.4.2. CTI Development Cost Threshold. CTI Developments Costs incurred on or after
January 1, 2014 will be allocated as follows: 
 9.4.2.1 CTI shall be responsible for the first ninety-six million U.S. dollars (USD 96,000,000) of such CTI Development Costs applicable to the Licensed Territory (such amount, the “CTI Development Cost Threshold”); provided,
however, that if any such CTI Development Costs relate exclusively to the Co-Promotion Territory, the Parties will confer and agree on an upward adjustment of the CTI Development Cost Threshold
commensurate with the corresponding increase in costs for the Co-Promotion Territory, and provided, further, and notwithstanding any other provision of this Agreement, that (a) one hundred
percent (100%) of those CTI Development Costs which are applicable primarily or solely to obtaining Marketing Approval for countries outside of the European Union and the Co-Promotion Territory and
(b) if paid initially by CTI, all fees for Regulatory Filings in the Baxter Exclusive Territory (except with respect to the EU prior to the first Marketing Approval in the EU of a Licensed Product) shall be reimbursed promptly by Baxter to CTI
and shall not be counted toward the CTI Development Cost Threshold. 
 9.4.2.2 For all CTI Development Costs which exceed
the CTI Development Cost Threshold: (a) subject to Section 9.4.2.3, those CTI Development Costs which are generally applicable to the Licensed Territory shall be shared by the Parties such that
seventy-five percent (75%) shall be borne by Baxter and reimbursed to CTI as set forth in Section 9.4.4, with the remaining twenty-five
percent (25%) to be borne by CTI, (b) those CTI Development Costs which are applicable exclusively to the Baxter Exclusive Territory, one hundred percent (100%) shall be borne by Baxter and reimbursed to CTI as set forth in
Section 9.4.4, and (c) those CTI Development Costs which are applicable exclusively to the Co-Promotion Territory shall be borne fifty percent (50%) by Baxter and reimbursed to CTI as
provided in Section 9.4.4, with the remaining fifty percent (50%) to be borne by CTI. For the avoidance of doubt, no CTI Development Costs shall be taken into consideration for purposes of calculating the Profit & Loss


  
 42 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Share for the Co-Promotion Territory. For purposes of Section 9.4, costs are considered “incurred” upon the delivery and acceptance
of the relevant services or goods. 
 9.4.2.3 Notwithstanding anything contained in this Agreement to the contrary and in
particular Section 9.4.2.1, if, at any time prior to receipt of the first Regulatory Approval of the Licensed Product in a country or region for Myelofibrosis, the CTI Development Costs associated with the Development of the Licensed
Product for Myelofibrosis (collectively, the “MF Development Costs”) exceed **, the obligations of the Parties with respect to the CTI Development Costs as set forth in Sections 9.4.2.1 and 9.4.2.2 above shall be
modified such that ** of the MF Development Costs shall be borne by **, with the remaining ** of MF Development Costs **. Any Development Costs related to manufacturing activities not currently contemplated, including without limitation scale-up
beyond current lot size of ** and qualification of a backup supplier, shall be excluded from such reallocation. For the avoidance of doubt, such reallocation shall only apply with respect to any CTI Development Costs that are associated with the
Development of the Licensed Product for Myelofibrosis. This re-allocation of responsibility shall continue until the receipt of the first Regulatory Approval of the Licensed Product. At the point of receipt of first Regulatory Approval of the
Licensed Product, the obligations of the Parties shall revert to the allocation set forth in Sections 9.4.2.1 and 9.4.2.2 such that if the first Regulatory Approval of the Licensed Product is received in the EU first, ** of the MF
Development Costs shall be borne ** and if the first Regulatory Approval of the Licensed Product is received in the Co-Promotion Territory, ** of the MF Development Costs shall be borne **. 

9.4.3. Adjustment of the CTI Development Cost Threshold. 

9.4.3.1 If the first Marketing Approval for a Licensed Product in the Co-Promotion Territory is obtained on or before
October 1, 2016, then the CTI Development Cost Threshold shall be reduced by ** to ** (the “Reduced Threshold”) and for all purposes of this Agreement, the Reduced Threshold shall be deemed to be the CTI Development Cost
Threshold. To the extent that the Reduced Threshold is lower than the aggregate of CTI Development Costs which have been incurred at the time of such Marketing Approval, such that ** incurred expenses in excess of the Reduced Threshold, then **
shall thereafter pay ** of ongoing CTI Development Costs (and not **, as the case may be), until such excess has been offset completely. 

9.4.3.2 There shall be no change in the CTI Development Cost Threshold if the first Marketing Approval for a Licensed Product
is obtained after October 1, 2016 but before February 1, 2017. 
 9.4.3.3 If the first Marketing Approval for a
Licensed Product in the Co-Promotion Territory is obtained on or after February 1, 2017, then 

  
 43 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
the CTI Development Cost Threshold shall be increased by ** to ** (the “Increased Threshold”) and for all purposes of this Agreement, the Increased Threshold shall be deemed to
be the CTI Development Cost Threshold. To the extent that the Increased Threshold is higher than the aggregate CTI Development Costs which have been incurred at the time of such Marketing Approval, such that Baxter payments will have been made
commencing prior to the attainment of the Increased Threshold resulting in an overpayment by Baxter, then CTI shall thereafter pay ** of ongoing CTI Development Costs (and not **, as the case may be), until such overpayment has been offset
completely. 
 9.4.4. Reimbursement. CTI shall charge all CTI Development Costs incurred by it or its Affiliates to a separate
account created by CTI on its books and records solely for the purpose of tracking CTI Development Costs (the “Development Account”). As soon as reasonably practicable following the end of each calendar month, CTI shall provide to
Baxter a report setting forth all CTI Development Costs incurred during the immediately ended calendar month and charged to the Development Account together with reasonable supporting documentation for such expenses and, to the extent that Baxter is
responsible for any portion thereof pursuant to this Section 9.4, an invoice setting forth the portion of such CTI Development Costs for which Baxter is responsible) (the invoice, summary and documentation, collectively, the
“Development Cost Summary”). Unless Baxter disputes any of the costs set forth therein or the apportionment of the Development costs, Baxter shall reimburse CTI for Baxter’s portion of the CTI Development Costs **, provided
that Baxter shall pay any undisputed costs within such time period. 
 9.4.5. Employee Efforts. The efforts of the employees of CTI
or its Affiliates in performing activities under this Agreement shall be charged to CTI’s Development Account at the FTE Rate. Only those efforts that are contemplated by the applicable Development Plan shall be chargeable by CTI to its
Development Account. All costs incurred by CTI owing to a Third Party in connection with the performance of its activities under a Development Plan shall be charged to CTI’s Development Account at CTI’s actual out-of-pocket cost. At the time of the annual update of the Development Plan for the Licensed Products, the CTI Development Cost Budget shall also be approved, as determined
by the JSC. If the JSC is unable to agree on any changes to the CTI Development Cost Budget, then CTI shall be entitled to continue its spending for activities budgeted in the most recent CTI Development Cost Budget approved by the JSC or agreed by
the Parties for which Baxter shall reimburse CTI in accordance with Section 9.4.2 and Section 9.4.4. 
 9.4.6.
Records and Audit. CTI shall keep and maintain accurate and complete records showing the expenses incurred by it in performing its activities under the Development Plan during the three (3) preceding Calendar Years, which books and
records shall be in sufficient detail such that CTI Development Costs can accurately be determined. Upon ** prior written notice from Baxter, on an audit date as mutually agreed by the Parties, CTI shall permit an independent certified public
accounting firm of nationally recognized standing, selected by Baxter and reasonably acceptable to CTI, to examine, at Baxter’s sole expense, the relevant 

  
 44 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
books and records of CTI and its Affiliates as may be reasonably necessary to verify the reports submitted by CTI in accordance with Section 9.4.4. An examination by Baxter under this
Section 9.4.6 shall occur not more than once in any Calendar Year and shall be limited to the pertinent books and records for any Calendar Year ending not more than two (2) years before the date of the request. The accounting firm
shall be provided access to such books and records at CTI’s facility(ies) where such books and records are normally kept and such examination shall be conducted during CTI’s normal business hours. CTI may require the accounting firm to
sign a standard non-disclosure agreement before providing the accounting firm access to CTI’s facilities or records. Upon completion of the audit, the accounting firm shall provide both CTI and Baxter a
written report disclosing whether the reports submitted by CTI are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Baxter. If the accounting firm concludes that CTI overstated the
CTI Development Costs and Baxter overpaid CTI for its portion of the CTI Development Costs as a result, CTI shall promptly pay Baxter the amount of such overpayment plus interest, which shall be calculated at the average of the **. ** Baxter shall
not reveal to such accounting firm the conditions under which the audit expenses are to be reimbursed hereunder. If the accounting firm concludes that CTI understated the Development costs incurred by Baxter and Baxter underpaid CTI for its portion
of the CTI Development Costs as a result, **. 
 9.4.7. Financial Information. All financial information of CTI which is subject to
review under this Section 9.4 shall be deemed to be CTI Confidential Information subject to the provisions of Article XIII hereof, and Baxter shall not disclose such CTI Confidential Information to any Third Party or use such CTI
Confidential Information for any purpose other than reviewing progress made or verifying payments to be made hereunder; provided, however, that such CTI Confidential Information may be disclosed by Baxter to Third Parties only to the
extent necessary to enforce Baxter’s rights under this Agreement. 
 9.4.8. Post-Marketing Approval Studies. For any Post-Marketing Approval Studies, costs shall be allocated as follows: (a) those costs which are applicable to both the Co-Promotion Territory and the Baxter Exclusive
Territory shall be shared by the Parties such that ** shall be borne ** pursuant to Section 9.4.4, with the remaining ** to be borne **, (b) those Costs which are applicable exclusively to the Baxter Exclusive Territory, ** shall be
**, and (c) those Costs which are applicable exclusively to the Co-Promotion territory shall be paid and borne **. All such expenses borne by CTI but reimbursed by Baxter shall be independent of the
provisions of Section 9.4.2. The above subsections (a) and (c) are applicable only after the CTI Development Cost Threshold has been surpassed (i.e., Post-Marketing Approval Studies are included in the CTI Development Cost
Threshold). 
 9.4.9. Investigator-Sponsored Trials. Notwithstanding anything contained in this Agreement to the contrary, CTI shall
bear all costs and expenses for Investigator-Sponsored Trials for the Licensed Product (for either the Initial Indication or any Additional Indications or both) up to an annual cap of ** per calendar year. Any costs and expenses for Investigator-Sponsored Trials for the Licensed Product in excess of this initial cap and up to a secondary cap of ** per calendar year **. Neither Party may approve, initiate or fund any


  
 45 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Investigator-Sponsored Trials which would result in either Party incurring any Investigator-Sponsored Trial costs and/or expenses in excess of such secondary cap unless mutually agreed by the
Parties. 
 9.4.10. Regulatory Filings Fees. All fees for Regulatory Filings for: (a) the Co-Promotion Territory shall be
considered ** and shall be borne by the Parties in accordance with **, (b) the First Marketing Authorization in the EU in the Baxter Exclusive Territory shall be considered ** and shall be borne by the Parties in accordance with ** and
(c) all other geographies and Regulatory Approvals (including any associated with Reimbursement Approvals) shall be borne **. 
 9.5.
Profit & Loss Share for Co-Promotion. The Parties will share ** with respect to Licensed Product for the Co-Promotion Territory as more specifically set forth in the Co-Promotion Terms (the
“Profit & Loss Share”). Procedures for reporting of actual results on a Calendar Quarter basis, review and discussion of potential discrepancies, reconciliation on a Calendar Quarter basis, reasonable forecasting, and other
finance and accounting matters, are set forth in Exhibit 1.34, and to the extent not set forth in Exhibit 1.34, will be established by the JCC, provided that Baxter’s Executive Officer shall not have the right to make final
decisions regarding any modifications or additions to Exhibit 1.34, but in the case of disagreement between the Parties within the JCC, the matter shall be decided pursuant to the dispute resolution procedures set forth in
Section 16.13. Notwithstanding the foregoing, to the extent expenses are incurred as a result of a lawsuit or settlement by or with a Governmental Authority or Third Party payor (e.g. resulting from a corporate integrity agreement) that
are unrelated to a Licensed Product, such expenses associated therewith ** from the Profit & Loss Share with respect to the Co-Promotion Territory. 

9.6. Upstream Agreements. CTI shall be solely responsible for paying all amounts due pursuant to the Upstream Agreements, including the
S*BIO Agreement. ** 
 9.7. Exchange Rate; Manner and Place of Payment. All payments to be made by either Party hereunder shall be
made in U.S. dollars. With respect to each quarter, for countries other than the U.S., whenever conversion of payments from any foreign currency shall be required, such conversion shall be made at the historical NY close rate (spot price) for the
relevant day or date range as reported by Bloomberg in its Historical Price Table. All payments owed under this Agreement shall be made in USD by wire transfer to a bank and account designated in writing by CTI, unless otherwise specified in writing
by CTI. 
 9.8. Taxes. All payments under this Agreement shall be made without any deduction or withholding for or on account of any
tax, except as set forth in this Section 9.8. The Parties agree to cooperate with one another and use reasonable efforts to minimize under applicable Law obligations for any and all income or other taxes required by Law to be withheld or
deducted from any of the royalty and other payments made by or on behalf of a Party hereunder (“Withholding Taxes”). The applicable paying Party under this Agreement (the “Paying Party”) shall, if required by Law,
deduct from any amounts that it is required to pay to the recipient Party hereunder (the “Recipient Party”) an amount equal to such Withholding Taxes; provided that the 

  
 46 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Paying Party shall give the Recipient Party reasonable notice prior to paying any such Withholding Taxes. Such Withholding Taxes shall be paid to the proper taxing authority for the Recipient
Party’s account and, if available, evidence of such payment shall be secured and sent to Recipient Party within thirty (30) days of such payment. The Paying Party shall, at the Recipient Party’s cost and expense, as mutually agreed by
the Parties, do all such lawful acts and things and sign all such lawful deeds and documents as the Recipient Party may reasonably request to enable the Paying Party to avail itself of any applicable legal provision or any double taxation treaties
with the goal of paying the sums due to the Recipient Party hereunder without deducting any Withholding Taxes. 
 9.9. Late Payments.
If CTI does not receive payment of any sum due to it under this Agreement on or before the due date, interest shall thereafter accrue on the sum due to CTI from the due date until the date of payment, such interest to be calculated at the average of
the prime rate reported by JPMorgan Chase, New York City, each month during the period from the time any payment was due until paid in full, plus two percent (2%) per annum. 

9.10. Reporting. All financial reporting hereunder shall be, if applicable, on the basis of U.S. GAAP, consistently applied. 

ARTICLE X. 
 INVENTIONS;
ACCESS TO IMPROVEMENTS; PATENTS 
 10.1. Improvements and Inventions. 

10.1.1. The Parties acknowledge that Baxter and its Sublicensees may improve or modify the Licensed Products or otherwise make Inventions in
the course of exercising Baxter’s rights and performing its obligations under this Agreement, and that CTI may improve or modify the Licensed Products and otherwise make Inventions as CTI continues to Develop the Licensed Product and to
manufacture Licensed Product (or, if Baxter exercises its Fill/Finish Option, Drug Product) for supply for the Licensed Territory. 

10.1.2. Any Improvements made by CTI shall be included in the CTI Know-How, and all Patents claiming
such Improvements shall be included in the CTI Patents. Any Improvements made by Baxter shall be included in the Baxter Know-How, and all Patents claiming such Improvements shall be included in the Baxter
Patents, subject to the provisions of Section 10.2. 
 10.1.3. Baxter will use Commercially Reasonable Efforts to obtain from
its Sublicensees Control of Improvements made or developed by or on behalf of such Sublicensees, as well as Control of all intellectual property rights therein that are owned or controlled by such Sublicensees, in each case as necessary to provide
CTI access to rights to such Improvements as part of the Baxter Information, Baxter Know-How or Baxter Patents, as applicable, pursuant to this Agreement. Any such Improvements made by or on behalf of
Baxter’s Sublicensees of which Baxter obtains Control shall be included in the Baxter Know-How, and all Patents claiming such Improvements of which Baxter obtains Control shall be included in the Baxter
Patents. 

  
 47 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 10.2. Ownership of Inventions. Inventorship shall be determined in accordance with
U.S. patent laws. Any Invention made solely by employees, agents, or independent contractors of a Party or its Affiliates in the course of performing activities under this Agreement, together with all intellectual property rights therein
(“Sole Inventions”), shall be owned by such Party; provided that CTI shall own, and Baxter (on behalf of itself and its Affiliates) hereby assigns to CTI, all Sole Inventions specifically related to the composition of matter
or use of Licensed Products and all other Sole Inventions otherwise specifically related to Licensed Products (in each case, solely to the extent of such specific relationship) (such Sole Inventions assigned to CTI together with all intellectual
property rights therein, “CTI Assigned Patents”). Any Invention made jointly by at least one (1) employee, agent, or independent contractor of each Party or such Party’s Affiliate, together with all intellectual property
rights therein (“Joint Inventions”, and all Patents covering such Joint Inventions, hereinafter, “Joint Patents”), shall be owned jointly by the Parties in accordance with joint ownership interests of co-inventors under U.S. patent laws, with each joint Party having, unless otherwise set forth in this Agreement, the unrestricted right to license and grant rights to sublicense any such Joint Invention;
provided that CTI shall own, and Baxter (on behalf of itself and its Affiliates) hereby assigns to CTI, all of its interest in Joint Inventions specifically related to the composition of matter or use of the Licensed Product and all other
Joint Inventions otherwise specifically related to the Licensed Product (in each case, solely to the extent of such specific relationship) (such interests in Joint Inventions assigned to CTI together with all intellectual property rights therein,
“CTI Assigned Joint Patents”). Each Party hereby grants to the other Party a nonexclusive, royalty-free, worldwide license, with the right to grant sublicenses, under such Party’s
interest in Joint Inventions, solely for the purpose of performing its obligations under this Agreement; provided that the foregoing shall not apply to any uses of such Joint Inventions for which the receiving Party otherwise retains an
exclusive license pursuant to this Agreement, with such proviso to apply only for so long as such receiving Party retains such exclusive license. 

10.3. Disclosure of Inventions. Each Party shall promptly disclose to the other Party in writing any Inventions and any written
Invention disclosures, or other similar documents, submitted to it by its employees, agents, or independent contractors describing each and every Invention that may be either a Sole Invention or a Joint Invention, and all Information relating to
such Invention. 
 10.4. Prosecution of Patents. 

10.4.1. CTI Patents Other than Joint Patents. CTI shall have the first right and authority to file, prosecute, and maintain CTI
Patents, CTI Assigned Patents and CTI Assigned Joint Patents (collectively, the “Subject Patents”), on a worldwide basis at its sole discretion, subject to this Section 10.4.1. ** CTI will submit quarterly invoices for
such costs and expenses (which must be accompanied by complete copies of the supporting invoices from CTI’s outside counsel) to Baxter and Baxter will pay each such invoice within **. CTI shall provide


  
 48 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Baxter with the opportunity to review and comment on any and all prosecution efforts, but in no case less than thirty (30) days prior to any filing deadlines, regarding the Subject Patents
within the Licensed Territory; provided that CTI shall have final control over such prosecution efforts after reasonably considering Baxter’s comments, if any. CTI shall provide Baxter with a copy of material communications from Patent
authorities in the Licensed Territory regarding the Subject Patents, and shall provide drafts of any material filings or responses to be made to such Patent authorities in a timely manner. Notwithstanding the foregoing, if CTI determines in its sole
discretion to abandon or not maintain in the Licensed Territory any Subject Patents, other than a Joint Patent not included in the Subject Patents, CTI shall provide Baxter with at least forty-five (45) days prior written notice of such
determination and, if Baxter so requests, shall provide Baxter with the opportunity to prosecute and maintain such CTI Patent in the Licensed Territory in the name of CTI. 

10.4.2. Other Joint Patents. With respect to any potentially patentable Joint Invention not covered by a Subject Patent (“Other
Joint Inventions”), the Parties shall meet and agree upon which Party shall file, prosecute and maintain Patent applications covering such Other Joint Invention (any such Patent application and any Patents issuing therefrom, an
“Other Joint Patent”) in particular countries and jurisdictions throughout the world. Unless otherwise agreed by the Parties, Baxter will file, prosecute and maintain any Other Joint Patents in the Licensed Territory, subject to the
Parties coordinating their efforts as appropriate to make such prosecution activities as efficient, convenient, and harmonious as possible. The Party that prosecutes an Other Joint Patent (the “Prosecuting Party”) shall be
responsible for all expenses of filing, prosecuting and maintaining such Other Joint Patents. The Prosecuting Party shall provide the other Party the opportunity to review and comment on any and all such prosecution efforts regarding the applicable
Joint Patent in the particular jurisdictions, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts; provided that the Prosecuting Party shall have final control over such prosecution efforts after
reasonably considering the other Party’s comments, if any. The Prosecuting Party shall provide the other Party with a copy of all material communications from any Patent authority in the applicable jurisdictions regarding the Other Joint Patent
being prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such Patent authorities a reasonable amount of time, but in no event less than thirty (30) days, in advance of submitting such filings
or responses. In particular, each Party agrees to provide the other Party with all information necessary or desirable to enable the other Party to comply with any duty of candor and/or duty of disclosure requirements of any Patent authority. Except
to the extent a Party is restricted by the licenses granted by such Party to the other Party under the terms of this Agreement, and/or the other covenants contained in this Agreement, each Party shall be entitled to practice, and grant licenses to
Third Parties and Affiliates of such Third Parties to practice, the Other Joint Patents and all Other Joint Inventions without restriction or an obligation to account to the other Party, and the other Party shall consent and hereby consents, without
additional consideration, to any and all such licenses. Notwithstanding anything contained herein to the contrary, if CTI determines that it shall no longer prosecute a Patent application directed to an Other Joint Invention or maintain an Other
Joint Patent, Baxter shall have the right to do so and Baxter shall thereafter own such Patent or Application and CTI shall execute appropriate documentation reflecting Baxter’s ownership thereof. 

  
 49 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 10.4.3. Cooperation in Prosecution. Each Party shall provide the other Party all
reasonable assistance and cooperation in the Patent prosecution efforts described above in this Article X, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.

 10.5. Infringement of Patents by Third Parties. 

10.5.1. Notification. Each Party shall promptly notify the other Party in writing of any existing or threatened infringement of the
Subject Patents of which it becomes aware in the Licensed Territory, and shall provide to the other Party any and all evidence and information available to such Party regarding such alleged infringement. 

10.5.2. Product Infringement of Subject Patents in the Licensed Territory. 

(a) If a Party becomes aware of any actual or alleged existing or threatened infringement by a Third Party of any Subject Patent, by making,
using, importing, offering for sale, or selling the Compound, Drug Product and/or Licensed Product (such activities, “Product Infringement”) in the Licensed Territory, such Party shall notify the other Party as provided in
Section 10.5.1. CTI shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity engaged in such Product Infringement in the Licensed Territory, subject to
Section 10.5.2(b). CTI shall have a period of thirty (30) days after such notification to or by Baxter, to elect to so enforce such Subject Patent in the Licensed Territory. If CTI does not so elect, CTI shall so notify Baxter in
writing during such thirty (30) day period, or ten (10) days prior to any deadline relating to loss of any rights with respect to the Product Infringement, whichever is earlier, and Baxter shall have the right, but not the obligation, to
commence a suit or take action to enforce such Subject Patent against such Third Party allegedly perpetrating such Product Infringement. Each Party shall provide to the Party enforcing any such rights under this Section 10.5.2(a)
reasonable assistance in such enforcement, including joining an action as a party plaintiff if so required by Laws to pursue such action, at the Enforcing Party’s sole expense. The Enforcing Party shall keep the other Party regularly informed
of the status and progress of such enforcement efforts, and shall reasonably consider the other Party’s comments on any such efforts. Except as set forth above, the Enforcing Party shall bear and be responsible for all costs incurred in
connection with each Party’s activities under this Section 10.5.2(a). 
 (b) The Party not bringing an action with respect
to Product Infringement under this Section 10.5.2 shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Party bringing
such action. Additionally, the Party not bringing an action under this Section 10.5.2 may have an opportunity to participate in such action to the extent that the Parties may mutually agree at the time the other Party elects to bring
such action hereunder. 

  
 50 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 10.5.3. Non-Product Infringement of Joint Patents Anywhere in the Licensed Territory.
For infringement of the Joint Patents that is not Product Infringement, the Parties shall confer to determine which Party shall have the first right to bring an appropriate suit or other action against any person or entity engaged in such
infringement, and the manner in which they shall bear costs and share related recoveries of such suit or action. The Party that brings such suit or actions (the “Enforcing Party”) shall keep the other Party regularly informed of the
status and progress of such enforcement efforts, and shall reasonably consider the other Party’s comments on any such efforts. The other Party shall cooperate with the enforcing Party in enforcing Joint Patents against such infringement,
without limitation joining an action as a party plaintiff if so required by Laws to pursue such action. If the Parties are unable to reach agreement upon which Party shall bring an appropriate suit or other action against any person or entity
engaged in such infringement of such Joint Patent within thirty (30) days, or ten (10) days prior to any deadline relating to loss of any rights with respect to such infringement, whichever is earlier, then Baxter shall have the first
right, but not the obligation, to bring such suit or other actions against such infringement in the Licensed Territory at its sole expense. The Party that does not bring such suit or action shall have the right to participate in such actions at its
expense upon written notice to the other Party. 
 10.5.4. Settlement. Baxter shall not settle any claim, suit, or action that it
brings under this Section 10.5 involving Subject Patents in any manner that would, in CTI’s reasonable judgment, negatively impact CTI, including settlements involving the ownership, validity or enforceability of any of the CTI
Patents, or that do not include a full and unconditional release from all liability of CTI, without the prior written consent of CTI, which shall not be unreasonably withheld, conditioned or delayed. CTI shall not settle any claim, suit, or action
that it brings under this Section 10.5 involving Subject Patents in the Licensed Territory in any manner that would, in Baxter’s reasonable judgment, negatively impact Baxter, without the prior written consent of Baxter, which shall
not be unreasonably withheld, conditioned or delayed. Moreover, any settlement by Baxter involving Subject Patents in the Licensed Territory, that (a) results in cross-licensing or (b) results in
sublicenses to Third Parties shall require CTI’s prior written consent. Neither Party shall settle any claim, suit, or action that it brings under this Section 10.5 involving Joint Patents (other than Subject Patents) in any manner
that would negatively impact the other Party, including the ownership, validity or enforceability of any of such Joint Patents, or if the settlement does not include a full and unconditional release from all liability of the other Party,
without the prior written consent of such other Party. 
 10.5.5. Allocation of Proceeds. Except as otherwise provided in this
Section 10.5, if either Party recovers monetary damages from any Third Party in a suit or action brought under this Section 10.5, whether such damages result from the infringement of Baxter Patents or CTI Patents, such
recovery shall be allocated as follows: 
 (a) First to the repayment of expenses with respect to the action; 

(b) ** of the remainder to the Party which brought the action (except in the Co-Promotion Territory, in
which such Party shall receive ** of the remainder); and 
 (c) ** of the remainder to the other Party (except in the Co-Promotion Territory, in which such Party shall receive ** of the remainder). 

  
 51 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 10.6. Infringement of Third Party Rights in the Licensed Territory. 

10.6.1. Notice. If the development, manufacture, use, sale, offer for sale, import or export of the Licensed Product in the Licensed
Field and in the Licensed Territory results in a claim for Patent infringement by a Third Party, the Party first having notice of such claim shall promptly notify the other Party in writing of such a claim. Following such notice, the Parties agree
to enter into either a joint defense or common interest agreement, under which agreement the Parties can share the known facts of such infringement in reasonable detail, if they are advised to do so by counsel. 

10.6.2. Third Party Claims. Baxter shall assume control of the defense of any claims brought by Third Parties alleging infringement of
Third Party intellectual property rights in connection with the development, manufacture, use, sale, offer for sale, import or export of the Licensed Product in the Licensed Field in the Licensed Territory, represented by its own counsel. If
requested by Baxter, CTI agrees to join in any litigation, and in any event shall reasonably cooperate with Baxter, at Baxter’s expense. Baxter shall have the exclusive right to settle any such claim without the consent of CTI, unless such
settlement shall negatively impact on CTI, including without limitation on the ownership, validity or enforceability of any CTI Patents. Any expenses incurred in defending any such claims shall be solely the responsibility of Baxter. CTI shall be
entitled to separate representation in the defense of any such claims brought by Third Parties using counsel of its own choice and at its own expense. 

10.6.3. Potential Third Party Claims. In the event that either Party becomes aware of a Third Party intellectual property right that
might reasonably be expected to give rise to a claim of infringement under this Section 10.6, that Party shall promptly notify the other Party of such intellectual property right and all relevant facts and circumstances known to the
discovering Party. Following such notice, the Parties agree to enter into either a joint defense or common interest agreement, under which agreement the Parties can share the known facts of such infringement in reasonable detail, if they are advised
to do so by counsel, and to consult thereafter regarding any corrective or preventive action to be taken to address such potential claim. 

10.7. Patent Oppositions and Other Proceedings. 

10.7.1. By the Parties. If either Party desires to bring an opposition, action for declaratory judgment, nullity action, interference,
declaration for non-infringement, reexamination, or other attack upon the validity, title, or enforceability of a Patent owned or controlled by a Third Party that covers, in the Licensed Territory, the
Compound, Drug Product and/or Licensed Product, or the manufacture, use, sale, offer for sale, or importation of the Compound, Drug Product and/or Licensed Product (except insofar as such action is a counterclaim to or defense of, or accompanies a
defense of, a Third Party’s claim or assertion of infringement under Section 10.6, in which case the provisions of Section 10.6 shall govern), such 

  
 52 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Party shall so notify the other Party, and the Parties shall promptly confer to determine whether to bring such action or the manner in which to settle such action. Baxter shall have the first
right, but not the obligation, to bring in its sole control and at its sole expense such action in the Licensed Territory. If Baxter does not bring such action within thirty (30) days of notification thereof pursuant to this
Section 10.7 (or earlier, if required by the nature of the proceeding), then CTI shall have the right, but not the obligation, to bring, in CTI’s sole control and at its sole expense, such action. The Party not bringing an action
under this Section 10.7 shall join the action as a joint party plaintiff if required to enable the other Party to bring such action, at the other Party’s expense. Additionally, if appropriate, the Party not bringing an action under
this Section 10.7 shall be entitled to separate representation, at its sole expense, in such proceeding by counsel of its own choice, and shall cooperate fully with the Party bringing such action. Any awards or amounts received in
bringing any such action shall be first allocated to reimburse the Parties’ expenses in such action, and any remaining amounts shall be retained by the Party bringing such action. 

10.7.2. By Third Parties. If a CTI Patent (including a Joint Patent) becomes the subject of any proceeding commenced by a Third Party
in the Licensed Territory in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference, or other attack upon the validity, title or enforceability thereof (except insofar as such action is a
counterclaim to or defense of, or accompanies a defense of, an action for infringement against a Third Party under Section 10.5, in which case the provisions of Section 10.5 shall govern), then CTI shall have the first right,
but not the obligation, to control such defense at its sole cost. CTI shall permit Baxter to participate in the proceeding to the extent permissible under Laws, and to be represented by its own counsel in such proceeding, at Baxter’s sole
expense. If CTI decides that it does not wish to defend against such action, then Baxter shall have a backup right to assume defense of such Third-Party action. Except as set forth above, all expenses incurred
by the Parties in such an action shall be borne by the Party controlling the defense of the Third-Party action. Any awards or amounts received in defending any such
Third-Party action, if any, shall be allocated between the Parties as provided in Section 10.5.5 as if the Party controlling the defense of the Third-Party
Action were the Party that brought an action against an alleged infringer. 
 10.8. Patent Term Extensions in the Licensed Territory.
The patent counsel of each Party shall discuss and recommend for which, if any, of the Subject Patents in the Licensed Territory the Parties should seek any term extensions, supplementary protection certificates, and equivalents thereof offering
Patent protection beyond the initial term with respect to any issued Patents (“Patent Term Extensions”) licensed to Baxter hereunder in the Licensed Territory. Baxter shall have the final
decision-making authority with respect to applying for any such Patent Term Extensions in the Licensed Territory; provided that Baxter shall not unreasonably fail or refuse to do so, and shall have the
sole right to apply for any such Patent Term Extensions Baxter decides to seek, at its expense; provided, however, that to the extent any such application for Patent Term Extension must be filed in the name of CTI, CTI hereby grants
Baxter the power to file such application on behalf of and/or as agent for CTI. CTI shall cooperate fully with Baxter, at Baxter’s expense, in making such filings or taking any related actions, for example and without limitation, making
available all required regulatory data and information and executing any required authorizations to apply for such Patent Term Extension. 

  
 53 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 10.9. Registration of License. CTI agrees that Baxter may, if applicable, register its
license under the Subject Patents with the Patent authorities in the Licensed Territory. Baxter shall, at its expense, prepare and deliver to CTI such instruments and other documents reasonably necessary and in proper form for such registration. The
Parties shall mutually agree on the form of documents to be used for such purpose, and shall cooperate to preserve confidentiality of this Agreement to the extent permitted under applicable Laws in the relevant country. CTI shall execute and
return to Baxter such instruments and documents within fifteen (15) days from the receipt thereof. 
 10.10. Patent Marking.
Baxter agrees to mark or have marked with the Subject Patents to the extent consistent with applicable Laws any Licensed Product sold by Baxter or by its Sublicensees in accordance with the statutes of any country within the Licensed Territory
relating to the marketing of patented articles. 
 ARTICLE XI. 

TRADEMARKS 
 11.1.
Baxter Trademarks. Baxter shall be responsible for the selection, registration and maintenance of all trademarks which it employs solely in connection with the Commercialization of any Licensed Product in the Licensed Territory under this
Agreement, other than the CTI Trademarks (the “Baxter Trademarks”). Baxter shall solely own the Baxter Trademarks and pay all relevant costs thereof. Baxter shall not select, register or otherwise use any trademark that is the same
as or confusingly similar to, misleading or deceptive with respect to or that dilutes any of the CTI Trademarks. CTI shall not use any trademark that is the same as or confusingly similar to, misleading or deceptive with respect to, or that dilutes,
any of the Baxter Trademarks. Baxter shall have the sole right to initiate at its own discretion legal proceedings against any infringement or threatened infringement of any Baxter Trademark. Baxter shall and hereby does grant to CTI a non-exclusive royalty-free license to use the Baxter Trademarks on or in connection with the Commercialization of Licensed Products in the
Co-Promotion Territory. 
 11.2. Use of CTI Trademarks. Licensed Products Commercialized in
the Co-Promotion Territory shall be co-branded with CTI and Baxter Trademarks, with equal prominence given to each. Each Party shall approve any labeling or promotional
materials containing its trademarks, such approval not to be unreasonably withheld or delayed. Licensed Products Commercialized in the Baxter Exclusive Territory shall have the following statement on all packaging, in legible size (but such size to
be subject to Baxter’s control of such packaging): “Under license from Cell Therapeutics, Inc.” 
 11.2.1. CTI shall and
hereby does grant to Baxter a non-exclusive royalty-free license, with the right to grant sublicenses through multiple tiers of Sublicensees (subject to
Section 2.4), to use the CTI Trademarks solely for purposes of the immediately preceding paragraph of this Section 11.2. 

  
 54 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 11.2.2. Baxter shall not use any trademark that is confusingly similar to, misleading or
deceptive with respect to, or that dilutes, any CTI Trademark. 
 11.2.3. Baxter shall properly designate the CTI Trademarks on the
packaging of the final Licensed Product, to the extent required or permissible by the applicable Marketing Approvals and Baxter agrees that all Licensed Products with which the CTI Trademarks are used shall conform to all requirements of any
Applicable Laws and any Regulatory Authorities in the Licensed Territory and shall be no less than a reasonable level of quality. 
 11.2.4.
Except as otherwise provided in this Section 11.2, CTI shall have the first right and authority, but not an obligation, to register and maintain the CTI Trademarks in the Licensed Territory (subject to this Section 11.2). CTI
shall be responsible for all costs and expenses of such registration and maintenance. CTI shall provide Baxter reasonable opportunity to review and comment on such registration efforts regarding the CTI Trademarks. CTI shall provide Baxter with a
copy of material communications from any Governmental Authority in the Licensed Territory regarding the CTI Trademark, and shall provide drafts of any material filings or responses to be made to such authorities in a timely manner. 

11.2.5. If a Party becomes aware of any actual or alleged existing or threatened infringement by a Third Party of any CTI Trademark in the
Licensed Territory (such activities, “Trademark Infringement”), such Party shall notify the other Party, and shall provide to the other Party any and all evidence and information available to such Party regarding such alleged
infringement. CTI shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity engaged in such Trademark Infringement, at its sole expense, subject to this Section 11.2.5.
CTI shall have a period of thirty (30) days after such notification to or by Baxter, to elect to so enforce such CTI Trademark. If CTI does not so elect, CTI shall so notify Baxter in writing during such thirty (30) day period, or
ten (10) days prior to any deadline relating to loss of any rights with respect to the Trademark Infringement, whichever is earlier, and Baxter shall have the right, but not the obligation, to commence a suit or take action to enforce such CTI
Trademark against such Third Party, at its sole expense. Each Party shall provide to the Party enforcing any such rights under this Section 11.2.5 reasonable assistance in such enforcement, at such enforcing Party’s request and
expense, including without limitation joining an action as a party plaintiff if so required by Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, and
shall reasonably consider the other Party’s comments on any such efforts. 
 11.2.6. The Party not bringing an action with respect to
Trademark Infringement under Section 11.2.5 shall be entitled to separate representation in such matter by counsel of its own choice and at its expense, but such Party shall at all times cooperate fully with the Party bringing such
action. Additionally, the Party not bringing an action under Section 11.2.5 may have an opportunity to participate in such action to the extent that the Parties may mutually agree at the time the other Party elects to bring an action
hereunder. 

  
 55 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 11.3. Infringement of Baxter Trademarks by Third Parties. With respect to any Baxter
Trademarks associated with Licensed Products in the Licensed Territory, each Party shall notify the other Party promptly upon learning of any actual or alleged threatened or existing infringement of any trademark or of any unfair trade practices,
trade dress imitation, passing off of counterfeit goods or like offenses, against such trademark. Baxter shall have the sole right, in its own discretion and at its own expense, to bring an action to address such infringement. 

ARTICLE XII. 

REPRESENTATIONS AND WARRANTIES 

12.1. The Parties’ Representations and Warranties. Each Party hereby represents and warrants to the other Party, as of the
Effective Date, as set forth below. In the case of Baxter, “Party” shall mean and refer to each of BII, BHC and BHSA. 
 12.1.1.
Such Party (a) is a corporation duly organized and subsisting under the applicable Laws of its jurisdiction of organization, and (b) has full power and authority and the legal right to own and operate its property and assets and to carry
on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement. 
 12.1.2. Such Party has the
power, authority and legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date. 

12.1.3. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of
such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other applicable Laws of general application affecting the enforcement of creditor rights and judicial principles affecting
the availability of specific performance and general principles of equity. 
 12.1.4. Such Party has taken all corporate action necessary to
authorize the execution and delivery of this Agreement. 
 12.1.5. Except with respect to Marketing Approvals and Reimbursement Approvals
for Licensed Products or as otherwise described in this Agreement, such Party has obtained all necessary consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by such Party in
connection with the execution and delivery of this Agreement and the performance of its obligations hereunder. 
 12.1.6. The execution and
delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable Laws or any provision of the articles of incorporation, bylaws, limited partnership
agreement, or any similar instrument of such Party, as applicable, in any material way, and (b) do not conflict with, violate, or breach or constitute a default or require any consent under, any applicable Laws or any contractual obligation or
court or administrative order by which such Party is bound. 

  
 56 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 12.1.7. All of such Party’s employees, officers, independent contractors, consultants,
and agents have executed agreements requiring assignment or licensing to such Party of all Inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the
confidential information of such Party; provided, however, that for employees of a Party’s Affiliates based in Germany, Austria, or any other jurisdiction where a prior obligation to assign is not permitted, the obligation under
this paragraph will be deemed satisfied if (a) each such employee is obligated to notify his employer of such Inventions and (b) the employer has an established program for receiving such notifications and timely claiming ownership of such
Inventions after notification. 
 12.1.8. Neither such Party, nor any of such Party’s employees, independent contractors, consultants,
agents or officers: (a) has ever been debarred or is subject to debarment or, to such Party’s knowledge, convicted of a crime for which a Person could be debarred before a Regulatory Authority under applicable Laws, or (b) to such
Party’s knowledge, has ever been under indictment for a crime for which a Person could be debarred under such Laws. 
 12.1.9. All
documents, information and know-how furnished or transferred by such Party to the other Party under this Agreement shall be, to its knowledge, free of errors in any material respect. 

12.1.10. Neither such Party is a party to or bound by any corporate integrity agreement or similar compliance agreement to which any
Governmental Authority or Third Party payor is a counterparty, and in the event either Party becomes aware of any potential or actual investigation or violation of applicable Law or regulations that may result in the entry by such Party into any
such agreement, such Party shall promptly notify the other Party of such action in accordance with Section 14.3.1. 
 12.2.
CTI’s Representations and Warranties. CTI hereby represents and warrants to Baxter, as of the Effective Date, as set forth below: 

12.2.1. A complete listing of all of the Upstream Agreements is attached hereto as Exhibit 1.160 and a true and complete copy (with
certain financial terms redacted) of each of the Upstream Agreements together with all exhibits, schedules, appendices, attachments and amendments thereto has been provided to Baxter prior to the Effective Date. The Upstream Agreements have not been
modified, supplemented or amended since such copy was provided to Baxter. The Upstream Agreements are, to CTI’s knowledge, in full force and effect, all payments to date required to be made thereunder by CTI have been made, and CTI is in
compliance in all material respects with its obligations thereunder. 
 12.2.2. CTI has not received or provided any notice of termination
of any of the Upstream Agreements, or any notices of breach of any of the Upstream Agreements. 
 12.2.3. CTI has sufficient legal and/or
beneficial title under its intellectual property rights necessary to grant the licenses contained in this Agreement. 

  
 57 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 12.2.4. There is no pending or, to CTI’s knowledge, threatened claim, litigation or any
other proceeding brought by a Third Party against CTI challenging the validity of the CTI Patent Rights in the Licensed Territory, or claiming that the Development, manufacture or Commercialization of the Licensed Product in the Licensed Field in
any portion of the Licensed Territory constitutes or would constitute infringement of such Third Party’s intellectual property right(s), and CTI has no present knowledge of any Third Party intellectual property right that would reasonably be
expected to give rise to any such claim, litigation or proceeding. To CTI’s knowledge as of the Effective Date, the use of the CTI Know-How and the CTI Patents in existence on the Effective Date for the Development, manufacture and
Commercialization of Licensed Products as contemplated by this Agreement does not infringe the intellectual property rights of any Third Party. 

12.2.5. There is no pending or, to CTI’s knowledge, threatened claim, litigation or any other proceeding brought by a Third Party against
CTI claiming that the Development of the Licensed Product or Drug Product or the manufacture of the Licensed Product or Drug Product at the location where CTI currently manufactures such Licensed Product or Drug Product constitutes or would
constitute infringement of such Third Party’s intellectual property right(s), and CTI has no present knowledge of any Third Party intellectual property right that would reasonably be expected to give rise to any such claim, litigation or
proceeding. 
 12.2.6. CTI has not received any written communications alleging that it has violated or that it would violate, through the
manufacture, use, import, export, sale, and/or offer for sale of the Licensed Product in the Licensed Field and in the Licensed Territory or any portion thereof, any intellectual property rights of any Third Party. 

12.2.7. To CTI’s knowledge, no invention claimed by the CTI Patents was made or reduced to practice using any funding of the U.S.
Government; provided that CTI does not make any representation or warranty with respect to inventions licensed under the Upstream Agreements. 

12.2.8. CTI is not in possession of any in-licensed Third Party
know-how, technology, trade secrets or patent rights that are necessary to manufacture a Licensed Product or Drug Product but are not Controlled by CTI. 

12.2.9. The issuance of the Securities has been duly authorized and, when issued and paid for in accordance with the terms of this Agreement,
will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by CTI other than restrictions on transfer provided for in this Agreement. At the Effective Time, CTI has reserved the Preferred Stock and Common
Stock for issuance from its duly authorized capital stock. 
 12.2.10. CTI has the requisite corporate power to issue and sell the
Securities. The issuance and sale of the Securities will not (a) result in any violation of, be in conflict with, or constitute a default under, with or without the passage of time or the giving of notice: (i) any provision of CTI’s
or its subsidiaries’ articles of incorporation or bylaws as in effect on the date hereof, (ii) any provision of any judgment, arbitration ruling, decree or order to which CTI or its 

  
 58 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
subsidiaries are a party or by which they are bound, (iii) any bond, debenture, note or other evidence of indebtedness, or any lease, contract, mortgage, indenture, deed of trust, loan
agreement, joint venture or other agreement, instrument or commitment to which CTI or any subsidiary is a party or by which they or their respective properties are bound, or (iv) any statute, rule, law or governmental regulation applicable to
CTI, or (b) result in the creation or imposition of any lien, encumbrance, claim, security interest or restriction whatsoever upon any of the properties or assets of CTI or any subsidiary or any acceleration of indebtedness pursuant to any
obligation, agreement or condition contained in any bond, debenture, note or any other evidence of indebtedness or any indenture, mortgage, deed of trust or any other agreement or instrument to which CTI or any subsidiary are a party or by which
they are bound or to which any of the property or assets of CTI or any subsidiary is subject. No consent, approval, authorization or other order of, or registration, qualification or filing with, any regulatory body, administrative agency, or other
governmental body is required for the valid issuance or sale of the Securities by CTI pursuant to this Agreement, other than such as have been made or obtained and that remain in full force and effect, and except for the filing of a Form D or any
filings required to be made under state securities laws. 
 12.2.11. CTI has made available to Baxter true, correct and complete copies of
the articles of incorporation and bylaws of CTI, as in effect on the date hereof. 
 12.2.12. The consolidated financial statements included
in CTI’s Annual Report on Form 10-K for the year ended December 31, 2012 and its quarterly reports on Form 10-Q for the year ending December 31, 2013 (such reports, including all exhibits and documents incorporated by reference
therein, together with any 8-Ks or proxy statements filed since January 1, 2013 and any exhibits and documents incorporated by reference therein, the “Company SEC Documents”) filed by CTI with the Securities and Exchange
Commission (the “SEC”): (a) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto when filed and were timely filed, (b) were prepared in accordance with
generally accepted accounting principles applied on a consistent basis throughout the periods covered, except as may be indicated in the notes to such financial statements and (in the case of unaudited statements) as permitted by Form 10-Q , and
except that unaudited financial statements may not contain footnotes and are subject to year-end audit adjustments, and (c) fairly present in all material respects the consolidated financial position of CTI and its subsidiaries as of the
respective dates thereof and the consolidated results of operations cash flows and the changes in shareholders’ equity of CTI and its subsidiaries for the periods covered thereby. 

12.2.13. Except as set forth in the financial statements included in the Company SEC Documents, neither CTI nor its subsidiaries has incurred
any liabilities, contingent or otherwise, other than (a) trade payables, accrued expenses, and other liabilities incurred in the ordinary course of business subsequent to September 30, 2013, and (b) liabilities of the type not
required under generally accepted accounting principles to be reflected in such financial statements. 
 12.2.14. Except as disclosed in the
Company SEC Documents, CTI has not issued any capital stock since its most recently filed periodic report filed with the SEC, other than pursuant 

  
 59 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
to the exercise and granting of employee stock options and stock awards pursuant to CTI’s equity incentive plans, or the issuance of shares of common stock pursuant to employee stock
purchase plans or pursuant to the conversion or exercise of outstanding warrants or other convertible securities as of the date of the most recently filed periodic report filed with the SEC. All issued and outstanding shares of common stock have
been duly authorized and validly issued, are fully paid and nonassessable, have been issued and sold in compliance with the registration requirements of federal and state securities laws or the applicable statutes of limitation have expired, and
were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. 
 12.2.15. Except as set
forth herein or in the Company SEC Documents, there are no (a) outstanding rights (including, without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued shares of
capital stock or other equity interest in CTI, or any contract, commitment, agreement, understanding or arrangement of any kind to which CTI or any subsidiary is a party and relating to the issuance or sale of any capital stock or convertible or
exchangeable security of CTI or any subsidiary, other than options or stock awards granted to directors and employees of CTI pursuant to existing equity incentive plans or (b) obligations of CTI to purchase, redeem or otherwise acquire any of
its outstanding capital stock or any interest therein or to pay any dividend or make any other distribution in respect thereof. Except as disclosed in the Company SEC Documents, there are no anti-dilution or price adjustment provisions, co-sale
rights, registration rights, rights of first refusal or other similar rights contained in the terms governing any outstanding security of CTI that will be triggered by the issuance of the Securities. 

12.2.16. Assuming the accuracy of the representations of Baxter in Section 12.3 of this Agreement on the date hereof, the offer,
issue and sale of the Securities to Baxter under the terms of this Agreement are exempt from the registration and prospectus delivery requirements of the Securities Act and have been or will be registered or qualified (or are or will be exempt from
registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. Neither CTI, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly
made any offers or sales of any security or solicited any offers to buy any security under circumstances that would require registration under the Securities Act of the issuance of the Securities to Baxter. 

12.2.17. CTI’s common stock is registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) and is listed on the Nasdaq Capital Market (the “Principal Market”), and CTI has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Principal Market. CTI is in compliance with all of the presently applicable requirements for continued listing of the Common Stock on the Principal Market. The issuance of the Securities does
not require shareholder approval including, without limitation, pursuant to the rules and regulations of the Principal Market. 

  
 60 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 12.2.18. CTI is eligible to register the Common Stock for resale by the holder thereof using
Form S-3 promulgated under the Securities Act. 
 12.2.19. All stock transfer or other taxes (other than income taxes) that are required to
be paid in connection with the issuance and sale of the Securities by CTI to Baxter will be, or will have been, fully paid or provided for by CTI and CTI will have complied with all applicable laws imposing such taxes. 

12.2.20. CTI is not required to register as an “investment company” under the Investment Company Act of 1940 and will not be
required to register as an “investment company” as a result of the issuance of the Securities pursuant to the terms of this Agreement and the receipt of the proceeds therefrom. 

12.2.21. The representations and warranties contained in this Section 12.2 do not contain any untrue statement of a material fact
or omit a material fact necessary to make the statements in this Section 12.2, in light of the circumstances in which they are made, not misleading. To the knowledge of CTI, there is no circumstance that has specific application to CTI
(other than general economic or industry conditions) that has had or CTI can reasonably foresee would have a material adverse effect on the assets, business, prospects, financial condition or results of operations of CTI and its subsidiaries taken
as a whole, except in each case that has been described in this Section 12.2 or any Company SEC Document. 
 12.3.
Baxter’s Representations and Warranties. 
 Baxter hereby represents and warrants to CTI, as of the Effective Date, that Baxter
is (a) an “accredited investor” within the meaning of Rule 501 of Regulation D under the Exchange Act, as presently in effect and is not an entity formed for the sole purpose of acquiring the Securities, and has a total in assets of
at least €20 million and net revenues of at least €40 million. Baxter has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective
investment in the Securities. Baxter has had access to such information as it deemed necessary in order to conduct any due diligence it has determined is necessary or appropriate in connection with the purchase and sale of the Securities and its
decision to participate in such purchase and sale. Baxter is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. Baxter understands that nothing in the
Agreement or any other materials presented to Baxter in connection with the transactions contemplated hereby constitutes legal, tax or investment advice. Baxter acknowledges that it must rely on legal, tax and investment advisors of its own choosing
in connection with its purchase of the Securities. Baxter’s decision to purchase the Securities was based solely upon the representations and warranties set forth herein, and Baxter has not relied upon any other information or representations
made by or on behalf of the Securities. 
 12.3.1. Immediately prior to the execution of this Agreement, neither Baxter nor any of its
Affiliates beneficially own any CTI equity securities or any securities convertible into CTI equity securities. Baxter has no present actual intent to seek to effect, or to assist others in effecting, a hostile acquisition of CTI. 

  
 61 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 12.3.2. Baxter understands that any Securities issued hereunder shall be characterized as
“restricted securities” under the federal securities Laws inasmuch as they are being acquired from CTI in a transaction not involving a public offering and that under such Laws and applicable regulations such securities may be resold with
registration under the Securities Act, only in certain limited circumstances. Baxter understands that any Securities issued as part of the Equity Consideration may bear the following or similar legend: 

“THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR
UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.” 
 12.3.3. Baxter understands that the issuance or delivery of any Securities has not
been registered with or cleared by the Commissione Nazionale per le Societa e la Borsa (“CONSOB”) pursuant to the European Union Directive 2003/71/EC (so-called Prospectus Directive) and Italian securities laws and
regulations and no prospectus has been or will be distributed in the Republic of Italy. 
 12.4. The Parties’ Covenants. Each
Party hereby covenants throughout the Term as set forth below: 
 12.4.1. Such Party shall not enter into any agreement with a Third Party
that will conflict with the rights granted to the other Party under this Agreement. 
 12.4.2. If during the term of this Agreement, a Party
has reason to believe that it or any of its employees, officers, independent contractors, consultants, or agents rendering services relating to the Licensed Product: (x) is or will be debarred or convicted of a crime for which such Person could
be debarred before a Regulatory Authority under applicable Laws, or (y) is or will be under indictment under such Laws, then such Party promptly shall notify the other Party of same in writing. 

12.5. CTI’s Covenants. 

12.5.1.Upstream Agreements. CTI hereby covenants that throughout the Term it shall not agree to amend any terms or conditions of the
Upstream Agreements in any manner that 

  
 62 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 would adversely affect the rights granted to Baxter under this Agreement in any respect without the prior
written consent of Baxter. CTI further agrees that it shall not terminate the Upstream Agreements, shall not cease to exercise its rights under the Upstream Agreements, and shall not amend the Upstream Agreements in any manner that would adversely
affect Baxter, in each case without the prior written consent of Baxter. CTI shall comply with the terms of the Upstream Agreements in all material respects; provided that CTI shall not be in breach of the foregoing obligations to the extent
that CTI’s failure to comply results from Baxter’s non-compliance with the terms of this Agreement, and further provided that if Section 15.4 applies, then CTI shall not be
deemed in breach of this Section 12.5 and the Parties shall have the rights and obligations set forth in Section 15.4. CTI shall notify Baxter of any anticipated termination of the Upstream Agreements by CTI prior to such
termination. CTI shall further notify Baxter when it has received any notice from any Third Party that is a party to an Upstream Agreement stating that such Third Party intends to terminate or is terminating such Upstream Agreement. 

12.5.2. Baxter Approved Supplier Status. CTI will (in cooperation with Baxter) undertake such activities (including an obligation by
such parties to undertake any remediation efforts) as are required to ensure that CTI and its applicable Third Party manufacturers for Licensed Product and/or Drug Product shall, no later than one hundred eighty (180) days prior to the
projected First Commercial Sale of a Licensed Product, become, and shall throughout the Term remain, Baxter Approved Suppliers, it being understood and agreed that any Baxter judgments in connection with audit assessments in relation to CTI becoming
a Baxter Approved Supplier shall be commercially reasonable and made in good faith. For purposes hereof, “Baxter Approved Supplier” shall mean a supplier approved in accordance with written criteria provided in advance to CTI. 

ARTICLE XIII. 

CONFIDENTIALITY 
 13.1.
Confidentiality Obligations of Baxter. 
 13.1.1. Subject to Section 13.3, during the term of this Agreement and for a
period of ** thereafter, or ** from the Effective Date, whichever is longer, Baxter: 
 (a) shall hold in strict confidence any and all
information disclosed to it by CTI, including CTI Information (together “CTI Confidential Information”), and shall not use, nor disclose or supply to any Third Party, nor permit any Third Party, to have access to the CTI
Confidential Information, without first obtaining the written consent of CTI, except as expressly permitted in this Agreement; 
 (b) shall
take all reasonable precautions necessary or prudent to prevent material in its possession or control that contains or refers to CTI Confidential Information from being destroyed or lost, or discovered, received, used, intercepted or copied by any
Third Party; and 

  
 63 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (c) may disclose the CTI Confidential Information only to its employees, consultants,
independent contractors, agents, Affiliates, actual and potential Sublicensees and actual and potential acquirers; provided that such employees, consultants, independent contractors, agents, Affiliates, actual and potential Sublicensees and
actual and potential acquirers are bound by terms and conditions of confidentiality no less protective than the terms and conditions that bind Baxter hereunder. 

For the avoidance of doubt, it is understood that Baxter shall be liable for any breach of the confidentiality obligation under this
Section 13.1 by any person or corporation to whom the CTI Confidential Information is disclosed by Baxter. 
 13.1.2.
Baxter’s obligations of confidentiality and non-use under this Section 13.1 shall not apply and Baxter shall have no further obligations with respect to any of the CTI Confidential
Information, to the extent that such CTI Confidential Information: 
 (a) is or becomes part of the public domain without breach by Baxter
of this Agreement; 
 (b) was rightfully in Baxter’s possession before disclosure by CTI and was not acquired directly or indirectly
from CTI; 
 (c) is obtained from a Third Party with no obligation of confidentiality to CTI, who has a right to disclose it to Baxter;

 (d) is developed independently by Baxter without use of the CTI Confidential Information, as evidenced by Baxter’s written records;
or 
 (e) is required to be revealed in response to a court decision or administrative order, or to comply with Laws of a Governmental
Authority or rules of a securities exchange, in which case Baxter shall inform CTI immediately by written notice and cooperate with CTI using its Commercially Reasonable Efforts either to seek protective measures for such CTI Confidential
Information, or to seek confidential treatment of such CTI Confidential Information, and in any case Baxter shall disclose only such portion of the CTI Confidential Information which is so required to be disclosed. 

13.1.3. Nothing herein shall prevent Baxter from disclosing any CTI Confidential Information to the extent that such CTI Confidential
Information is required to be used or disclosed for the purposes of seeking or obtaining Marketing or Reimbursement Approvals of Licensed Products in the Licensed Territory or seeking patent protection for Inventions it owns or has responsibility
for prosecuting under Article X. Baxter shall further have the right to present CTI Confidential Information at conferences or to publish CTI Confidential Information in journals (collectively “Publications”); provided
that if the CTI Confidential Information concerned has not been previously published, Baxter shall give CTI reasonable notice thereof and such Publication shall be subject to CTI’s prior written consent, not to be unreasonably withheld,
conditioned or delayed. 

  
 64 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 13.2. Confidentiality Obligations of CTI. 

13.2.1. Subject to Section 13.3, during the term of this Agreement and for a period of ** thereafter, or ** from the Effective
Date, whichever is longer, CTI: 
 (a) shall hold in strict confidence any and all information disclosed to it by Baxter, including Baxter
Information (together “Baxter Confidential Information”), and shall not use, nor disclose or supply to any Third Party nor permit any Third Party to have access to the Baxter Confidential Information, without first obtaining the
written consent of Baxter, except as expressly permitted in this Agreement; 
 (b) shall take all reasonable precautions necessary or
prudent to prevent material in its possession or control that contains or refers to Baxter Confidential Information from being destroyed or lost, or discovered, received, used, intercepted or copied by any Third Party; and 

(c) may disclose the Baxter Confidential Information to its employees, consultants, independent contractors, agents, Affiliates, and actual
and potential acquirers; provided that such employees, consultants, independent contractors, agents, Affiliates, and actual and potential acquirers are bound by terms and conditions of confidentiality no less protective than the terms and
conditions that bind CTI hereunder. 
 For the avoidance of doubt, it is understood that CTI shall be liable for any breach of the
confidentiality obligation under this Section 13.2 by any person or corporation to whom the Baxter Confidential Information is disclosed by CTI. 

13.2.2. CTI’s obligations of confidentiality and non-use under this Section 13.2
shall not apply and CTI shall have no further obligations with respect to any of the Baxter Confidential Information to the extent that such Baxter Confidential Information: 

(a) is or becomes part of the public domain without breach by CTI of this Agreement; 

(b) was rightfully in CTI’s possession before disclosure by Baxter to CTI and was not acquired directly or indirectly from Baxter; 

(c) is obtained from a Third Party with no obligation of confidentiality to Baxter, who has a right to disclose it to CTI; 

(d) is developed independently by CTI without use of the Baxter Confidential Information, as evidenced by CTI’s written records; or 

(e) is required to be revealed in response to a court decision or administrative order, or to comply with Laws of a Governmental Authority or
rules of a securities exchange, in which case CTI shall inform Baxter immediately by written notice and 

  
 65 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
cooperate with Baxter using its Commercially Reasonable Efforts either to seek protective measures for such Baxter Confidential Information, or to seek confidential treatment of such Baxter
Confidential Information, and in any case CTI shall disclose only such portion of the Baxter Confidential Information which is so required to be disclosed. 

13.2.3. Nothing herein shall prevent CTI from disclosing any Baxter Confidential Information to the extent that such Baxter Confidential
Information is required to be used or disclosed for the purposes of seeking or obtaining Marketing Approvals of Licensed Products or seeking patent protection for Inventions it owns or has responsibility for prosecuting under Article X. CTI
shall further have the right to disclose any Baxter Confidential Information in a Publication; provided that if the Baxter Confidential Information concerned has not been previously published, CTI shall give Baxter reasonable notice thereof
and such Publication shall be subject to Baxter’s prior written consent, not to be unreasonably withheld, delayed or conditioned. 

13.2.4. Other Initiatives. Each Party understands that the other Party may have present or future initiatives, including initiatives
with third parties, involving similar products, technologies or processes that compete with a product, technology or process contemplated or offered by the other Party. Accordingly, the Parties agree that nothing in this Agreement other than its
agreement to use Commercially Reasonable Efforts with respect to certain obligations hereunder shall be construed as a representation or inference that either Party will not develop for itself, or enter into business relationships with other Third
Parties that involve products, technologies or processes that are similar to or compete with any product, technology or process contemplated or offered by the other Party, provided that Confidential Information is not used or disclosed in
breach of this Agreement or is otherwise in contravention of this Agreement. 
 13.3. Press Releases; Publicity. 

13.3.1. Except with respect to the press release attached hereto as Exhibit 13.3.1 (or any press release, public disclosure or any
other disclosure to a Third Party with content substantially similar thereto) which may be issued by either or both of the Parties upon execution of this Agreement, no disclosure shall be made by either Party concerning the execution of this
Agreement or the terms and conditions hereof without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that neither Party will be prevented from complying
on a timely basis with any duty of disclosure it may have pursuant to Law or pursuant to the rules of any recognized stock exchange or quotation system. Notwithstanding the foregoing, either Party may disclose the existence of this Agreement and the
terms and conditions hereof without the prior written consent of the other pursuant to Section 13.1.2(e) or Section 13.2.2(e), as applicable, or in connection with a due diligence process associated with any future financing
by either Party or the negotiation or exploration of a possible strategic transaction involving such Party; provided that such disclosure is made in the course of such diligence, negotiation or exploration pursuant to confidentiality
obligations consistent with those set forth in this Agreement. Each Party may issue a press release or public announcement concerning the development of the Product, provided that such 

  
 66 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Party shall provide the other Party with a copy of such press release or public announcement at least ten (10) days in advance of its intended publication or release thereof and shall
consider in good faith the comments of the other Party which comments shall be provided as promptly as reasonably practicable following receipt of the press release or public announcement from the Party desiring to make the disclosure. 

13.3.2. Each Party agrees that it shall cooperate fully and in a timely manner with the other Party with respect to all disclosures required
by the Securities and Exchange Commission and any other Governmental Authority or Regulatory Authority, including requests for confidential treatment of confidential information of either Party included in any such disclosure. Notwithstanding any
other provision of this Agreement, either Party may issue any public announcement or other disclosure that it is advised by legal counsel is required under applicable Laws or the rules of any recognized stock exchange or quotation system,
provided that the Parties shall coordinate with each other with respect to the timing, form and content of such required disclosure to the extent practicable under the circumstances, and the Party seeking such disclosure shall use
Commercially Reasonable Efforts to provide the other Party with reasonable notice thereof in advance of any disclosure. Any request for revision to the content of said disclosure by the non-disclosing Party
shall be furnished to the disclosing Party as promptly as necessary for the disclosing Party to comply with such requirements in a timely manner. Without limiting the foregoing, each Party shall consult with the other Party on the provisions of this
Agreement, together with exhibits or other attachments attached hereto, to be redacted in any filings made by CTI and/or Baxter with the Securities and Exchange Commission or as otherwise required by Law. 

13.3.3. Once a disclosure is disclosed in accordance with the terms of this Agreement, the content of such disclosure (or any portion thereof)
may be repeated in a subsequent disclosure by either Party without regard to the notification or other requirements of this Section 13.3. 

ARTICLE XIV. 

INDEMNIFICATION 
 14.1.
CTI Indemnity. CTI shall defend, indemnify and hold harmless Baxter and its Affiliates and their respective directors, officers, agents, successors, assignees and employees (the “Baxter Indemnitees”) from and against any and
all claims, liabilities, losses, costs, actions, suits, damages and expenses, including reasonable attorneys’ fees (collectively “Damages”), to the extent arising from any claim, action or proceeding made or brought against
Baxter Indemnitees by a Third Party in connection with (a) the gross negligence, recklessness, or intentional wrongful acts or omissions of CTI or its Affiliates or their respective employees, officers, independent contractors, consultants, or
agents, in connection with the performance by or on behalf of CTI of CTI’s obligations or exercise of its rights under this Agreement, (b) any breach by CTI, or its Affiliates or their respective independent contractors of any
representation, warranty, covenant, or obligation of CTI set forth in this Agreement, **; except in any such case to the extent such Damages are reasonably attributable to any gross negligence, recklessness, willful misconduct, or breach of this
Agreement by Baxter or a Baxter Indemnitee. 

  
 67 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 14.2. Baxter Indemnity. Baxter shall defend, indemnify and hold harmless CTI and its
Affiliates, directors, officers, agents, successors, assignees and employees (the “CTI Indemnitees”) from and against any and all Damages to the extent arising from any claim, action or proceeding made or brought against CTI
Indemnitees by a Third Party in connection with (a) the gross negligence, recklessness, or intentional wrongful acts or omissions of Baxter or its Affiliates or their respective employees, officers, independent contractors, consultants, or
agents, in connection with the performance by or on behalf of Baxter of Baxter’s obligations or exercise of its rights under this Agreement, (b) any breach by Baxter or its Affiliates or their respective independent contractors of any
representation, warranty, covenant, or obligation of Baxter set forth in this Agreement, or **; except in any such case to the extent such Damages are reasonably attributable to any gross negligence, recklessness, willful misconduct, or breach of
this Agreement by CTI or a CTI Indemnitee. 
 14.3. Indemnification Procedure. 

14.3.1. Each Party shall notify the other in the event it becomes aware of a claim for which indemnification may be sought pursuant to this
Article XIV. In case any proceeding (including any governmental investigation) shall be instituted involving any Party in respect of which indemnity may be sought pursuant to this Article XIV, such Party (the “Indemnified
Party”) shall promptly notify the other Party (the “Indemnifying Party”) in writing (an “Indemnification Claim Notice”). The Indemnifying Party and Indemnified Party shall promptly meet to discuss how to
respond to any claims that are the subject matter of such proceeding. At its option, the Indemnifying Party may assume the defense of any Third Party claim subject to indemnification as provided for in this Section 14.3 by giving written
notice to the Indemnified Party within thirty (30) days or until such time provided in any applicable extension to appropriately answer any complaint, if any, but no longer than sixty (60) days (the “Election Time
Period”); with the Indemnified Party being obligated to make all reasonable efforts to obtain any such extension after the Indemnifying Party’s receipt of an Indemnification Claim Notice, solely for claims (a) that solely seek
monetary damages and (b) as to which the Indemnifying Party expressly agrees in writing that, as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge the claim in
full (the matters described in (a) and (b), the “Litigation Conditions”). The Indemnified Party may assume responsibility for such defense if the Litigation Conditions are not satisfied, by written notice to the
Indemnifying Party within the Election Time Period. If the Indemnified Party fails to promptly provide an Indemnification Claim Notice, and such failure materially prejudices the defense of such claim, then the Indemnifying Party shall be relieved
of its responsibility to indemnify the Indemnified Party. 
 14.3.2. Upon assuming the defense of a Third Party claim in accordance with
this Section 14.3, the Indemnifying Party shall be entitled to appoint lead and any local counsel in the defense of the Third Party claim. Should the Indemnifying Party assume and continue the


  
 68 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
defense of a Third Party claim, except as otherwise set forth in this Section 14.3, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses
subsequently incurred by such Indemnified Party after the date of assumption of defense in connection with the analysis, defense, countersuit or settlement of the Third Party claim. Without limiting this Section 14.3, any Indemnified
Party will be entitled to participate in, but not control, the defense of a Third Party claim for which it has sought indemnification hereunder and to engage counsel of its choice for such purpose; provided, however, that such
engagement will be at the Indemnified Party’s own expense unless (a) the engagement thereof has been specifically requested by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume and actively further
the defense and engage counsel in accordance with this Section 14.3 (in which case the Indemnified Party will control the defense), or (c) the Indemnifying Party no longer satisfies the Litigation Conditions. 

14.3.3. Subject to the Litigation Conditions being satisfied, the Indemnifying Party will have the sole right to consent to the entry of any
judgment, enter into any settlement or otherwise dispose of such Damages, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that such terms shall include a complete and
unconditional release of the Indemnified Party from all liability with respect thereto), and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay pursuant to such settlement or disposal of such claim
prior to the time such payments become due by the Indemnified Party. With respect to all other Damages in connection with Third Party claims, where the Indemnifying Party has assumed the defense of the Third Party claim in accordance with this
Section 14.3, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Damages; provided it obtains the prior written consent of the
Indemnified Party, not to be unreasonably withheld, conditioned or delayed. 
 14.3.4. The Indemnifying Party that has assumed the defense
of the Third Party claim in accordance with this Section 14.3 will not be liable for any settlement or other disposition of any Damages by an Indemnified Party that is reached without the written consent of such Indemnifying Party. The
Indemnified Party will not admit any liability with respect to, or settle, compromise or discharge, any Third Party claim without first offering to the Indemnifying Party the opportunity to assume the defense of the Third Party claim in accordance
with this Section 14.3. If the Indemnifying Party chooses to defend or prosecute any Third Party claim, the Indemnified Party will cooperate in the defense or prosecution thereof and will furnish such records, information and testimony,
provide such witnesses including to the extent possible, former employees and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with such Third Party claim. Such cooperation
will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party claim, and making employees and
agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. The Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses incurred in connection with such cooperation. 

  
 69 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 14.3.5. Each Party shall maintain, at its cost, a program of insurance and/or self-insurance against liability and other risks associated with its activities and obligations under this Agreement, including its Clinical Trials, the Commercialization of any Licensed Products and its
indemnification obligations hereunder, in such amounts, subject to such deductibles and on such terms as are customary for the activities to be conducted by it under this Agreement. All insurance required by this Section 14.3.5 shall be
maintained during the Term and each Party shall, from time to time, provide copies of certificates of such insurance to the other Party upon request. Further, each Party shall list the other Party as an additional insured on all insurance policies.
All insurance required by this Section 14.3.5 shall be maintained for at least three (3) years following expiration or termination of this Agreement. 

14.4. Limitation of Liability; Exclusion of Damages; Disclaimer. 

14.4.1. EXCEPT WITH RESPECT TO DAMAGES AWARDED TO A THIRD PARTY BY A COURT OF COMPETENT JURISDICTION THAT ARE REQUIRED TO BE INDEMNIFIED UNDER
SECTION 14.1 OR SECTION 14.2, AND EXCEPT IN THE CASE OF A BREACH OF ARTICLE XIII, AND WITHOUT LIMITING THE LIABILITY OF A PARTY FOR INFRINGEMENT OR MISAPPROPRIATION OF THE INTELLECTUAL PROPERTY RIGHTS OF THE OTHER PARTY OR
FOR FRAUD OR WILLFUL MISCONDUCT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION
OR LOSS OF BUSINESS, DIMINUTION OF VALUE, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 

14.4.2. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED,
REGARDING THE LICENSED PRODUCT AND EACH PARTY HEREBY DISCLAIMS ALL OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS AND IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND FREEDOM
FROM INFRINGEMENT OF THIRD PARTY RIGHTS. 
 ARTICLE XV. 

TERM; TERMINATION 
 15.1.
Term. This Agreement shall expire in its entirety upon the expiration of all applicable Royalty Terms in the Licensed Territory and satisfaction of the applicable payment obligations (including Milestone payments) under this Agreement with
respect to all Licensed Products in all countries in the Licensed Territory (the “Term”). 

  
 70 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 15.1.1. Effect of Expiration. Upon expiration of this Agreement in accordance with
Section 15.1: 
 (a) the Licensed Rights shall continue in full force and effect and be considered to be fully paid-up; and 
 (b) Subject to the Confidentiality obligations contained in Article XIII, Baxter
and CTI shall each have the right to freely use all Information disclosed to it by the other Party hereunder solely in connection with the development, manufacture and commercialization of Licensed Products. 

15.2. Early Termination. 

15.2.1. By Either Party for Breach. Without prejudice and in addition to any other contractual remedy the non-defaulting Party may have under this Agreement, either Party may terminate this Agreement in writing forthwith, if the other Party commits a material breach of any provision of this Agreement and such breach is
not cured within sixty (60) days after written notice of the breach is received by the other Party, which notice shall specify the nature of the breach and demand its cure. Notwithstanding the foregoing, if a material breach is not susceptible
to cure within the cure period specified above, the non-breaching Party’s right of termination shall be suspended only if, and for so long as, (a) the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated to effect a cure, (b) such plan is reasonably acceptable to the non-breaching Party and (c) the
breaching Party commits to and does carry out such plan; provided, however, that, unless otherwise mutually agreed by the Parties in such plan, in no event shall such suspension of the
non-breaching Party’s right to terminate extend beyond sixty (60) days after the original cure period. 

15.2.2. By Either Party for Force Majeure. The Agreement may be terminated by either Party in the event of a Force Majeure (as
hereinafter defined) pursuant to Section 15.4.3. 
 15.2.3. By Either Party for Insolvency. Either Party may terminate
this Agreement upon written notice if the other Party is dissolved or liquidated, files or has filed against it a petition under any bankruptcy or insolvency law that is not dismissed within sixty (60) days, makes an assignment for the benefit
of its creditors or has a receiver or trustee appointed for all or substantially all of its property. 
 15.2.4. By CTI for Baxter Patent
Challenge. In the event that Baxter or any of its Affiliates commences or otherwise, directly or indirectly, pursues (or, other than as required by Law or legal process, voluntarily assists any Third Party to pursue in any material respect where
Baxter has knowledge that its assistance will be used by the Third Party to pursue) any proceeding seeking to have any of the CTI Patents revoked or declared invalid, unpatentable, or unenforceable, CTI may declare a material breach hereunder,
terminate this Agreement on written notice to Baxter and shall then have the right to exercise the remedies available under Section 15.3 with immediate effect. 

15.2.5. By Baxter for CTI Development Costs. In the event Baxter determines in good faith based on documentary evidence (including
without limitation information contained in the Development Account) that the CTI Development Costs that are reasonably projected to 

  
 71 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
be incurred on or after January 1, 2014 with respect to the Initial Indication that are (A) applicable to both the Baxter Exclusive Territory and the
Co-Promotion Territory, or (B) exclusive to the Co-Promotion Territory, in the case of either (A) or (B), exceed or will exceed **, Baxter may terminate this
Agreement. If Baxter determines that it desires to so terminate, it shall notify CTI in writing and such notification shall be accompanied by a reasonably detailed description of the CTI Development Costs involved, including without limitation the
territory or territories with respect to which such CTI Development Costs were or are expected to be incurred, and such other information as CTI may reasonably request. Unless CTI, within thirty (30) days of receipt of Baxter’s
notification pursuant to this Section 15.2.5, delivers to Baxter a written objection setting forth in reasonable detail its determination as to why it disagrees with Baxter’s calculations, the Agreement shall terminate on the
expiration of such thirty (30) day period. If CTI responds in writing with such a written objection within such thirty (30) day period, and Baxter disagrees with such response, the Parties shall follow the dispute resolution procedures set
forth in Section 16.13. In the event the matter is decided in Baxter’s favor, then Baxter shall have the right to terminate this Agreement effective immediately upon the decision rendered pursuant to Section 16.13. 

15.2.6. By Baxter for Commercial Failure. In the event of a Commercial Failure, Baxter shall have the right to terminate this Agreement
on a country-by-country basis or in its entirety upon ninety (90) days’ prior written notice to CTI. 
 15.2.7. By Baxter for
Convenience. Baxter may terminate this Agreement without cause upon written notice to CTI at any time following the one year anniversary of the Effective Date; provided, however, that such termination shall not be effective for a
period of six (6) calendar months following delivery to CTI of the termination notice, provided that during such 6-month period Baxter continues to perform its obligations hereunder, including without limitation participation in Committees,
payment of amounts due and using Commercially Reasonable Efforts to perform its Commercialization Obligations . 
 15.3. Obligations upon
Early Termination. 
 15.3.1. In the event of termination of this Agreement by either Party in accordance with Section 15.2:

 (a) all Licensed Rights shall revert to CTI without any compensation to be paid by CTI; 

(b) Baxter shall promptly return to CTI any and all CTI Information; 

(c) Baxter shall promptly transfer to CTI or its designee any and all Marketing Approvals and all other filings and submissions with and to
Regulatory Authorities owned by Baxter or its Affiliates with respect to the Licensed Product. To this end Baxter shall make Commercially Reasonable Efforts to file for transfer with the relevant Regulatory Authorities and to give all other
notifications and approvals necessary under law for the transfer of Marketing Approvals and such other filings and submissions; 

  
 72 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (d) Baxter shall grant to CTI a worldwide license, with the right to sublicense, through
multiple tiers of Sublicensees, to use any Baxter Trademarks (including, without limitation, the goodwill symbolized by such Baxter Trademarks) used to brand Licensed Products, and a license to reproduce, distribute, perform, display and prepare
derivative works of Baxter’s copyrights used to brand or Promote the Licensed Product, in each case solely to the extent necessary or useful for Commercializing the Licensed Product; provided that such license shall bear a commercially
reasonable royalty to be agreed by the Parties in good faith and provided further that the term of the license shall be no greater than ** unless agreed to by Baxter; 

(e) The licenses granted by Baxter to CTI pursuant to Section 2.2 and other provisions of this Agreement shall continue in
effect, but shall also from such time forward include the right to grant sublicenses through multiple tiers of Sublicensees, but solely to the extent necessary or useful for Developing or Commercializing the Licensed Product, in addition to those
sections that also survive pursuant to Section 15.5; 
 (f) Baxter shall furnish CTI with reasonable cooperation, at
Baxter’s expense, to assure a smooth transition of any clinical or other studies in progress then being conducted by Baxter or its Affiliates related to the Compound, Drug Product and/or Licensed Product which CTI determines to continue in
compliance with applicable Laws and ethical guidelines applicable to the transfer or termination of any such studies. In the event that CTI informs Baxter that it does not intend to continue specific development activities then in progress, each
Party shall bear its own costs incurred in closing out such activities; and 
 (g) Baxter shall not withdraw or cancel any Marketing
Approval or Reimbursement Approval or application for either, unless expressly instructed so by CTI in writing; provided that CTI shall be responsible for all costs and expenses for the maintenance of all Marketing Approvals and Reimbursement
Approvals following receipt of notice of termination. 
 15.4. Force Majeure. 

15.4.1. No failure or delay by either Party in the performance of any obligation hereunder shall be deemed a breach of this Agreement nor
create any liability for any damages, increased cost or losses which the other Party may sustain by reason of such failure or delay of performance, if the same shall arise from any cause or causes beyond the control of that Party, such as
earthquake, storm, flood, fire, other acts of nature, epidemic, war, riot, hostility, public disturbance, cessation of transport, act of public enemies, prohibition or act by a Government Authority or public agency, strike or other labor dispute or
work stoppage (collectively “Force Majeure”); provided, however, that the Party so prevented shall continue to take all commercially reasonable actions within its power to comply with its obligations hereunder as fully
as possible and to mitigate possible damages. 
 15.4.2. The Party so prevented shall without undue delay notify the other Party in writing
thereof. 

  
 73 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 15.4.3. Should the event of Force Majeure continue for more than ninety (90) days, the
Parties shall promptly discuss their further performance under this Agreement and whether to modify or terminate this Agreement in view of the effect of the event of Force Majeure. If no agreement can be reached within sixty (60) days after
expiration of such ninety (90) day period, either Party may terminate this Agreement effective immediately upon written notice to the other Party. 

15.5. Survival. For the avoidance of doubt, it is understood that the following Sections of this Agreement shall survive expiration or
termination of this Agreement for any reason: 1.1 (Definitions), 7.4 (Recalls), 9.3.4 (Royalty Payment Timing; Royalty Reports), 9.3.5 (Audit), 10.2 (Ownership of Inventions), 13 (Confidentiality), 14 (Indemnification), 15 (Term; Termination), and
16 (General Provisions). The following Sections of this Agreement shall survive expiration or termination of this Agreement with respect to payments accrued before such expiration or termination: 9.2 (Milestones), 9.3.1 (Royalty Payments), 9.7
(Exchange Rate; Manner and Place of Payment) and 9.8 (Taxes). 
 15.6. Other Remedies. Termination or expiration of this Agreement
for any reason shall not release any Party from any liability or obligation that has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive termination.
Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies, or claims, whether for damages or otherwise, that a Party may have
hereunder or that may arise out of or in connection with such termination or expiration. 
 ARTICLE XVI. 

GENERAL PROVISIONS 
 16.1.
Assignment. This Agreement is binding upon and will inure to the benefit of the Parties and their respective permitted assignees or successors in interest, including without limitation those that may succeed by assignment, transfer or
otherwise to the ownership of either of the Parties or of the assets necessary to the conduct of the business to which this Agreement relates. This Agreement may not be assigned or otherwise transferred by either Party without the prior written
consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without such consent, assign this Agreement together with all of its rights and obligations
hereunder to its Affiliates, or to a successor in interest in connection with the transfer or sale of all or substantially all of its business to which this Agreement relates, or in the event of its merger or consolidation or similar transaction,
subject to the assignee agreeing to be bound by the terms of this Agreement. Any purported assignment in violation of the preceding sentences shall be void. Any permitted successor shall assume and be bound by all obligations of its assignor or
predecessor under this Agreement. 
 16.2. Headings. Headings are inserted for convenience and shall not affect the meaning or
interpretation of this Agreement. 

  
 74 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 16.3. Waiver. No waiver of any default hereunder by either Party or any failure to
enforce any rights hereunder shall be deemed to constitute a waiver of any subsequent default with respect to the same or any other provision hereof. 

16.4. Notices. Any and all notices given by one Party to the other Party under this Agreement must be in writing and shall be delivered
by hand, sent by registered or certified air mail (postage prepaid), international courier service, email or fax to the other Party’s address as set forth below or to the latest address of such Party as shall have been communicated to the other
Party. 
 If to CTI: 
 CELL
THERAPEUTICS, INC. 
 3101 Western Avenue 

Suite #600 
 Seattle, WA 98121

 Attention: Executive Vice President, Corporate Development 

Telephone: (206 282-7100 

Facsimile: (206) 284-6206 

Email: ** 
 with a copy to CTI
Legal Affairs at the above address. 
 with a copy (which copy shall not constitute legal notice to CTI) to: 

O’Melveny & Myers LLP 

Two Embarcadero Center 
 San
Francisco, CA 94111 
 Facsimile: +1 (415) 984-8701 

Email: ** 
 Attention: C. Brophy
Christensen, Esq. 
 If to Baxter: 

Baxter Healthcare SA 
 Postfach

 8010 Zürich, Switzerland 

Telephone: +41 44 878 60 00 

Facsimile: +41 44 878 63 50 

Attention: Legal Department 

  
 75 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 with a copy (which copy shall not constitute legal notice to Baxter) to counsel: 

Baxter Healthcare Corporation 

One Baxter Parkway 
 Deerfield,
Illinois 60015 
 Telephone: (224) 948-3440 

Facsimile: (224) 948-2590 

Email: ** 
 Attention: General
Counsel 
 16.5. Severability. Should any part of this Agreement be held unenforceable or in conflict with the applicable Laws of any
jurisdiction, the invalid or unenforceable part or provision shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder
of this Agreement shall remain binding upon the Parties hereto. 
 16.6. Entire Agreement. This Agreement constitutes the whole
agreement between the Parties and shall cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof,
including without limitation the Confidentiality Agreement. 
 16.7. Amendment; No Waiver. Any amendment or modification to this
Agreement shall only be made in writing and shall only be valid when signed by the due representatives of the Parties. No provision of this Agreement may be waived except by a writing signed by the Party against which such waiver is sought to be
enforced. 
 16.8. Counterparts. This Agreement may be executed in more than one counterpart (including by electronic transmission),
each of which shall be deemed an original, but all of such counterparts taken together shall constitute one and the same agreement. 
 16.9.
Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer, or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any
contracts in the name of, or on behalf of the other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 

16.10. Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts,
as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 16.11. Compliance with Laws.
Each Party will comply with all Laws in performing its obligations and exercising its rights hereunder, including without limitation all Laws relating to the export, re-export or other transfer of any
Information transferred pursuant to this Agreement or the Licensed Product. 
 16.12. Governing Law. The construction, validity and
performance of this Agreement shall be governed in all respects by the laws of the state of New York, excluding its provisions regarding conflicts of law. The UNCITRAL Convention on the International Sale of Goods shall not apply. 

  
 76 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 16.13. Dispute Resolution; Jurisdiction. Any disputes under this Agreement shall be
submitted initially by either Party for resolution by the Executive Officers. The Executive Officers shall meet and discuss such matter within fifteen (15) days after a Party proposes that such Executive Officers meet to discuss the dispute. In
the event the Executive Officers of each Party are unable to resolve the dispute within thirty (30) days after receiving notice of the dispute (or such longer period as the Parties may mutually agree upon), then such dispute shall, after
expiration of the thirty (30) day period, be submitted to the International Institute for Conflict Prevention & Resolution (“CPR”) for final and binding arbitration pursuant to the arbitration clause set forth in
Exhibit 16.13. Notwithstanding the foregoing, no matters relating to breach or alleged breach of the provisions of Article XIII or the ownership of intellectual property or rights in intellectual property (including without limitation
Improvements and Inventions) or the validity or enforceability thereof shall be subject to resolution by the CPR, but rather shall be determined by a U.S. federal court of appropriate jurisdiction. 

16.14. Bankruptcy Code. All rights and licenses granted under or pursuant to this Agreement by CTI or Baxter are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code and of any similar provisions of applicable Laws under any other jurisdiction (collectively, the “Bankruptcy Laws”), licenses of right to
“intellectual property” as defined under the Bankruptcy Laws. CTI agrees that Baxter, as a licensee of rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws. 

16.15. Joint and Several Obligations. As among the entities comprising Baxter hereunder, consisting of BII, BHC and BHSA, all
obligations and liabilities of Baxter under or in connection with this Agreement shall be joint and several. 
 [Signature Page
Follows] 

  
 77 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 [Signature Page to Development, Commercialization and License Agreement] 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in duplicate by their respective duly authorized officers or
representatives. 
  

			
	CELL THERAPEUTICS, INC.
		
	By:	 	 /s/ James Bianco

		
	Name:	 	 James Bianco

		
	Title:	 	 President & CEO

	
	BAXTER INTERNATIONAL INC.
		
	By:	 	 /s/ Ludwig N. Hantson

		
	Name:	 	 Ludwig N. Hantson

		
	Title:	 	 CVP/President BioScience

	
	BAXTER HEALTHCARE CORPORATION
		
	By:	 	 /s/ Ludwig N. Hantson

		
	Name:	 	 Ludwig N. Hantson

		
	Title:	 	 CVP/President BioScience

	
	BAXTER HEALTHCARE SA
		
	By:	 	 /s/ Philippe Francois

		
	Name:	 	 Philippe Francois

		
	Title:	 	 Vice President - Supply Chain

		
	By:	 	 /s/ Pier Pollini

		
	Name:	 	 Pier Pollini

		
	Title:	 	 Senior Director - Supply Chain



  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.26 

Chemical Structure of Pacritinib Citrate 
  

 
 



 
 Chemical name: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]
heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.34 

Co-Promotion Terms 

**** 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.46 

CTI Patents 
  

					
	 “OXYGEN LINKED PYRIMIDINE
DERIVATIVES”

	 Jurisdiction
	  	 Application No.
	  	 Patent No. (if any)

	Australia	  	2006316071	  	2006316071
	Brazil	  	PI0618552-5	  	
	Canada	  	2,629,443	  	
	China	  	200680050676.5	  	ZL200680050676.5
	Europe	  	06813132.5	  	
	Hong Kong	  	09100412.1	  	
	India	  	2191/KOLNP/2008	  	
	Indonesia	  	WO200801506	  	
	Japan	  	2008-541128	  	5225856
	Malaysia	  	PI 20081674	  	
	Mexico	  	MX/a/2008/006432	  	MX298029
	New Zealand	  	568325	  	568325
	PCT	  	PCT/SG2006/000352	  	
	Philippines	  	1-2008-501125	  	
	Philippines	  	1-2012-501002	  	
	Philippines	  	1-2012-501003	  	
	Singapore	  	200803992-7	  	142892
	South Africa	  	2008/04208	  	2008/04208
	South Korea	  	10-2008-7013543	  	
	Taiwan	  	095142296	  	
	Thailand	  	0601005660	  	
	USA	  	12/093,867	  	8,153,632
	USA	  	13/438,989	  	8,415,338
	USA	  	13/771,546	  	
	Vietnam	  	1-2008-01477	  	

  

					
	
“11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),
3,5,8,10,12(27),16,21,23-DECAENE
 CITRATE SALT”

	 Jurisdiction
	  	 Application No.
	  	 Patent No. (if any)

	Argentina	  	P090104834	  	
	Australia	  	2009325147	  	
	Brazil	  	PI 0922736-9	  	
	Canada	  	2,746,058	  	
	China	  	200980150325.5	  	
	Europe	  	09788621.2	  	
	GCC	  	14895	  	
	Hong Kong	  	12102375.7	  	
	India	  	2306/KOLNP/2011	  	


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  


					
	
“11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),
3,5,8,10,12(27),16,21,23-DECAENE
 CITRATE SALT”

	 Jurisdiction
	  	 Application No.
	  	 Patent No. (if any)

	Indonesia	  	W00201102475	  	
	Israel	  	213418	  	
	Japan	  	2011-540664	  	
	Malaysia	  	PI 2011002647	  	
	Mexico	  	MX/A/2011/006206	  	
	New Zealand	  	593223	  	
	PCT	  	PCT/SG2009/000473	  	
	Philippines	  	1-2011-501084	  	
	Russia	  	2011126173	  	
	Singapore	  	201104006-0	  	171907
	South Africa	  	2011/04032	  	2011/04032
	South Korea	  	10-2011-7015738	  	
	Taiwan	  	098142605	  	
	Thailand	  	0901005538	  	
	USA	  	13/133,297	  	
	Vietnam	  	1-2011-01814	  	

  

					
	
“11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),
3,5,8,10,12(27),16,21,23-DECAENE
 MALEATE SALT”

	 Jurisdiction
	  	 Application No.
	  	 Patent No. (if any)

	Argentina	  	P090104835	  	
	Europe	  	09793626.4	  	
	GCC	  	14896	  	
	PCT	  	PCT/SG2009/000474	  	
	Taiwan	  	098142603	  	
	Thailand	  	0901005537	  	
	USA	  	13/133,288	  	


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.47 

CTI Trademarks 
 CTI 

CELL THERAPEUTICS 
 CELL THERAPEUTICS, INC. 

 
 



 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.54 

Development Plan 

**** 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.54 

Target Product Profile 

**** 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.54 

Development Plan Gantt Chart and Budget 

**** 









			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.132 

Form of Registration Rights Agreement 

REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of November 14, 2013, by and among (i) Cell
Therapeutics, Inc., a Washington corporation (the “Company”), (ii) Baxter Healthcare SA, a company organized under the laws of Switzerland (the “Initial Holder”), and (iii) each person or entity that
subsequently becomes a party to this Agreement pursuant to, and in accordance with, the provisions of Section 12 hereof (collectively, the “Holder Permitted Transferees,” and each individually, a “Holder
Permitted Transferee”). 
 WHEREAS, pursuant to the terms and conditions set forth in that certain Development, Commercialization
and License Agreement, dated as of November 14, 2013, between the Company and the Initial Holder (the “DCLA”), the Initial Holder has agreed to purchase from the Company, and the Company has agreed to issue and sell to Baxter,
shares of the Company’s Series 19 Preferred Stock and/or shares of the Company’s common stock, all upon the terms and conditions set forth in the DCLA. 

WHEREAS, the terms of the DCLA provide for the Company and the Initial Holder to execute and deliver this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto hereby agree as follows: 

1. Definitions. The following terms shall have the meanings provided therefor below or elsewhere in this Agreement as described below: 

“Agreement” has the meaning set forth in the Preamble. 

“Board” means the board of directors of the Company. 

“Business Day” means any day other than a Saturday, a Sunday or a day on which banks in New York are authorized or obligated
by law or executive order to close. 
 “Company” has the meaning set forth in the Preamble. 

“DCLA” has the meaning set forth in the Preamble. 

“Effective Date” has the meaning set forth in the DCLA. 

  
 3 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and
all of the rules and regulations promulgated thereunder. 
 “Holder Indemnified Person” has the meaning set forth in
Section 9.1. 
 “Holder Permitted Transferee” and “Holder Permitted Transferees” have the
meanings set forth in the Preamble. 
 “Holders” means, collectively, the Initial Holder and the Holder Permitted
Transferees; provided, however, that the term “Holders” shall not include the Initial Holder or any of the Holder Permitted Transferees if such Holder ceases to own or hold any Registrable Shares. 

“Initial Holder” has the meaning set forth in the Preamble. 

“Loss” has the meaning set forth in Section 9.1. 

“Mandatory Registration Termination Date” has the meaning set forth in Section 3.2. 

“Majority Holders” means, at the relevant time of reference thereto, those Holders holding more than fifty percent
(50%) of the Registrable Shares held by all of the Holders. 
 “Qualifying Holder” has the meaning set forth in
Section 12. 
 “Registrable Shares” means (i) any shares of common stock of the Company issued to the
Initial Holder, (ii) any shares of common stock of the Company issuable upon conversion of any shares of Series 19 Preferred Stock issued to the Initial Holder or (iii) any common stock issued as (or issuable upon the conversion or
exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such common stock or Series 19 Preferred Stock. For the avoidance of doubt, a security
shall cease to be a Registrable Share once it has been sold in an SEC-registered transaction or pursuant to Rule 144. 

“Registration Statement” has the meaning set forth in Section 3.1. 

“Rule 144” means Rule 144 promulgated under the Securities Act and any successor or substitute rule, law or provision. 

“SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and all of the rules and regulations promulgated thereunder.

 “Suspension Period” has the meaning set forth in Section 11. 

2. Effectiveness. This Agreement shall become effective and legally binding on the Effective Date. 

  
 4 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 3. Mandatory Registration. 

3.1. Within thirty (30) calendar days after the Effective Date, the Company will prepare and file with the SEC a registration statement
on Form S-3, or any other available form if the Company is not eligible to use Form S-3, for the purpose of registering under the Securities Act all of the Registrable Shares for resale by, and for the account of, the Holders as selling stockholders
thereunder (the “Registration Statement”). The Registration Statement shall permit the Holders to offer and sell, on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, any or all of the Registrable Shares.
The Company agrees to use commercially reasonable efforts to cause the Registration Statement to become effective as soon as practicable after the filing thereof, and in no event later than the earlier of (i) ninety (90) calendar days
following the Effective Date (subject to reasonable extension to the extent necessary to accommodate a delay resulting from unresolved SEC comments or the need to file financial statements within the time periods prescribed by the SEC) and
(ii) the fifth calendar day following the date on which the Company is notified by the SEC that (a) such Registration Statement will not be reviewed or is no longer subject to further review and comments and that (b) the SEC is
willing to declare the Registration Statement effective. The Registration Statement filed pursuant to this Section 3.1 (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be
provided to each Holder and its counsel prior to its filing or other submission. 
 3.2. The Company shall be required to keep the
Registration Statement effective until such date that is the earlier to occur of (i) the date as of which all of the Holders may sell all of the Registrable Shares to the public without restriction pursuant to Rule 144 (or the successor rule
thereto) promulgated under the Securities Act, and (ii) the date when all of the Registrable Shares registered thereunder shall have been sold pursuant to the Registration Statement or Rule 144 (such date is referred to herein as the
“Mandatory Registration Termination Date”). Thereafter, the Company shall be entitled to withdraw the Registration Statement and the Holders shall have no further right to offer or sell any of the Registrable Shares pursuant to the
Registration Statement (or any prospectus relating thereto). The Company shall not be required to register the offer and sale of the Registrable Shares pursuant to the Registration Statement in an underwritten offering. 

3.3. The Company shall not, and shall not agree to (i) allow the holders of any securities of the Company, other than holders of the
Registrable Shares, to include any of their securities in the Registration Statement under Section 3.1 hereof or any amendment or supplement thereto without the consent of the Holders or (ii) offer any securities for its own account
or the account of others in the Registration Statement under Section 3.1 hereof or any amendment or supplement thereto without the consent of the Holders, in each such case, subject to, and other than with respect to, any registration
obligations of the Company under any agreement entered into prior to the Effective Date; provided, however, that the Company at all times reserves the right to provide registration rights, pursuant to a separate registration statement,
to the holders of any securities of the Company. 

  
 5 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 4. Notification of Effectiveness. Company shall notify the Holders by facsimile or e-mail (as provided
by Holders) as promptly as practicable, and in any event, within twenty-four (24) hours, after the Registration Statement is declared effective and shall simultaneously provide the Holders with copies of any related prospectus to be used in
connection with the sale or other disposition of the securities covered thereby. 
 5. Obligations of the Company. In connection with the
Company’s obligation under Sections 3 and 4 hereof to file the Registration Statement with the SEC and to use commercially reasonable efforts to cause the Registration Statement to become effective as soon as practicable, the
Company shall, as expeditiously as reasonably possible: 
 5.1. Prepare and file with the SEC such amendments and supplements to the
Registration Statement and the prospectus used in connection therewith as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Shares covered by the Registration Statement, and
furnish to each Holder and the single firm of counsel designated by the Holders to the extent requested by such Holder or counsel, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including
financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits (including those previously furnished or incorporated by reference) promptly after the filing of such documents with
the SEC; 
 5.2. Furnish to the Holders, without charge, such number of copies of a prospectus, including a preliminary prospectus, in
conformity with the requirements of the Securities Act, and such other documents (including, without limitation, prospectus amendments and supplements as are prepared by the Company in accordance with Section 5.1 above) as the Holders
may reasonably request in order to facilitate the disposition of such Holders’ Registrable Shares. The Company hereby consents to the use of such prospectus and each amendment or supplement thereto by each of the selling Holders in connection
with the offering and sale of the Registrable Shares covered by such prospectus and any amendment or supplement thereto. 
 5.3. Notify the
Holders as promptly as reasonably possible, at any time when a prospectus relating to the Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in or
relating to the Registration Statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading; and, thereafter, the Company will promptly prepare (and, when completed, give notice to
each Holder) a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Shares, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to
make the statements therein not misleading; upon such notification by the Company, the Holders will not offer or sell Registrable Shares until the Company has notified the Holders that it has prepared a supplement or amendment to such prospectus and
delivered copies of such supplement or amendment to the Holders (it being understood and agreed by the Company that the foregoing clause shall in no way diminish or otherwise impair the Company’s obligation to promptly prepare a prospectus
amendment or supplement as above provided in this Section 5.3 and deliver copies of same as above provided in Section 5.2 hereof); 

  
 6 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 5.4. Promptly respond to any and all comments received from the SEC, with a view towards
causing the Registration Statement or any amendment thereto to be declared effective by the SEC as soon as practicable, and file an acceleration request as soon as practicable, but no later than five (5) Business Days, following the resolution
or clearance of all SEC comments or, if applicable, notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review; 

5.5. Use commercially reasonable efforts to register and qualify the Registrable Shares covered by the Registration Statement under such other
securities or Blue Sky laws of such states where such registration and/or qualification is required as shall be reasonably requested by a Holder, provided that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and provided further that (notwithstanding anything in this Agreement to the contrary with respect to the bearing of expenses) if any
jurisdiction in which any of such Registrable Shares shall be qualified shall require that expenses incurred in connection with the qualification therein of any such Registrable Shares be borne by the Holders, then the Holders shall, to the extent
required by such jurisdiction, pay their pro rata share of such qualification expenses; 
 5.6. Subject to the terms and conditions of this
Agreement, use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Shares for sale in
any jurisdiction in the United States, and (ii) if such an order or suspension is issued, obtain the withdrawal of such order or suspension at the earliest practicable moment and notify each holder of Registrable Shares of the issuance of such
order and the resolution thereof or its receipt of notice of the initiation or threat of any proceeding such purpose; 
 5.7. Permit a
single firm of counsel designated by the Holders to review the Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof), at Holders’ own cost, a reasonable period of
time prior to their filing with the SEC (not less than five (5) Business Days) and use commercially reasonable efforts to reflect in such documents any comments as such counsel may reasonably propose (so long as such comments are provided to
the Company at least (2) Business Days prior to the expected filing date) and will not request acceleration of such Registration Statement without prior notice to such counsel, provided, however that the Company shall not file the Registration
Statement or any amendments or supplements thereto to which the Majority Holders and the counsel designated by the Holders shall reasonably object in good faith; 

5.8. Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Shares to be
delivered to a transferee pursuant to the Registration Statement, which certificates shall be free, to the extent permitted by law, of all restrictive legends, and to enable such Registrable Shares to be in such denominations and registered in such
names as any such Holders may request; 

  
 7 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 5.9. Comply with all applicable rules and regulations of the SEC; 

5.10. Use commercially reasonable efforts to cause all the Registrable Shares covered by the Registration Statement to be listed on the NASDAQ
National Market, or such other securities exchange on which the Company’s common stock is then listed; and 
 5.11. Comply with all
requirements of the Financial Industry Regulatory Authority, Inc. with regard to the issuance of the Registrable Shares and the listing thereof on the NASDAQ National Market, and engage a transfer agent and registrar to maintain the Company’s
stock ledger for all Registrable Shares covered by the Registration Statement not later than the effective date of the Registration Statement. 
 6.
Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Agreement that the Holders shall furnish to the Company such information regarding them and the securities held by them
as the Company shall reasonably request and as shall be required in order to effect any registration by the Company pursuant to this Agreement. Each Holder shall promptly notify the Company of any changes in the information furnished to the Company.

 7. Expenses of Registration. All fees and expenses incurred by the Company in connection with the registration of the Registrable Shares pursuant
to this Agreement, including, without limitation, all registration and qualification and filing fees, printing (including, without limitation, expenses of printing certificates for Registrable Shares and of printing prospectuses if the printing of
prospectuses is reasonably requested by the holders of a majority of the Registrable Shares included in the Registration Statement), fees and disbursements of counsel for, or other persons retained by, the Company, and fees and expenses incident to
the performance of or compliance with this Agreement by the Company, shall be borne by the Company. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions
contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the
listing of the Registrable Shares on any securities exchange as required hereunder. Any expenses incurred by a Holder, including, without limitation, fees and disbursements of counsel for such Holder or any brokerage and other selling commissions
and discounts shall be borne by such Holder. 
 8. Delay of Registration. The Holders shall not take any action with the primary intent to restrain,
enjoin or otherwise delay any registration as the result of any controversy which might arise with respect to the interpretation or implementation of this Agreement. In the event such a delay occurs because of such action, the dates by which the
Registration Statement is required to be filed and become effective pursuant to this Agreement shall be extended by the same number of days of such delay. 

  
 8 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 9. Indemnification. 

9.1. The Company will, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors,
agents and employees of each of them, each person who controls each Holder within the meaning of the Securities Act or the Exchange Act, if any, and the officers, directors, agents and employees of each such controlling person (in each case, a
“Holder Indemnified Person”), to the fullest extent permitted by applicable law, from and against any loss, claim, damage, cost (including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees),
expenses, or liability (“Loss”), to which such Holder Indemnified Person may become subject under the Securities Act or otherwise, insofar as such Loss arises out of or is based upon (i) any untrue or alleged untrue statement
of any material fact contained in the Registration Statement, in any preliminary prospectus or final prospectus relating thereto or in any amendments or supplements to the Registration Statement or any such preliminary prospectus or final
prospectus, or (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; provided, however, that the indemnity agreement
contained in this Section 9.1 shall not apply to amounts paid in settlement of any such Loss if such settlement is effected without the consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed), nor
shall the Company be liable in any such case for any such Loss to the extent, but only to the extent, that it arises solely out of or is based solely upon (1) an untrue statement or alleged untrue statement or omission or alleged omission made
in connection with the Registration Statement, any preliminary prospectus or final prospectus relating thereto or any amendments or supplements to the Registration Statement or any such preliminary prospectus or final prospectus, based upon and in
conformity with written information furnished expressly for use in connection with the Registration Statement or any such preliminary prospectus or final prospectus by a Holder, any underwriter for such Holder or controlling person with respect to
such Holder, or (2) any breach by any Holder of this Agreement or the failure of such Holder to comply with the covenants and agreements contained in this Agreement respecting sales of the Registrable Shares. 

9.2. Each Holder will severally and not jointly indemnify and hold harmless the Company, each of its directors, each of its officers who have
signed the Registration Statement, each person, if any, who controls the Company within the meaning of the Securities Act, and all other Holders against any Loss to which the Company or any such director, officer, controlling person, or such other
Holder may become subject to, under the Securities Act or otherwise, insofar as such Loss arises solely out of or is based solely upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement or any
preliminary prospectus or final prospectus, relating thereto or in any amendments or supplements to the Registration Statement or any such preliminary prospectus or final prospectus, or arises out of or is based upon the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent and only to the extent that such untrue statement or alleged untrue statement or omission or
alleged omission was made in the Registration Statement, in any preliminary prospectus or final prospectus relating thereto or in any amendments or supplements to the Registration 

  
 9 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Statement or any such preliminary prospectus or final prospectus, in reliance upon and in conformity with written information furnished by the Holder expressly for use in connection with the
Registration Statement, or any preliminary prospectus or final prospectus; and provided, further, however, that the indemnity agreement contained in this Section 9.2 shall not apply to amounts paid in settlement of
any such Loss if such settlement is effected without the consent of those Holder(s) against which the request for indemnity is being made. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of
the net proceeds received by such Holder upon the sale of the Registrable Shares giving rise to such indemnification obligation. 
 9.3.
Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 9, notify the indemnifying party in writing of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party desires, jointly with any other indemnifying
party similarly noticed, to assume at its expense the defense thereof with counsel mutually satisfactory to the indemnifying parties and the indemnified parties. In the event that the indemnifying party assumes any such defense, the indemnified
party may participate in such defense with its own counsel and at its own expense, provided, however, that the counsel for the indemnifying party shall act as lead counsel in all matters pertaining to such defense or settlement of such
claim. The failure to notify an indemnifying party promptly of the commencement of any such action shall not relieve such indemnifying party of any liability to the indemnified party under this Section 9, except (and only) to the extent
the indemnifying party is actually and materially adversely prejudiced in its ability to defend such action. 
 9.4. If the indemnification
provided for in this Section 9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Loss referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall, to the extent permitted by applicable law, contribute to the amount paid or payable by such indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such Loss as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The indemnity and contribution agreements contained in this Agreement are in addition to any
liability that the indemnifying parties may have to the indemnified parties. 
 10. Reports Under The Exchange Act. With a view to making available
to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit the Holders to sell the Registrable Shares to the public without registration until the Mandatory Registration Termination Date, the
Company agrees to use commercially reasonable efforts: (i) to make and keep public information available as those terms are understood in Rule 144, (ii) to file with the SEC in a timely manner all reports and other documents required to be
filed by an issuer of securities registered under the Securities Act or the Exchange Act, (iii) as long as any Holder owns any Registrable Shares, to furnish in writing upon such Holder’s request a written statement by the Company that it
has complied with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act, and (iv) undertake any additional actions reasonably necessary to maintain the availability of the Registration Statement or the use of
Rule 144. 

  
 10 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 11. Suspension. Notwithstanding anything in this Agreement to the contrary, if the Company shall
furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company stating that the Board has made the good faith determination (i) that continued use by the Holders of the Registration Statement for purposes
of effecting offers or sales of Registrable Shares pursuant thereto would require, under the Securities Act, premature disclosure in the Registration Statement (or the prospectus relating thereto) of material, nonpublic information concerning the
Company, its business or prospects or any proposed material transaction involving the Company, (ii) that such premature disclosure would be materially adverse to the Company, its business or prospects or any such proposed material transaction
or would make the successful consummation by the Company of any such material transaction significantly less likely and (iii) that it is therefore essential to suspend the use by the Holders of such Registration Statement (and the prospectus
relating thereto) for purposes of effecting offers or sales of Registrable Shares pursuant thereto, then the right of the Holders to use the Registration Statement (and the prospectus relating thereto) for purposes of effecting offers or sales of
Registrable Shares pursuant thereto shall be suspended for a period (the “Suspension Period”) of not more than forty-five (45) days after delivery by the Company of the certificate referred to above in this
Section 11; provided that the Company shall be entitled to no more than two (2) such Suspension Periods during any twelve (12) month period. During the Suspension Period, none of the Holders shall offer or sell any Registrable
Shares pursuant to or in reliance upon the Registration Statement (or the prospectus relating thereto). The Company shall use commercially reasonable efforts to terminate any Suspension Period as promptly as practicable. 

12. Transfer of Registration Rights. None of the rights of any Holder under this Agreement shall be transferred or assigned to any person unless
(i) such person is a Qualifying Holder (as defined below), and (ii) such person agrees to become a party to, and bound by, all of the terms and conditions of, this Agreement by duly executing and delivering to the Company an Instrument of
Adherence in the form attached as Exhibit A hereto. For purposes of this Section 12, the term “Qualifying Holder” shall mean, with respect to any Holder, (a) any corporation, partnership controlling,
controlled by, or under common control with, such Holder or any partner thereof, or (b) any other direct transferee from such Holder of at least 25% of those Registrable Shares held by such Holder. None of the rights of any Holder under this
Agreement shall be transferred or assigned to any Person (including, without limitation, a Qualifying Holder) that acquires Registrable Shares in the event that and to the extent that such Person is eligible to immediately resell such Registrable
Shares pursuant to Rule 144 of the Securities Act or any 

  
 11 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
other exemption from the registration provisions of the Securities Act. After any transfer in accordance with this Section 12, the rights and obligations of a Holder as to any
transferred Registrable Shares shall be the rights and obligations of the Holder Permitted Transferee holding such Registrable Shares. 
 13.
Confidentiality of Records. Each Holder agrees not to disclose any material non-public information provided by the Company in connection with a registration (including, without limitation, the contemplated filing and timing of filing of a
Registration Statement). 
 14. Entire Agreement. This Agreement constitutes and contains the entire agreement and understanding of the parties with
respect to the subject matter hereof, and it also supersedes any and all prior negotiations, correspondence, agreements or understandings with respect to the subject matter hereof. 

15. Miscellaneous. 
 15.1. This Agreement
may not be amended, modified or terminated, and no rights or provisions may be waived, except with the written consent of the Majority Holders and the Company. 

15.2. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, and shall be
binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors or assigns, provided that the terms and conditions of Section 12 hereof are satisfied. 

15.3. This Agreement shall be binding upon and inure to the benefit of any transferee of any of the Registrable Shares provided that the terms
and conditions of Section 12 hereof are satisfied. Notwithstanding anything in this Agreement to the contrary, if at any time any Holder shall cease to own any Registrable Shares, all of such Holder’s rights under this Agreement
shall immediately terminate. 
 15.4. All notices and communications hereunder shall be deemed to have been duly given and made if in
writing and if served by personal delivery upon the party for whom it is intended or delivered by registered or certified mail, return receipt requested, or if sent by facsimile or email, provided that the facsimile or email is promptly confirmed by
telephone confirmation thereof, to the person at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such person: 

If to the Company: 

Cell Therapeutics, Inc. 

3101 Western Avenue, Suite 600 

Seattle, Washington 98121 

Telephone: (206) 272-4000 

Facsimile: (206) 272-4302 

Email: 

Attention: James A. Bianco, M.D., Chief Executive Officer 

  
 12 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 with copies to: 

O’Melveny & Myers LLP 

Two Embarcadero Center 

San Francisco, CA 94111-3823 

Telephone: (415) 984-8700 

Facsimile: (415) 984-8701 

Email: 

Attention: C. Brophy Christensen, Esq. and Eric Sibbitt, Esq. 

and 

CTI Legal Affairs 

Attention: Lisa Luebeck, Director, Legal Corporate Development & Securities 

If to the Initial Holder: 

Baxter Healthcare SA 

Postfach 

8010 Zurich, Switzerland 

Telephone: +41 44 878 60 00 

Facsimile: +41 44 878 63 50 

Attention: Legal Department 

with a copy to counsel, provided that such copy shall not constitute legal notice to the Initial Holder: 

Baxter Healthcare Corporation 

One Baxter Parkway 

Deerfield, Illinois 60015 

Telephone: (224) 948-3440 

Facsimile: (224) 948-2590 

Email: 

Attention: General Counsel 

15.5. Any person may change the address to which correspondence to it is to be addressed by notification as provided for herein. 

15.6. The parties acknowledge and agree that in the event of any breach of this Agreement, remedies at law may be inadequate, and each of the
parties hereto shall be entitled to seek specific performance of the obligations of the other parties hereto and such appropriate injunctive relief as may be granted by a court of competent jurisdiction, without the necessity of showing economic
loss and without any bond or other security being required. 

  
 13 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 15.7. This Agreement may be executed in a number of counterparts, including by electronic
transmission, any of which together shall for all purposes constitute one Agreement, binding on all the parties hereto notwithstanding that all such parties have not signed the same counterpart. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 14 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 IN WITNESS WHEREOF, each Holder and the Company have caused their respective signature pages
to this Registration Rights Agreement to be duly executed as of the day and year first above written. 
  

	
	CELL THERAPEUTICS, INC.
	
	  

	Name:
	Title:


 [SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT] 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 IN WITNESS WHEREOF, each Holder and the Company have caused their respective signature pages
to this Registration Rights Agreement to be duly executed as of the day and year first above written. 
  

	
	BAXTER HEALTHCARE SA
	
	  

	Name:
	Title:


 [SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT] 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 EXHIBIT A 

Instrument of Adherence 

Reference is hereby made to that certain Registration Rights Agreement, dated as of November 14, 2013, among Cell Therapeutics, Inc., a
Washington corporation (the “Company”), the Initial Holder and the Holder Permitted Transferees, as amended and in effect from time to time (the “Registration Rights Agreement”). Capitalized terms used herein
without definition shall have the respective meanings ascribed thereto in the Registration Rights Agreement. 
 The undersigned, in order to
become the owner or holder of [                ] shares of Series 19 Preferred Stock (the “Preferred Stock”) or shares of common stock of the Company
issuable upon conversion of the Preferred Stock (collectively, “Subject Securities”), of the Company, hereby agrees that, from and after the date hereof, the undersigned has become a party to the Registration Rights Agreement in the
capacity of a Holder Permitted Transferee, and is entitled to all of the benefits under, and is subject to all of the obligations, restrictions and limitations set forth in, the Registration Rights Agreement that are applicable to Holder Permitted
Transferees. The notice information for purposes of the Registration Rights Agreement is provided below. This Instrument of Adherence shall take effect and shall become a part of the Registration Rights Agreement immediately upon execution. 

Executed as of the date set forth below under the laws of New York. 

 

			
	Signature:	 	  

		 	Name:
		 	Title:
		 	Telephone:
		 	Facsimile:
		 	Email:
		 	Attention:


  

			
	Accepted:
	
	 CELL THERAPEUTICS, INC.

		
	 By:
	 	  

		 	 Name:

		 	 Title:


 Date:            , 2013 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 1.160 

Upstream Agreement 
  

	1.	The Asset Purchase Agreement, dated May 31, 2012, between S*BIO Pte Ltd. and CTI, as amended from time to time. 


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 8.2 

Manufacturing and Supply Agreement Terms 

The following is a summary of certain material terms relating to the manufacture and supply of Licensed Product from CTI to Baxter that will
be contained in a definitive Manufacturing and Supply Agreement (the “Supply Agreement”). An initial draft of the Supply Agreement was prepared by Baxter and commented upon by CTI to reflect the Parties initial positions on certain
manufacturing and supply related matters (the “Draft Supply Agreement”). The length of time of the negotiation with respect to the Supply Agreement and the efforts and manner in which the Parties shall negotiate are as set forth in
the Development, Commercialization and License Agreement (“DCLA”) to which this Exhibit is attached. All terms not defined herein shall have the respective meanings attached to such terms in the DCLA. The following material terms of
the Supply Agreement shall be binding on the Parties and shall not be subject to modification unless mutually agreed by the Parties. 
  

			
	 Supply Agreement Term
	 	 Details

	Term	 	Supply Agreement will be coterminous with the DCLA; provided, however that upon expiration (but not termination) of the DCLA the Parties shall discuss in good faith an extension of the Supply Agreement and/or a technology transfer
to ensure that Baxter (and CTI as applicable) will continue to have a supply of Licensed Product and/or Drug Product (as applicable).
		
	Fill/Finish Option	 	The Parties acknowledge that the DCLA provides that Baxter shall have an option to perform, by itself or through one or more CMOs, the packaging, finishing and labeling activities to produce Licensed Product from Drug Product, and
that upon exercise of this Fill/Finish Option the Supply Agreement will be appropriately modified and that the Parties will enter into a second supply agreement which shall, to the extent practicable and in accordance with industry custom and the
circumstances, ensure that the Parties will be is comparable positions with respect to such second supply agreement as with respect to the Supply Agreement. In the event that Baxter exercises the Fill/Finish Option and supplies finished Licensed
Product to CTI, it shall be at Baxter’s COGS therefor.
		
	Supply Price	 	The purchase price for the Licensed Product under the Supply Agreement will be ** through manufacture of the Licensed Product in Drug Product form, subject to the Supply Cap. For purposes of clarification, fill & finish (such as
blistering and package inserts), freight, insurance and other subsequent supply chain expenses are not subject to the Supply Cap but shall **.
		
	Supply Cap	 	Notwithstanding ** for Licensed Product referenced above, ** of Licensed Product (the “Supply Cap Prices”) shall apply to all Pacritinib Citrate ** delivered to Baxter under the Supply Agreement. The ** shall be
increased at the beginning of each subsequent Calendar Year over the prior year amount by **


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  


					
	 Volume
	 	2014 Supply Cap
Price Per Capsule	 
	 **
	 	 	 	** 
	 **
	 	 	 	** 
	 **
	 	 	 	** 
	 **
	 	 	 	** 

  

			
		 	 For the avoidance of doubt, the above prices are not incremental. That is, if Baxter purchases ** capsules in a calendar year, the maximum
supply price (excluding packaging) is ** (subject to the annual adjustment noted above).
  

As noted above, ** will be charged for each unit of Licensed Product delivered under the Supply Agreement (subject to the Supply Cap). However the Supply
Agreement will also contain a “true-up” mechanism to ensure that, based upon the above Supply Cap, upon the completion of the applicable calendar year, any payment overages for the purchase of Licensed Product are refunded to Baxter or any
payment deficits are paid to CTI, in either case, within 60 days following the end of the applicable calendar year.
  

The Parties agree that the foregoing Supply Cap Prices are based upon the assumption of one (1) Drug Substance manufacturing run per Calendar Year, produced by
a single Drug Substance manufacturer. Should the Parties agree to greater than one Drug Substance manufacturing run per Calendar Year, then the JSC shall adjust the Supply Cap Prices to reflect any expected incremental expense. The Supply Cap Prices
only apply to Drug Product by a single primary supplier. Should Drug Product be produced under any Back-Up Manufacturing provisions, then the Supply Prices Cap shall not apply to any such Drug Product.

		
	Binding Orders	 	The timeframe for forecasting and any binding order provisions in the Supply Agreement shall be aligned with the contractual provisions with any CMOs engaged to perform such work, as well as any provisions for Safety Stock, for
which Baxter will have approval authority according to the terms of the DCLA.
		
	Supply Failure	 	The Supply Agreement will include appropriate technology transfer provisions (including provision of drug master files and other customary terms in the industry) sufficient to enable Baxter to manufacture (or have manufactured) the
Licensed Product in the event that there is a Supply Failure (as defined in the Draft Supply Agreement). **
		
	Back-up Manufacturing	 	The Supply Agreement will include a covenant from CTI requiring CTI, within an agreed upon period of time (as determined by the JMC but no


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  


			
		
		 	later than 30 months following first commercial sale), to have engaged and qualified a CMO to provide back-up manufacturing and supply for the Licensed Product (a “Secondary Supply Source”). Expenses with any
scale-up, tech transfer and validation of Back-up Manufacturing are Development expenses. Expenses associated with producing any Licensed Product under Back-up Manufacturing shall be provided at actual COGS but not subject to the Supply Cap. With
notice suitable for any contemplated contracts, Baxter may waive or extent the timeframe for this provision for Back-up Manufacturing.
		
	Safety Stock	 	Until such time as CTI has engaged and qualified a Secondary Supply Source, CTI will agree to maintain, a safety stock of Licensed Product as forecast and ordered by Baxter sufficient to supply Baxter with its requirements of
Licensed Product for the Territory for a period of not less than six (6) months. The cost for the safety stock will be shared by the Parties such that Baxter is responsible for ** of the cost and CTI shall be responsible for ** of the cost. For the
avoidance of doubt, as such safety stock of Licensed Product is depleted, Baxter shall be responsible under the Supply Agreement only for the remaining ** that was previously borne by CTI, until aforementioned 6-month requirement is
fulfilled.
		
	 Representations/

Warranties/
 Indemnification
	 	The Supply Agreement will contain customary representations and warranties relating to the manufacture and supply of the Licensed Product including each Party’s obligation to comply with all applicable Laws. Further, the Supply
Agreement will include appropriate indemnification language (a draft of which is set forth in the Draft Supply Agreement).
		
	Recalls	 	Section 7.4 of the Agreement shall govern the Parties’ obligations with respect to Recalls, Withdrawals and/or Field Corrections.
		
	Confidentiality	 	Article XIII of the Agreement shall govern the Parties’ obligations with respect to confidentiality.
		
	Dispute Resolution	 	Section 16.13 of the Agreement shall govern the Parties’ rights and obligations with respect to the resolution of any disputes under the Supply Agreement.
		
	CTI CMO Agreement(s)	 	Baxter has the right to approve in writing any supply agreement CTI enters into with CTI’s CMOs before execution thereof.


  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 9.1.2 

Preferred Stock Terms 

ARTICLES OF AMENDMENT TO 

AMENDED AND RESTATED ARTICLES OF 

CELL THERAPEUTICS, INC. 

DESIGNATION OF PREFERENCES, 

RIGHTS AND LIMITATIONS 

OF 
 SERIES 19 PREFERRED
STOCK 
 Pursuant to the Washington Business Corporation Act, Chapter 23B.10, the undersigned officer of Cell Therapeutics, Inc., a
Washington corporation (the “Corporation”), does hereby submit for filing these Articles of Amendment: 
 FIRST: The name
of the Corporation is Cell Therapeutics, Inc. 
 SECOND: This amendment to the Corporation’s Amended and Restated Articles of
Incorporation, as amended to date (the “Restated Articles”), was adopted by the Board of Directors of the Corporation (the “Board”) on November 9, 2013 as set forth in resolutions adopted by the Board on
November 9, 2013. Shareholder action was not required on this amendment pursuant to Article II.2 of the Restated Articles. 
 THIRD: A
new Section 2(z) of Article II is added to the Restated Articles to add the designations, rights and preferences of a new series of preferred stock as follows, such Section to be effective as of November 15, 2013: 

“(z) Series 19 Preferred Stock  

TERMS OF PREFERRED STOCK 

Section 1. Definitions. For the purposes hereof, the following terms shall have the following meanings: 

“Affiliate” means any person or entity controlling, controlled by or under common control with a Holder. 

“Alternate Consideration” has the meaning set forth in Section 7(d). 

“Business Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Change of Control Transaction” means the occurrence after the date hereof of any of (i) an acquisition by an
individual, legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of 33% of the voting securities
of the Corporation (other than by means of conversion of shares of Series 19 Preferred Stock), or (ii) the Corporation merges into or consolidates with any other person, or any person merges into or consolidates with the Corporation and, after
giving effect to such transaction, the shareholders of the Corporation immediately before such transaction own less than 66% of the aggregate voting power of the Corporation or the successor entity of such transaction, or (iii) the Corporation
sells or transfers all or substantially all of its assets to another person and the shareholders of the Corporation immediately before such transaction own less than 66% of the aggregate voting power of the acquiring entity immediately after the
transaction, or (iv) a replacement at one time or within a one-year period of more than one-half of the members of the Board which is not approved by a majority of those individuals who are members of the Board on the date hereof (or by those
individuals who are serving as members of the Board on any date whose nomination to the Board was approved by a majority of the members of the Board who are members on the date hereof), or (v) the execution by the Corporation of an agreement to
which the Corporation is a party or by which it is bound, providing for any of the events set forth in clauses (i) through (iv) herein. 

“Common Stock” means the Corporation’s common stock, no par value per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed into. 
 “Common Stock Equivalents” means any
securities which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock; provided, however, that Common Stock Equivalents shall not include any debt securities of the Corporation. 

“Conversion Amount” means the sum of the Stated Value at issue. 

“Conversion Date” has the meaning set forth in Section 6(a). 

“Conversion Price” has the meaning set forth in Section 6(c). 

“Conversion Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series 19
Preferred Stock in accordance with the terms hereof. 
 “Exchange Act” means the Securities Exchange Act of 1934 and the
rules and regulations promulgated thereunder. 
 “Fundamental Transaction” means, at any time while the Series 19 Preferred
Stock is outstanding, (i) the Corporation effects any merger or consolidation of the Corporation with or into another person in which the Corporation is not the surviving person, (ii) the Corporation effects any sale of all or
substantially all of its assets in one transaction or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Corporation or another person) is completed pursuant to which holders of Common Stock are permitted
to tender or exchange a material portion of the Corporation’s shares for other securities, cash or property, or (iv) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the
Common Stock is effectively converted into or exchanged for other securities, cash or property; provided, however, that for the purposes of clause (ii) above, a “Fundamental Transaction” shall not include the
Corporation entering into a license or other agreement that licenses any intellectual property to an unaffiliated and unrelated person so long as the Corporation and its subsidiaries continue to have bona fide, substantial and continuing


  
 2 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
business operations and activities after such license or other agreement is entered into; provided, further, however, that a “Fundamental Transaction” shall not
include a reverse stock split with respect to the Common Stock. 
 “Holder” means a holder of shares of Series 19 Preferred
Stock. 
 “Junior Securities” means (i) the Common Stock and all other Common Stock Equivalents of the Corporation
other than those securities which are explicitly senior to or pari passu with the Series 19 Preferred Stock as to dividend rights or liquidation preference and (ii) the Series ZZ Junior Participating Cumulative Preferred Stock of
the Corporation. 
 “Liquidation” has the meaning set forth in Section 5. 

“Notice of Conversion” has the meaning set forth in Section 6(a). 

“Non-Senior Securities” means (i) the Common Stock and all other Common Stock Equivalents of the Corporation other than
those securities which are explicitly senior to the Series 19 Preferred Stock as to dividend rights or liquidation preference and (ii) the Series ZZ Junior Participating Cumulative Preferred Stock of the Corporation. 

“Original Issue Date” means the date of the first issuance of any shares of Series 19 Preferred Stock regardless of the
number of transfers of any particular shares of Series 19 Preferred Stock and regardless of the number of certificates which may be issued to evidence such Series 19 Preferred Stock. 

“Series 19 Preferred Stock” has the meaning set forth in Section 2. 

“Stated Value” has the meaning set forth in Section 2, as the same may be increased pursuant to
Section 3(a). 
 “Trading Day” means a day on which the New York Stock Exchange is open for business. 

“Trading Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: The NYSE Amex, The NASDAQ Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market, the New York Stock Exchange or the Mercato Telematico Azionario (MTA) organized and managed by Borsa Italiana S.p.A. 

“Transfer” has the meaning set forth in Section 10. 

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (i) if the Common
Stock is then listed or quoted on a national securities exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the national securities exchange on which the Common Stock is then listed
or quoted for trading as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)); (ii) if the Common Stock is then listed or traded on the OTC Bulletin Board and the OTC Bulletin
Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (iii) if the Common Stock is not then quoted for trading on a national securities
exchange or the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share 

  
 3 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
of the Common Stock so reported; or (iv) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by a majority
in interest of the Holders and reasonably acceptable to the Corporation, the fees and expenses of which shall be paid by the Corporation. 

Section 2. Designation, Amount, Par Value and Rank. The series of preferred stock shall be designated as the
Corporation’s Series 19 Preferred Stock (the “Series 19 Preferred Stock”) and the number of shares so designated shall be 30,000. Each share of Series 19 Preferred Stock shall have no par value per share and a stated value
equal to $1,000, subject to increase as set forth in Section 3(a) below (the “Stated Value”). 

Section 3. Dividends. 

(a) Dividends. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series 19 Preferred Stock
equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock or other Non-Senior Securities when, as and if such dividends
(other than dividends in the form of Common Stock) are paid on shares of the Common Stock or other Non-Senior Securities. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series 19 Preferred Stock; and
the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock or other Non-Senior Securities unless it simultaneously complies with the previous sentence. All declared but unpaid dividends on
shares of Series 19 Preferred Stock shall increase the Stated Value of such shares, but when such dividends are actually paid any such increase in the Stated Value shall be rescinded. 

(b) So long as any shares of Series 19 Preferred Stock remain outstanding, neither the Corporation nor any subsidiary thereof shall redeem,
purchase or otherwise acquire directly or indirectly any material amount of Non-Senior Securities except as expressly permitted by Section 9(b). 

Section 4. Voting Rights. Except as otherwise expressly provided herein or as otherwise required by law, Holders of shares
of Series 19 Preferred Stock shall have no voting rights. 
 Section 5. Liquidation. Upon any liquidation, dissolution or
winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value for
each outstanding share of Series 19 Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire
assets to be distributed to the Holders shall be ratably distributed among the Holders and the holders of all securities which are pari passu with the Series 19 Preferred Stock as to liquidation in accordance with the respective
amounts that would be payable on all such securities if all amounts payable thereon were paid in full. A Fundamental Transaction or Change of Control Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such
Fundamental Transaction or Change of Control Transaction shall be treated as if it were a Liquidation. The Corporation shall mail written notice of any such Liquidation, not less than 25 days before the payment date stated therein, to each Holder.


  
 4 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Section 6. Conversion and Exchange Rights. 

(a) Conversions at Option of Holder. 

(i) Each share of Series 19 Preferred Stock shall be convertible at any time and from time to time from and after the Original
Issue Date, at the option of the Holder thereof, into that number of shares of Common Stock determined by dividing the Stated Value of such share of Series 19 Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the
Corporation or its designated conversion agent with the form of conversion notice attached hereto as Annex A (a “Notice of Conversion”), which may be delivered before the date of conversion. Each Notice of Conversion shall
specify the number of shares of Series 19 Preferred Stock to be converted, the number of shares of Series 19 Preferred Stock owned before the conversion at issue, the number of shares of Series 19 Preferred Stock owned subsequent to the conversion
at issue and the date on which such conversion is to be effected, which date must be on or after the Original Issue Date and may not be before the date the applicable Holder delivers such Notice of Conversion to the Corporation in accordance with
Section 11(a) (such date, the “Conversion Date”); provided, however, that in the case of an automatic conversion pursuant to Section 6(b), the “Conversion Date” shall be the first to
occur of the dates set forth in clauses (A) through (C) of Section 6(b). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the
Corporation is deemed delivered hereunder (or the first date thereafter that conversion is permitted pursuant to this Section 6(a) or Section 6(b), as applicable). The calculations and entries set forth in the Notice of
Conversion shall control in the absence of manifest or mathematical error. To effect conversions of shares of Series 19 Preferred Stock, a Holder shall be required to (and by delivering a Notice of Conversion shall thereby be deemed to agree to)
forthwith surrender the certificate(s) representing such shares of Series 19 Preferred Stock to the Corporation. Notwithstanding anything to the contrary set forth herein, upon conversion of shares of Series 19 Preferred Stock in accordance with the
terms hereof, no Holder thereof shall be required to physically surrender the certificate representing such Holder’s shares of Series 19 Preferred Stock to the Corporation unless (A) the full or remaining number of shares of Series 19
Preferred Stock represented by such certificate are being converted or (B) such Holder has provided the Corporation with prior written notice (which notice may be included in a Notice of Conversion) requesting reissuance of a certificate
representing the remaining shares of Series 19 Preferred Stock upon physical surrender of any certificate representing the shares of Series 19 Preferred Stock being converted. Each Holder and the Corporation shall maintain records showing the number
of shares of Series 19 Preferred Stock so converted by such Holder and the dates of such conversions or shall use such other method, reasonably satisfactory to such Holder and the Corporation, so as not to require physical surrender of the
certificate representing the shares of Series 19 Preferred Stock upon each such conversion. In the event of any dispute or discrepancy, such records of the Corporation establishing the number of shares of Series 19 Preferred Stock to which the
record holder is entitled shall be controlling and determinative in the absence of manifest error. 
 (ii) Notwithstanding
the foregoing, no shares of Series 19 Preferred Stock shall be convertible by a Holder to the extent (but only to the extent) that such conversion would result in such Holder and its affiliates beneficially owning more than 19.99% of the Common
Stock (the “Beneficial Ownership Limitation”). To the extent the Beneficial Ownership Limitation applies, the determination of whether the shares of Series 19 Preferred Stock held by such Holder shall be convertible
(vis-à-vis other convertible, exercisable or exchangeable securities owned by such Holder) shall, subject to such Beneficial Ownership Limitation, be determined on the basis of the first submission to the Corporation for conversion, exercise
or exchange (as the case may be). No prior inability of a Holder to convert shares of Series 19 Preferred Stock pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent
determination of convertibility or issuance (as the case may be). For purposes of this paragraph, beneficial ownership and all determinations and calculations (including, without limitation, with respect to calculations of percentage ownership)
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder; provided, however, that in effecting any conversion, the Corporation shall be entitled to assume that
no Holder, together with its affiliates, beneficially owns more than 19.99% of the Common Stock unless written notice specifying the number of shares of Common Stock beneficially held by such Holder and its affiliates is sent to the Corporation by
the Holder within the three Business Day period before the date of the automatic conversion. 

  
 5 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
The provisions of this paragraph shall be implemented in a manner otherwise than in strict conformity with the terms of this paragraph to correct this paragraph (or any portion hereof) which may
be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such Beneficial Ownership Limitation. The limitations contained in
this paragraph shall apply to a successor Holder. The holders of Common Stock shall be third party beneficiaries of this paragraph and the Corporation may not waive this paragraph without the consent of holders of a majority of its Common Stock. For
any reason at any time, upon the written or oral request of a Holder, the Corporation shall within two Business Days confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding, including by virtue of any prior
conversion or exercise of convertible or exercisable securities into Common Stock. 
 (b) Automatic Conversion. Upon the earliest to
occur of the events described in the following clauses (A), (B) and (C) of this Section 6(b), each outstanding share of Series 19 Preferred Stock shall automatically convert into that number of shares of Common Stock determined by
dividing the Stated Value of such share of Series 19 Preferred Stock by the Conversion Price (A) on the 30th day after the Original Issue Date, (B) on the date on which 5,000 or less
shares of Series 19 Preferred Stock remain outstanding, or (C) immediately upon the adoption by the Board of a resolution that it intends to adopt an amendment to the Restated Articles without shareholder approval to effect a reverse stock
split of the outstanding Common Stock and the number of authorized shares of Common Stock in the same proportions in order to achieve compliance with the listing rules of The NASDAQ Capital Market or for other good-faith business reasons. 

Upon a Conversion Date, a Holder shall be required to forthwith surrender any certificate(s) representing such shares of Series 19 Preferred
Stock to the Corporation within two Trading Days of the date established for such conversion and set forth in a written notice from the Corporation; provided, however, that the failure by a Holder to surrender the certificate(s)
representing such converted shares of Series 19 Preferred Stock shall not prevent the Corporation from delivering the shares of Common Stock issuable upon automatic conversion thereof and, upon receipt of such consideration by such Holder, such
shares of Series 19 Preferred Stock shall be converted for all purposes hereunder. 
 (c) Conversion Price. The conversion price for
the Series 19 Preferred Stock shall equal $1.914, subject to adjustment as provided herein (the “Conversion Price”). 
 (d)
Mechanics of Conversion. 
 (i) Delivery of Certificate upon Conversion. Not later than three Trading Days
after each Conversion Date, whether pursuant to Section 6(a) or (b), the Corporation shall deliver, or cause to be delivered, to the converting Holder a certificate or certificates, which shall be free of restrictive legends and
issuer-imposed trading restrictions (provided that a registration statement covering resales of the Conversion Shares is then in effect), representing the number of shares of 

  
 6 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
Common Stock being acquired upon the conversion of shares of Series 19 Preferred Stock. The Corporation shall use its best efforts to, if the Holder is not an affiliate of the Corporation,
deliver any certificate(s) required to be delivered by the Corporation under this Section 6 electronically through The Depository Trust Company or its nominee (“DTC”) or another established clearing corporation performing
similar functions (provided that a registration statement covering resales of the Conversion Shares is then in effect). If, in the case of any Notice of Conversion, such certificate(s) are not delivered to or as directed by the applicable Holder by
the seventh Trading Day after the Conversion Date, then (without limiting the Holder’s other rights and remedies hereunder for the Corporation’s failure to comply with its obligations under the preceding portion of this paragraph) the
applicable Holder shall be entitled to elect to rescind such Conversion Notice by written notice to the Corporation at any time on or before its receipt of such certificate(s), in which event the Corporation shall promptly return to such Holder any
original Series 19 Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return any Common Stock certificates representing the shares of Series 19 Preferred Stock tendered for conversion to the Corporation. 

(ii) Obligation Absolute. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion
of shares of Series 19 Preferred Stock in accordance with the terms hereof is absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the
recovery of any judgment against any person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other person of any obligation to the
Corporation or any violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of
such Conversion Shares; provided, however, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder. In the event a Holder shall elect to convert any or
all of the Stated Value of its Series 19 Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for
any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series 19 Preferred Stock of such Holder shall have been sought and obtained. In the absence of such an
injunction, the Corporation shall issue Conversion Shares upon a properly noticed conversion. Nothing herein shall limit a Holder’s right to pursue actual damages for the Corporation’s failure to deliver Conversion Shares within the period
specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such rights
shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law. 

(iii) Reservation of Shares Issuable upon Conversion. The Corporation covenants that it will at all times use reasonable
best efforts to reserve and keep available out of its authorized and unissued shares of Common Stock, for the sole purpose of issuance upon conversion of the Series 19 Preferred Stock, as herein provided, free from preemptive rights or any other
actual contingent purchase rights of persons other than the Holders of the Series 19 Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments and restrictions of
Section 7) upon the conversion of all outstanding shares of Series 19 Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid
and nonassessable. 

  
 7 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (iv) Fractional Shares. Upon a conversion of the Series 19 Preferred
Stock hereunder, the Corporation shall not be required to issue fractions of shares of Common Stock, but shall instead, if otherwise permitted, round the total number of Conversion Shares for such conversion up or down to the nearest whole number of
shares of Common Stock. 
 (v) Transfer Taxes. The issuance of certificates for shares of the Common Stock issued upon
conversion of shares of Series 19 Preferred Stock shall be made without charge to any Holder for any documentary stamp, issuance or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the
Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holder of such shares of Series 19
Preferred Stock so converted and the Corporation shall not be required to issue or deliver such certificates unless or until the person or persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall
have established to the satisfaction of the Corporation that such tax has been paid. 
 Section 7. Certain Adjustments.

 (a) Stock Dividends and Stock Splits. If the Corporation, at any time while the Series 19 Preferred Stock is outstanding:
(A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of
Common Stock issued by the Corporation upon conversion of the Series 19 Preferred Stock); (B) subdivides outstanding shares of Common Stock into a larger number of shares; (C) combines (including by way of a reverse stock split)
outstanding shares of Common Stock into a smaller number of shares; or (D) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and any
other adjustments to the Holders’ conversion rights necessary to reflect such event shall be made. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of
shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification. 

(b) Subsequent Rights Offerings. If the Corporation, at any time while the Series 19 Preferred Stock is outstanding, shall issue
rights, options or warrants to all holders of Common Stock (and not proportionately to the Holders) entitling them to subscribe for or purchase shares of Common Stock at a price per share that is lower than the VWAP on the record date for such
issuance, and do not offer the same rights to the Holders, then the Conversion Price shall be adjusted to reflect such rights, options or warrants offering by multiplying the Conversion Price by a fraction, the numerator of which shall be the number
of shares of Common Stock outstanding before the record date for such issuance plus the number of shares of Common Stock which the aggregate offering price of the total number of shares of Common Stock so offered (assuming delivery to the
Corporation in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP on the record date for such issuance and the denominator of which shall be the number of shares of the Common Stock
outstanding on such record date plus the aggregate number of additional shares of Common Stock offered 

  
 8 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
for subscription or purchase. Such adjustment shall be made whenever such rights, options or warrants are issued, and shall become effective immediately after the record date for the
determination of shareholders entitled to receive such rights, options or warrants. 
 (c) Pro Rata Distributions. If the
Corporation, at any time while the Series 19 Preferred Stock is outstanding, distributes (other than as a dividend) to all holders of Common Stock (and not proportionately to the Holders) evidences of its indebtedness or assets or rights or warrants
to subscribe for or purchase any security (other than Common Stock, which shall be subject to Section 7(b)), then in each such case the Conversion Price shall be adjusted by multiplying such Conversion Price in effect immediately before
the record date fixed for determination of shareholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on
such record date less the then fair market value at such record date of the portion of such assets, evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board in
good faith. In either case the adjustments shall be described in a statement delivered to the Holders describing the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock.
Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. For avoidance of doubt, distributions that are dividends shall be subject to Section 3(a)
and not subject to this Section 7(c). 
 (d) Fundamental Transaction. If, at any time while the Series 19 Preferred Stock
is outstanding, a Fundamental Transaction occurs, then, upon any subsequent conversion of the Series 19 Preferred Stock, the Holders shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion
immediately before the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately
before such Fundamental Transaction, the holder of one share of Common Stock (the “Alternate Consideration”); and the Holders shall no longer have the right to receive Conversion Shares per se upon such conversion. For purposes of
any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of the Series 19
Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall adopt articles of incorporation or an
amendment to its articles of incorporation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’ right to convert such preferred stock into Alternate
Consideration. Unless the Corporation elects to treat such Fundamental Transaction as a Liquidation, the terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving
entity to comply with the provisions of this Section 7(d) and ensuring that the Series 19 Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction. 
 (e) Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest
1/100th of a share, as the case may be. 

  
 9 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (f) Notice to the Holders. 

(i) Adjustment to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this
Section 7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 

(ii) Notice to Allow Conversion by Holder. If (A) the Corporation shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the
Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Corporation shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each
office or agency maintained for the purpose of conversion of the Series 19 Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 20 calendar days
before the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or
other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Corporation or any of its subsidiaries, the Corporation shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder is entitled to convert the Stated Value of its Series 19 Preferred Stock during the 20-day period commencing on the date of such notice through
the effective date of the event triggering such notice. 
 Section 8. [Reserved.] 

Section 9. Negative Covenants. As long as at least 20% of the aggregate number of originally issued shares of Series 19
Preferred Stock are outstanding (as appropriately adjusted for share splits and similar transactions), the Corporation shall not, without the Corporation obtaining the affirmative written consent of Holders of a majority of the then outstanding
shares of the Series 19 Preferred Stock: 
 (a) amend these articles of incorporation, its bylaws or other charter documents so as to
materially, specifically and adversely affect any rights of any Holder with respect to Series 19 Preferred Stock; 

  
 10 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (b) repay, repurchase or offer to repay, repurchase or otherwise acquire any material amount
of its Junior Securities (other than securities described in clause (ii) of the definition of “Junior Securities”); provided, however, that this restriction shall not apply to the repurchase of up to 5,750,000
shares of Common Stock in any 12-month period (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the Original Issue Date) from
employees, officers, directors, consultants or other persons performing services for the Corporation or any subsidiary pursuant to agreements approved by a majority of the Board or under which the Corporation has the option to repurchase such shares
at cost or at cost upon the occurrence of certain events, such as termination of employment; 
 (c) authorize or create any class or series
of stock ranking senior to the Series 19 Preferred Stock as to dividend rights or liquidation preference; or 
 (d) enter into any agreement
or understanding with respect to any of the foregoing. 
 Notwithstanding the foregoing, this Section 9 shall not prohibit the
issuance of additional series of preferred stock that do not rank senior to the Series 19 Preferred Stock as to dividend rights or liquidation preference. 

Section 10. Transferability. The Series 19 Preferred Stock may only be sold, transferred, assigned, pledged or otherwise
disposed of (any of the foregoing, a “Transfer”) in accordance with U.S. state and federal securities laws. The Corporation shall keep at its principal office, or at the offices of the transfer agent, a register of the Series 19
Preferred Stock. In connection with any such permitted Transfer, upon the surrender of any certificate representing Series 19 Preferred Stock at such place, the Corporation, at the request of the record Holder of such certificate, shall execute and
deliver (at the Corporation’s expense) a new certificate or certificates in exchange therefor representing in the aggregate the number of shares represented by the surrendered certificate; provided that the Corporation shall not be required to
pay any tax that may be payable in respect of any such Transfer involved in the issuance and delivery of any such new certificate in a name other than that of Holder and the Corporation shall not be required to issue or deliver such new
certificate(s) unless or until the person or persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. Each such
new certificate shall be registered in such name and shall represent such number of shares as is requested by the Holder of the surrendered certificate and shall be substantially identical in form to the surrendered certificate. 

Section 11. Miscellaneous. 

(a) Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder shall be in writing and
delivered personally, by facsimile or by email, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 3101 Western Avenue, Suite 600, Seattle, Washington 98121, facsimile number (206) 272-4302, or email
jbianco@ctiseattle.com, Attention: James Bianco, or such other street address, facsimile number or email address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 11(a).
Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, by email or sent by a nationally recognized overnight courier service addressed to each
Holder at the facsimile number, email address or street address of such Holder appearing on the books of the Corporation, or if no such facsimile number, email address or street address appears on the books of the Corporation, at the principal place
of business of the Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile or email to the
facsimile number or email address specified in this Section 11(a) before 5:30 p.m. (New York City time) on any date, (ii) the date immediately following the date of transmission, if such notice or communication is delivered via
facsimile or email to the facsimile number or email address specified in this Section 11(a) between 5:30 p.m. and 11:59 p.m. (New York City time) on any date, (iii) the second Business Day following the date of dispatch, if sent by
nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. 

  
 11 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 (b) Lost or Mutilated Series 19 Preferred Stock Certificate. If a Holder’s Series
19 Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost,
stolen or destroyed certificate, a new certificate for the shares of Series 19 Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership
thereof reasonably satisfactory to the Corporation. 
 (c) Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this instrument shall be governed by and construed and enforced in accordance with the internal laws of the State of Washington, without regard to the principles of conflict of laws thereof. 

(d) Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this instrument shall not operate as or be
construed to be a waiver of any other breach of such provision or of any breach of any other provision of this instrument or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of
this instrument on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this instrument. Any waiver by the
Corporation or a Holder must be in writing. 
 (e) Severability. If any provision of this Article II.2(z) is invalid, illegal or
unenforceable, the balance of this Article II.2(z) shall remain in effect, and if any provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances. 

(f) Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day. 
 (g) Headings. The headings contained herein are for convenience only, do not
constitute a part of this Article II.2(v) and shall not be deemed to limit or affect any of the provisions hereof. 
 (h) Status of
Converted or Redeemed Series 19 Preferred Stock. If any shares of Series 19 Preferred Stock are converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and
shall no longer be designated as Series 19 Preferred Stock. 
 (i) Remedies, Characterizations, Other Obligations, Breaches and
Injunctive Relief. The remedies provided herein shall be cumulative and in addition to all other remedies available hereunder, at law or in equity (including a decree of specific performance and/or other injunctive relief), and no remedy
contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy. Nothing herein shall limit a Holder’s right to pursue actual damages for any failure by the Corporation to


  
 12 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
comply with the terms hereof. The Corporation covenants to each Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set
forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by a Holder and shall not, except as expressly provided herein, be subject to any other obligation of
the Corporation (or the performance thereof). The Corporation acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holders and that the remedy at law for any such breach may be inadequate. The Corporation
therefore agrees that, in the event of any such breach or threatened breach, the Holders shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and
without any bond or other security being required. 
 [Signature page follows.] 

  
 13 










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 I certify that I am a duly appointed and incumbent officer of the above named Corporation and
that I am authorized to execute these Articles of Amendment on behalf of the Corporation. 
 EXECUTED, this 15th day of November, 2013. 

 

			
	 CELL THERAPEUTICS, INC.,
 a
Washington corporation

		
	By:	 	  

		 	Name:  James A. Bianco, M.D.
		 	Title:    President and Chief Executive Officer


 [Articles of Amendment (Series 19)] 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 ANNEX A 

NOTICE OF CONVERSION 
 (TO
BE EXECUTED BY THE HOLDER IN ORDER TO CONVERT SHARES 
 OF SERIES 19 PREFERRED STOCK) 

The undersigned hereby elects to convert the number of shares of Series 19 Preferred Stock, no par value per share (the “Preferred Stock”),
of Cell Therapeutics, Inc., a Washington corporation (the “Corporation”), indicated below into shares of common stock, no par value per share (the “Common Stock”), of the Corporation, according to the
conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such
certificates and opinions as may be reasonably required by the Corporation. No fee will be charged to the Holders for any conversion of Preferred Stock, except for any such transfer taxes. 

Conversion calculations: 
  

					
		 	Date to Effect Conversion:	 	  



					
			
		 	Number of shares of Preferred Stock owned before Conversion:	 	 CUSIP 150934 859



					
			
		 	Number of shares of Preferred Stock to be Converted:	 	  



					
			
		 	Stated Value of shares of Preferred Stock to be Converted:	 	  



					
			
		 	Number of shares of Common Stock to be Issued:	 	 CUSIP 150934 883



					
			
		 	Applicable Conversion Price per share of Common Stock:	 	  



					
			
		 	Number of shares of Preferred Stock subsequent to Conversion:	 	  

			
		 	Address of Record:	 	

  

					
	By:	 	  

			
		 	Name:	 	  

			
		 	Title:	 	  



  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 13.3.1 

Form of Press Release 

(See attached.) 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 



 
 FOR IMMEDIATE RELEASE 

Baxter Media Contacts 
 Brian Kyhos or Deborah Spak 

(224) 948-5353 
 media@baxter.com 

Baxter Investor Contact 
 Mary Kay Ladone,
(224) 948-3371 
 CTI Contact 
 Monique Greer 

206-272-4343 
 mgreer@ctiseattle.com 

BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC 

COLLABORATION TO DEVELOP AND COMMERCIALIZE PACRITINIB 

Pacritinib Pivotal Phase III Clinical Program for Myelofibrosis Underway 

DEERFIELD, Ill., and SEATTLE, Wash., November 15, 2013 – Baxter International Inc. (NYSE:BAX) and Cell Therapeutics, Inc. (CTI) (NASDAQ and
MTA: CTIC) today jointly announced that they have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations
linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder. 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE
PACRITINIB – PAGE TWO 
 Under the terms of the agreement, Baxter gains exclusive commercialization rights for all indications for pacritinib
outside the United States and Baxter and CTI will jointly commercialize pacritinib in the United States. Baxter will make an upfront payment of $60 million, including an equity investment in CTI of $30 million. In addition, CTI is eligible to
receive clinical, regulatory, and commercial launch milestone payments of up to $112 million, $40 million of which relates to clinical milestones that may be achieved in 2014. Assuming regulatory approval and commercial launch, CTI may receive
additional sales milestone payments. CTI will receive royalties on net sales of pacritinib in ex-US markets, and the companies will share U.S. profits equally. Baxter will record a special pre-tax in-process research and development charge in the
fourth quarter of 2013 of approximately $30 million. 
 “The collaboration will complement Baxter’s existing oncology business and
growing oncology pipeline, and will leverage our global commercialization capacity to extend the availability of pacritinib, which we believe has the potential to address a significant unmet medical need,” said Ludwig Hantson, Ph.D., president
of Baxter BioScience. “As an established leader in hematology and rare diseases, we are committed to advancing novel therapies in an effort to broaden patient access to care.” 

“We believe Baxter represents the ideal strategic partner to achieve the full potential of pacritinib,” said James A. Bianco, M.D., President and
CEO of CTI. “Our two companies share a dedication to oncology and a vision for bringing this unique oral JAK2/FLT3 inhibitor to patients with certain blood cancers and solid tumors. This collaboration will provide additional financial
resources and commercial expertise to position us to pursue the development, commercialization and market potential of pacritinib.” 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE
PACRITINIB – PAGE THREE 
 Pacritinib is an oral tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FLT3. The
JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown
to be directly related to the development of certain blood related cancers including myeloproliferative neoplasms, leukemia and lymphoma. 
 About the
Pacritinib Phase III Program 
 Results from earlier Phase I and II studies of pacritinib demonstrated encouraging results, including
meaningful clinical benefits coupled with good tolerability among patients with advanced myelofibrosis. Based on the efficacy and tolerability profile demonstrated to date, the pivotal program for pacritinib includes two Phase III clinical trials:
PERSIST-1 is studying efficacy and safety in a broad set of patients with myelofibrosis without limitations on blood platelet counts, and PERSIST-2 will evaluate efficacy and safety in patients with low platelet counts, and is expected to begin in
the fourth quarter of 2013. 
 About Baxter in Oncology 

Baxter continues to expand its portfolio of branded products and R&D programs in oncology. Current products include chemotherapy agents
used alone or in 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
combination with other products to treat cancers such as non-Hodgkin’s lymphoma, as well as anti-emetic products designed to relieve the side effects of cancer therapeutics. Recent
collaborations and development programs have further expanded Baxter’s footprint in hematology/oncology, building upon the company’s expertise in treating patients with life-threatening medical conditions. 

About Baxter International Inc. 
 Baxter
International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute
medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. 

About Cell Therapeutics 
 Cell
Therapeutics Inc. (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA.
For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com. 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE
PACRITINIB – PAGE FOUR 
 This press release includes forward-looking statements concerning a collaboration agreement between Baxter
International Inc. and Cell Therapeutics Inc., which are within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of
which could materially and/or adversely affect actual future results and the trading price of the issuers’ securities. Such statements include, but are not limited to, expectations with respect to milestone and royalty payments, the expected
benefits of the collaboration and the ability to maximize the potential of pacritinib and extend its applicability to additional malignancies, including solid tumors. The statements are based on assumptions about many important factors, including
the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; clinical trial
results; changes in laws and regulations; product quality or patient safety issues; product development risks; the impact of competitive products and pricing and reimbursement; and other risks identified in each issuer’s most recent filings on
Form 10-K and other Securities and Exchange Commission filings. Neither Baxter nor CTI undertakes to update its forward-looking statements. 

### 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 Exhibit 16.13 

Alternative Dispute Resolution 
 (a) In
accordance with and subject to the procedures set forth in Section 3.1.6 and Section 16.13, and without adding any additional time to such procedures, the Parties shall attempt to resolve any and all disputes, claims or
controversies arising out of or relating to this Agreement promptly by negotiation between executives who have authority to settle the controversy. If such disputes, claims or controversies are not resolved through such negotiation or the
Section 3.1.6 and Section 16.13 procedures, then they shall be submitted for final and binding arbitration pursuant to the arbitration clause set forth below. Either Party may initiate arbitration with respect to the matters
submitted to negotiation by filing a written demand for arbitration at any time following the initial negotiation session. 
 (b) To the extent not resolved
by mediation, any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to
arbitrate, shall be determined by arbitration in New York, NY, in the language in which the contract was written. The arbitration shall be administered by the CPR pursuant to its Arbitration Rules and Procedures. References herein to any arbitration
rules or procedures mean such rules or procedures as amended from time to time, including any successor rules or procedures, and references herein to the CPR include any successor thereto. The arbitration shall be before
three (3) arbitrators. Each Party shall designate one arbitrator in accordance with the “screened” appointment procedure provided in Rule 5.4 of the CPR Rules. The two
(2) Party-appointed arbitrators will select the third, who will serve as the panel’s chair or president. All three (3) arbitrators shall have experience in biotechnology licensing, development
and/or commercialization matters. This arbitration provision, and the arbitration itself, shall be governed by the laws of the state of New York and the Federal Arbitration Act, 9 U.S.C. §§ 1-16.

 (c) Consistent with the expedited nature of arbitration, each Party will, upon the written request of the other Party, promptly provide the other with
copies of documents on which the producing Party may rely in support of or in opposition to any claim or defense. At the request of a Party, the arbitrators shall have the discretion to order examination by deposition of witnesses to the extent the
arbitrator deems such additional discovery relevant and appropriate. Depositions shall be limited to a maximum of five per Party and shall be held within forty-five (45) days of the grant of a request. Additional depositions may be scheduled
only with the permission of the arbitrators, and for good cause shown. Each deposition shall be limited to a maximum of one day’s duration. All objections are reserved for the arbitration hearing except for objections based on privilege and
proprietary or confidential information. The Parties shall not utilize any other discovery mechanisms, including international processes and U.S. 

  










			
	**	  	Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
	****	  	Indicates that the amount of information omitted was a page or more in length, and such information has been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions

  

 
federal statutes, to obtain additional evidence for use in the arbitration. Any dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrators, which
determination shall be conclusive. All discovery shall be completed within sixty (60) days following the appointment of the arbitrators. All costs and/or fees relating to the retrieval, review and production of electronic discovery shall be
paid by the Party requesting such discovery. 
 (d) The arbitrators will have no authority to award punitive or other damages not measured by the prevailing
Party’s actual damages, except as may be required by statute. Each Party expressly waives and foregoes any right to consequential, punitive, special, exemplary or similar damages or lost profits. The arbitrators shall have no power or
authority, under the CPR Rules for Non-Administered Arbitration or otherwise, to relieve the Parties from their agreement hereunder to arbitrate or otherwise to amend or disregard any provision of this
Agreement. The award of the arbitrators shall be final, binding and the sole and exclusive remedy to the Parties. Either Party may seek to confirm and enforce any final award entered in arbitration, in any court of competent jurisdiction. The cost
of the arbitration, including the fees of the arbitrators, shall be borne by the Party the arbitrator determines has not prevailed in the arbitration. 

(e) If an arbitral award does not impose an injunction on the losing Party or contain a money damages award in excess of five million dollars USD
($5,000,000), then the arbitral award shall not be appealable and shall only be subject to such challenges as would otherwise be permissible under the Federal Arbitration Act, 9 U.S.C. §§ 1-16. In
the event that the arbitration does result in an arbitral award, which imposes an injunction or a monetary award in excess of five million dollars USD ($5,000,000), such award may be appealed to a tribunal of appellate arbitrators via the CPR
Arbitration Appeal Procedure. 
 (f) Except as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of
any arbitration hereunder without the prior written consent of both Parties.